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Abstract 
 
A number of transgenic mouse models have been developed to study the  
molecular and pathological alterations associated with Alzheimer’s disease (AD). 
The 3xTg mouse is widely used as a research tool and carries mutations in the 
amyloid precursor protein (Swedish APP K670N/M671L), presenilin 1 (PS1M146V) and 
tau (TauP301L) which results in the development of pathological features simlar to 
the plaques and tangles observed in human AD. The TASTPM mouse carries both 
the APP K670N/M671L and PS1M146V  mutations but does not possess a tau transgene, 
so develops only plaque-like structures in the brain. 
This thesis aims to systematically characterise biochemical, electrophysiological 
and behavioural changes present in the 3xTg and TASTPM mouse models of AD. 
The widely studied amyloid cascade hypothesis proposes that the generation of 
Aβ through abnormal APP  processing is a key initiating process in AD, and so 
molecular or electrophysiological changes which are observed in both models 
could represent a common pathway of disease development. In addition, 
comparison between the two models could help to elucidate the role of the tau 
transgene in early phenotypic changes. 
The studies of hippocampal electrophysiology presented in this thesis show that 
the marked deficits in long-term potentiation (LTP) originally reported at the age 
of 6 months (Oddo et al., 2003) are not present in our colony of 3xTg mice. In 
support of this, although these mice do overexpress APP and tau the expected 
hyperphosphorylation of tau is not observed even at the advanced ages of 12-17 
months. This suggests that some of the processes associated with the development 
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of pathological features are occurring more slowly in our colony. In addition, 
studies using a T-maze paradigm in 6 month 3xTg mice suggest that major 
cognitive deficits are not present at this age. This suggests that drift of the 
phenotype has occured in the 3xTg mouse and has implications for further studies 
using this model. 
The 3xTg mouse does, however, present a deficit in basal synaptic transmission 
which is progressive with increasing age from 6-17 months. Similarly, 
hippocampal synaptic function is normal in TASTPM mice studied at 2 months, 
when no biochemical changes are present, but is markedly reduced at the age of 6 
months when it proved difficult to make any electrophysiological recordings. The 
data in this thesis shows that treatment with 1mM kynurenic acid during the 
slicing process markedly improved baseline synaptic transmission to the level 
observed in control mice. This shows that kynurenic acid can improve the 
viability of the slices, and as the compound is a glutamate receptor antagonist, 
suggests that reduction of glutamate-induced excitotoxicity during the slicing 
process results in its neuroprotective effects. This data suggests that alterations 
common to the 3xTg and TASTPM models, and therefore due to the presence of 
the APP or PS1 transgenes, may result in an increased susceptibility of 
hippocampal neurons  to cellular stressors such as excitotoxicity. 
To summarise, this thesis presents data which characterises in detail aspects of the 
electrophysiological, biochemical and behavioural phenotype of the 3xTg and 
TASTPM mouse models of AD, with the aim of observing early changes which 
may be associated with the mechanisms of AD development. 
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1.1 Alzheimer’s disease 
 
Alzheimer’s disease (AD) is a progressive form of dementia which is becoming 
increasingly common in today’s aging population. Dementia is classed as an 
impairment of memory, particularly in the learning of new information. It may 
also include other cognitive symptoms such as deterioration in judgement, 
planning, and information processing of a severity that causes impairment in 
daily living. In addition, dementia often causes alterations in emotional 
behaviour, such as apathy or emotional lability, or difficulties with social 
functioning (ICD-10, World Health Organisation). Dementia progresses over a 
number of years from mild memory loss to a condition where the individual 
affected is completely reliant on others for their care. 
In the UK, 820 000 individuals suffer from dementia with the cost to the 
economy reaching £23 billion per year. The majority of dementia sufferers (61%) 
are 80 years or older, but 8% of sufferers are under 65 years of age. There is 
currently no conclusive test for AD: a definitive diagnosis can only be obtained 
post mortem so the exact number of sufferers of the condition is unknown. 
However, it is the most common form of dementia, making up 50-60% of all 
cases (Dementia 2010, Alzheimer’s Research Trust). 
 
1.1.1: Risk factors in AD 
 
 
The majority of cases of AD are sporadic and occur in individuals without a 
family history of the disease. The causes of AD are currently unknown and it can 
be considered a multifactorial condition. However, a number of non-genetic risk 
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factors are associated with the development of AD. Clearly, the most important is 
age, as the prevalence of AD increases exponentially from the age of 65 onwards 
(Fig. 1.1A). This suggests that mechanisms occur within the ageing brain which 
make it more susceptible to neurodegeneration. However, due to the difficulties 
of studying the intact human brain, the effects of ageing are not well understood 
although they are hypothesised to include alterations in gene transcription, 
neurotransmitter release and neuronal plasticity, with a reduction in brain weight 
and loss of grey matter associated with increasing age (Good et al., 2001). 
However, the age-dependent mechanisms which promote the increased formation 
and aggregation of proteins such as Aβ or tau are not currently well understood. 
There are many lifestyle and environmental factors which have been associated 
with AD risk but scientific studies into many of these factors have given mixed 
and often inconclusive results. One of the most significant correlations is with 
education, as individuals with a low education level are at increased risk of 
developing AD; it is suggested that mentally stimulating activities have a 
preventative effect (Gatz et al., 2007). Another major risk factor is previous 
neuronal damage due to traumatic head injury; this has been shown to result in a 
transient increase in brain amyloid levels and may have long-term effects 
(Hartman et al., 2002). Cardiovascular risk factors, such as hyperlipidaemia, 
hypercholesterolaemia, high blood pressure and smoking markedly increase the 
risk of vascular forms of dementia such as multi-infarct dementia. However, 
there is evidence to suggest these factors may also be associated with AD 
(Altman and Rutledge, 2010), and other medical conditions such as 
hyperinsulinaemia and type II diabetes also increase the risk of AD (Cole et al., 
2007a).  
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Figure 1.1A: Prevalence of dementia by age and gender. Data from the 
MRC CFAS study of England and Wales (1998). 
Figure 1.1B: Pathological features of AD. Amyloid plaque (A, black 
arrow) and neurofibrillary tangles (B, black arrows) in human brain tissue 
visualised with silver staining. Image from Gorrie et al. 2007. 
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Finally, multiple other variables such as diet, exercise, and psychological factors 
such as stress and depression may also influence susceptibility. It is likely that a 
number of diverse and overlapping genetic, biological and environmental factors 
play a role in the likelihood of an individual developing AD in later life. 
 
1.1.2: Genetic risk factors in AD 
 
 
The second greatest risk factor for AD, following age, is the apolipoprotein E 
(ApoE) genotype carried by an individual. ApoE can bind to Aβ to regulate its 
clearance and degradation (Jiang et al., 2008). The protein has three alleles, ε2, 
ε3 and ε4; carriers of the ApoE ε4 allele have an increased probability of 
developing AD with a lower age of onset (Corder et al., 1993).  
A number of other genes have been implicated in susceptibility to AD using 
genome-wide association studies and are shown in Table 1.1. The most 
frequently observed associations are with the CLU and PICALM genes, 
encoding clusterin/apolipoprotein J protein and phosphatidylinositol-binding 
clathrin assembly protein respectively. Clusterin is a protein upregulated in states 
of cellular stress and is involved in pro- and anti-apoptotic events and protein 
clearance, while PICALM is involved in clathrin-mediated endocytosis (Harold 
et al., 2009). Other genes implicated in AD can be broadly divided into proteins 
mediating synaptic vesicle fusion or protein endocytosis, and those involved in 
immune responses or the breakdown and clearance of cellular products. This 
suggests that mechanisms which are not yet fully understood such as cellular 
protein trafficking may have an important role in the pathogenesis of AD.  
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Table 1.1: Genetic risk factors for AD    
 
Gene Protein Odds 
ratio 
Function Reference 
ApoE Apolipoprotein E (ε4 allele) 4.1 Lipoprotein and cholesterol transport, enhances 
proteolytic breakdown of Aβ peptide 
 
Bertram et al. 2007 
CLU Clusterin/ apolipoprotein J 0.86 Regulates apoptotic mechanisms, involved in the 
clearance of cellular proteins including Aβ peptide 
 
Harold et al. 2009 
PICALM Phosphatidylinositol-binding 
clathrin assembly protein 
0.85 Involved in clathrin-mediated endocytosis. 
Directs the trafficking of synaptic vesicle fusion proteins 
Harold et al. 2009 
CR1 Complement receptor 1 1.21 Processing and clearance of immune complexes 
 
Lambert et al. 2009 
BIN1 Bridging integrator 1 1.18 Involved in synaptic vesicle endocytosis Hollingworth et al. 2011 
EPHA1 Epherin receptor A1 0.85 Influences cell morphology and motility 
 
Naj et al. 2011 
CD33 Myeloid cell surface antigen 
CD33 
0.88 Involved in immune responses, mediates endocytosis 
through a clathrin-independent mechanism 
 
Naj et al. 2011 
CD2AP CD2-associated protein 1.14 Scaffold adaptor protein 
 
Naj et al. 2011 
ABCA7 ATP-binding cassette, subfamily 
A, member 7 
1.22 Involved in lipid transport across membranes, regulates 
APP processing, modulates phagocytosis of apoptotic 
cells 
Hollingworth et al. 2011 
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A small proportion of cases of AD are familial with a clear monogenetic link, 
however these affect only an estimated 1% of sufferers. The majority of these 
cases result from genetic mutations (discussed in section 1.2) which cause an 
early-onset form of the disease, affecting individuals in their 60s and younger. 
The most common cause of familial AD are mutations in the presenilin genes, 
primarily PS1, with over 170 different mutations recorded to date and new 
mutations still being discovered (Antonell et al., 2011). In addition, over 20 
mutations have been reported in the APP gene (Basun et al., 2008). Tau 
mutations are not associated with AD but with other neurodegenerative 
conditions such as frontotemporal dementia (Hutton et al., 1998). It is these 
familial genetic mutations that have been used to generate transgenic animal 
models which develop features of AD. 
 
1.1.3: Diagnosis of AD 
 
 
AD is usually diagnosed based on a detailed clinical history and the presence of 
memory impairment in structured tests. Neuronal loss is a prominent feature of 
the disease with an average loss of 8% of total brain weight (Terry et al., 1981) 
and cortical atrophy is often observable on a brain scan. However, a definitive 
diagnosis of AD can only be obtained post mortem, and relies on the presence of 
two main pathological features within the brain: the extracellular deposition of 
amyloid plaques, and intraneuronal neurofibrillary tangles (Fig. 1.1B). 
Neurofibrillary tangles are a feature of other forms of dementia, such as 
frontotemporal dementia, but plaques are only found in AD. However, the 
presence of some plaques and tangles is common in the brain of cognitively 
normal individuals (Fukumoto et al., 1996). Variation between pathological 
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features in individuals with AD is often apparent, with amyloid plaques being 
diffuse or focal and tangles present in the cell body, axon or dendrites. These 
may be present in cortical regions as well as subcortical areas such as the 
hippocampus and can be graded according to severity (Braak and Braak, 1991). 
The progression of tangle pathology is used as the grading scale for post-mortem 
analysis of AD brain tissue, and this follows severity of clinical symptoms more 
closely than plaque deposition. 
 
1.1.4: Treatment of AD 
 
 
The current treatments available for AD are able to slow the progression of the 
disease in some cases but do not cure or reverse it. Two types of medication are 
currently available: acetylcholinesterase (AChE) inhibitors (donepezil, 
galantamine, rivastigmine) and memantine, a glutamate receptor antagonist.  
In AD, one of the earliest pathological events is a loss of cholinergic basal 
forebrain neurons and a reduction in cortical acetylcholine (ACh) (Perez et al., 
2007). AChE inhibitors such as donepezil prevent the breakdown of ACh by 
these enzymes, leading to an increased level of the neurotransmitter within the 
synaptic cleft. This may result in an improvement of some of the cognitive 
symptoms and behavioural alterations associated with AD, such as apathy and 
attention, which involve cortical circuits (Rockwood et al., 2004).  
Memantine is a NMDA receptor channel blocker which is used therapeutically to 
prevent glutamate-induced neuronal death. It has been shown to act preferentially 
at extrasynaptic NMDA receptors (Bordji et al., 2010), which are activated by 
synaptic glutamate spillover and play a role in excitotoxicity (Frasca et al., 2011). 
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In addition, the modulation of glutamatergic synaptic transmission may have an 
important role in memory processes. Treatment with memantine, as well as 
prolonging neuronal survival, may therefore also enhance cognitive function in 
AD.  
Unfortunately, despite a number of new treatments aimed at preventing or 
disrupting amyloid pathology showing potential in animal models none of these 
have translated into clinical progress. An initial trial of anti-Aβ immunisation, 
which stimulated plaque clearance and improved cognitive function in mice 
(Schenk et al., 1999), was halted due to the development of meningoencephalitis 
in several patients (Vellas et al., 2009). Work continues into the development of 
other Aβ peptide vaccines along with novel strategies such as γ-secretase 
inhibition (Basi et al., 2010), although the first phase III trial of a γ-secretase 
inhibitor was recently halted with the finding that it worsened the symptoms of 
AD (Eli Lilly, press release, August 2010). It is clear that a better understanding 
of the initiation and progression of AD is needed to allow future treatments to be 
developed against novel drug targets. 
 
 
1.2: Proteins involved in AD 
 
 
Analysis of the familial forms of AD has identified several proteins crucial to the 
disease process, with the most important being amyloid precursor protein (APP), 
presenilin 1 (PS1) and tau. APP is cleaved to form a small peptide, Aβ, which 
forms the amyloid plaques characteristic of the disease. Also mutated in some 
cases of familial AD are the presenilins, a component of the γ-secretase complex 
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involved in the processing of APP. Tau is the major protein constituent of 
neurofibrillary tangles and its abnormal aggregation is crucial for tangle 
generation. Mutated and overexpressed forms of these three proteins have been 
used to develop the majority of mouse models for the study of AD. The role of 
these proteins in normal function and the effects of their mutation are discussed 
below. 
 
1.2.1: Amyloid precursor protein (APP) 
 
 
Amyloid precursor protein (APP) is a type I transmembrane protein with an 
intracellular cytoplasmic C-terminal, an extracellular N-terminal and a single 
alpha-helical transmembrane domain. The gene for APP is located on 
chromosome 21 and contains 19 exons, with alternative splicing creating three 
major human isoforms of APP of 695, 751 and 770 amino acids; the isoform of 
695 amino acids is the most abundant in neuronal tissue (Konig et al., 1992). 
 
1.2.1.1: Physiological functions of APP  
 
 
The normal cellular function of APP is not clear, although there is most evidence 
for its role as a trophic factor as APP has been shown to stimulate neural 
outgrowth (Qiu et al., 1995). APP knockout mice show reactive gliosis and 
locomotor deficits (Zheng et al., 1995), along with abnormal neuronal 
morphology, impairments in long-term potentiation (LTP) and cognitive deficits 
(Seabrook et al., 1999, Dawson et al., 1999). There is evidence to suggest APP 
may have a role as a modulator of synaptic function through Ca2+ channel 
regulation and alterations in GABAergic short term plasticity (Yang et al., 2009), 
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or by the promotion of NMDA receptor activity (Hoe et al., 2009). APP 
possesses a heparin binding domain which allows binding to proteoglycans in the 
extracellular matrix (Small et al., 1994). Consistent with this finding, it has been 
suggested that APP may act as a synaptic adhesion molecule through studies of 
the mouse neuromuscular junction (Wang et al., 2009) and also mediate cell-cell 
and cell-surface adhesion (Breen et al., 1991).  
 
1.2.1.2: Cleavage of APP 
 
 
APP undergoes a two-step process known as regulated intramembrane 
proteolysis, with an extracellular N-terminal cleavage step followed by cleavage 
within the transmembrane domain of the protein and the release of an 
intracellular C-terminal fragment. APP can be cleaved through one of two 
pathways: the amyloidogenic and non-amyloidogenic pathways (Fig. 1.2). 
Although it is thought that the non-amyloidogenic pathway is regulated in part 
by protein kinase C (PKC) (Hung et al., 1993), the reason for the cellular choice 
between the two pathways is not fully understood. In familial AD, increased 
levels of the peptide Aβ are caused by a shift to processing through the 
amyloidogenic pathway. 
The initial enzymatic processing step, which determines the final cleavage 
products, is mediated by α or β-secretase and releases the majority of the N-
terminal domain. This produces either the soluble APP-α or β protein fragments, 
and leaves the C-terminal domain attached to the membrane, either as the α (C83) 
C-terminal fragment (if cleaved by α -secretase) or β (C99) C-terminal fragment 
(if cleaved by β-secretase). The α-secretase zinc metalloproteinase enzymes 
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mediate the non-amyloidogenic pathway by cleavage within the Aβ sequence, 
preventing the generation of Aβ (Allinson et al., 2003). Processing by the 
aspartic-acid protease β-secretase (BACE1) generates the longer N-terminal 
extension of Aβ within the β C-terminal fragment and thus mediates the 
amyloidogenic pathway. 
The second enzymatic processing step involves the cleavage of either the α or β 
C-terminal fragment by an enzyme complex known as γ-secretase. This complex 
consists of four proteins: presenilin, nicastrin, APH-1 (anterior pharynx 
defective-1) and PEN2 (presenilin enhancer 2). The catalytic subunit is the 
presenilin protein, which can be either the PS1 or PS2 isoform (DeStrooper et al., 
1995, Francis et al., 2002). Cleavage of the α C-terminal fragment results in the 
generation of the cytoplasmic APP intracellular domain (AICD) and a small 
peptide known as p3, while cleavage of the β C-terminal fragment results in the 
generation of AICD and Aβ. Dependent on the cleavage site several forms of Aβ 
can be generated, ranging from 39-43 amino acids in length. Although the 40 
amino acid (Aβ40) is the most commonly produced form of the peptide, the 42 
amino acid (Aβ42) is thought to be the more ‘toxic’ form of Aβ; it has a tendency 
to aggregate more readily than Aβ40 and is the predominant form deposited in 
human amyloid plaques (Gravina et al., 1995). The role of Aβ in the 
pathogenesis of AD is discussed in more detail in section 1.3. 
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Figure 1.2: APP processing. APP can be cleaved by α-secretase to progress down the non-amyloidogenic pathway or by β-
secretase in the amyloidogenic pathway. Processing of APP by α-secretase results in the generation of the α-CTF and sAPPα, with 
further processing by γ-secretase generating AICD and a small fragment p3. Processing of APP by β-secretase results in the 
generation of the β-CTF and sAPPβ, while further processing by γ-secretase generates AICD and the Aβ peptide. The most common 
forms of Aβ are 40 and 42 amino acids in length, with the 42 amino acid form most prone to aggregation. 
 
Abbreviations: APP (amyloid precursor protein), α-CTF (alpha C-terminal fragment), sAPPα (soluble APP alpha), sAPPβ (soluble 
APP beta) AICD (APP intracellular domain), Aβ (beta amyloid). 
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1.2.1.3: Familial APP mutations 
 
 
There are around 20 known APP mutations, each named after the country (or 
region) in which they were discovered (Fig. 1.3). For example, the 
K670N/M671L mutation was first observed in two large Swedish families with 
early-onset AD (Mullan et al., 1992), while the Indiana mutation (V717F) was 
observed in an American family with markedly early-onset AD beginning in the 
mid to late- thirties (Murrell et al., 2000). The common feature of all APP 
mutations is that they increase brain levels of the Aβ42 form of the peptide, either 
through an overall increase in Aβ production or an alteration in the ratio of Aβ40 
to Aβ42 generated. For example, the Swedish mutation lies within the N-terminal 
sequence of Aβ (Fig. 1.3) and results in an alteration of the cellular location of β-
secretase cleavage, putting it in direct competition with α-secretase and resulting 
in a three to six-time increased production of Aβ (Haass et al., 1995). Multiple 
mutations are also clustered round the C-terminal γ-secretase site (e.g. Florida, 
London, Indiana), where they result in a selective increase of Aβ42 generation 
(De et al., 2001). Finally, several mutations near the α-secretase site (Dutch, 
Flemish, Arctic) result in the generation of forms of Aβ which show an enhanced 
propensity to form fibrils and a resistance to proteolytic degradation (Walsh et al., 
2001, Tsubuki et al., 2003).  
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Selecte
d 
familia
l APP 
mutati
ons 
 
K670N + M671L Swedish 
A673T  
H677R  
D678N Tottori 
A692G Flemish 
E693Q / E693G Dutch / Arctic 
D694N Iowa 
A713T  
T714I / T714A Austrian / Iranian 
V715A / V715M German / French 
I716V Florida 
V717I  / V717F London / Indiana 
T719P  
ISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITL 
671 
Aβ1-42 
713 
β γ α 
Selected familial APP mutations 
β 
Figure 1.3: Amino acid sequence of the Aβ42 peptide. Residues mutated 
in familial AD are shown in bold. The majority of familial AD mutations, 
shown in the table on the left, are clustered around the two terminals of the 
protein at the β- and γ-secretase cleavage sites. Some mutations also occur 
at the α-secretase cleavage site. These mutations all increase the levels of 
Aβ generated within the neuron. 
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1.2.2: Tau 
 
 
Tau is a microtubule-stabilising protein generated from the MAPT (microtubule-
associated protein tau) gene present on chromosome 17. In humans, there are six 
tau isoforms generated by alternative splicing of this gene. At the N-terminus, 
zero, one or two 28 amino-acid inserts can be present through the alternative 
splicing of exons 2 and 3, while at the C-terminus, three or four 31-35 amino-
acid microtubule-binding inserts can be present, giving rise to 3R (3 repeat) or 
4R tau (4 repeat) tau. Functionally, the ability of 4R tau to stabilise and prevent 
microtubule shortening is greater than 3R tau due to the presence of the 
additional insert (Panda et al., 2003). There are species-dependent differences in 
isoform expression, as adult humans express approximately equal ratios of 3R 
and 4R tau (Takuma et al., 2003), while adult mice and rats express only the 
three 4R forms (Kampers et al., 1999).  
Although it would be expected that tau is critical for neuronal function, tau 
knockout mice are viable and show only minor changes in neuronal maturation 
and outgrowth in culture (Dawson et al., 2001). This suggests that compensatory 
mechanisms such as the expression of other microtubule-associated proteins 
(MAP1/MAP2) can maintain microtubule function in the absence of tau. 
 
1.2.2.1: Phosphorylation of tau 
 
 
The primary role of tau is to bind and stabilise tubulin within microtubules and 
help maintain cellular structure and axonal transport. The phosphorylation of tau 
is an important mechanism to regulate this interaction with microtubules, with its 
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biological activity dependent on the degree of phosphorylation. There are over 40 
different phosphorylation sites on tau, with multiple sites in the microtubule-
binding domains. These are a mixture of serine, threonine and tyrosine residues 
which can be phosphorylated by a number of kinases, including glycogen 
synthase kinase 3 (GSK3), cyclin-dependent kinase 5 (Cdk5), protein kinase A 
(PKA) and casein kinase 1 (CK1) (Hanger et al., 2009a). The regulation of tau 
phosphorylation is a complex process and the role of individual phosphorylation 
sites on tau function is not fully established. 
Tau can be transiently hyperphosphorylated in a number of states such as 
hypothermia (Planel et al., 2007). However, long-term hyperphosphorylation of 
tau at a number of sites is a characteristic feature of AD and a subset of diseases 
known as tauopathies (Grundke-Iqbal et al., 1986). This hyperphosphorylation 
results in the disruption of microtubule function and the formation of insoluble 
tau aggregates, resulting in the characteristic tangle pathology observed in AD. 
This is discussed further in section 1.3.4. 
 
1.2.2.2: Familial tau mutations 
 
 
There are around 25 mutations which have been discovered in the tau protein. 
However, these are not associated with AD but with a rare form of dementia, 
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-
17). Individuals with FTDP-17 show behavioural and personality changes, with 
symptoms of dementia and motor difficulties such as frequent falls, bradykinesia 
and rigidity (Wszolek et al., 2006). Pathologically, this is accompanied by 
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progressive cortical atrophy and the presence of tau-positive inclusions 
containing both 3R and 4R tau (Cairns et al., 2007). 
Familial tau mutations consist of missense, silent or deletion mutations in the 
coding region of the gene, with several intronic mutations also discovered 
(Spillantini and Goedert, 2000). All tau mutations are autosomal dominant, and it 
has been suggested that this is due to the production of tau with altered 
conformational states and a tendency for hyperphosphorylation which can 
sequester normal tau into fibrils, causing a toxic gain of function (Alonso et al., 
2004). The coding region mutations generally result in a reduced ability of tau to 
bind to and stabilise microtubules, or the generation of forms of tau with an 
increased propensity to form fibrils. Several coding region mutations and all 
those observed in the intron region of the gene influence alternative splicing, 
resulting in the overproduction of 4R tau and an alteration of the 3R:4R ratio. As 
4R tau has an enhanced ability to bind to microtubules, it displaces the 3R tau, 
resulting in an alteration of microtubule binding kinetics and the formation of 
fibrillar tau aggregates (Lu and Kosik, 2001). 
 
1.2.3: Presenilins 
 
 
The presenilin proteins, presenilin 1 (PS1) and presenilin 2 (PS2), are encoded 
by the PSEN1 and PSEN2 genes present on chromosome 14. They are the main 
catalytic component of the γ-secretase enzyme complex which is involved in the 
second enzymatic cleavage step of APP, resulting in the generation of Aβ (see 
section 1.2.1.2). PS1 and PS2 show a high degree of structural similarity (~65%), 
with both proteins highly expressed in the neuronal population (Lee et al., 1996). 
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Although widely known for its role in APP processing, the γ-secretase complex 
has a number of type I membrane protein substrates, including the Notch 
receptor (De et al., 1999). Notch is a protein which is critical for the control of 
cellular differentiation during embryonic development, (Ables et al., 2011) and 
likely due to disruption of this signalling pathway PS1 knockout mice die shortly 
after birth with a phenotype of marked skeletal deformities, cerebral 
haemorrhage and neuronal loss (Shen et al., 1997). In contrast, PS2 knockout 
mice are viable and show only mild pulmonary haemorrhage and fibrosis with 
age, suggesting that its role in development can be compensated for by PS1 
(Herreman et al., 1999). However, mice in which PS1 knockout is conditionally 
restricted to postnatal cortex show reduced Aβ accumulation and mild 
impairments of spatial memory (Yu et al., 2001). In addition to its role in APP 
processing, PS1 has been suggested to be involved in the regulation of 
intracellular Ca2+ homeostasis and synaptic plasticity (discussed in detail in 
Chapter 3).  
 
1.2.3.1: Familial presenilin mutations 
 
 
The majority of known familial AD mutations are associated with presenilin 
function. Over 170 mutations in PS1 and over 10 mutations in PS2 have been 
reported which are all autosomal dominant. In general, PS1 mutations result in 
an earlier age of onset and more rapid disease progression than PS2 mutations 
(Bertram and Tanzi, 2004). PS1 is an eight-pass transmembrane protein, and the 
majority of mutations are clustered within the transmembrane domain, although 
some are also observed in the cytoplasmic or extracellular regions. Almost all of 
these are single amino acid point mutations, suggesting that minor sequence 
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changes within the structure of the protein may have a major effect on its 
function. 
The majority of known PS1 mutations result in an overall increase in Aβ42 
generation through an influence on γ-secretase cleavage of the β C-terminal 
fragment. As different mutations widely spread throughout the protein can cause 
a similar phenotype it has been suggested that these result in similar 
conformational changes. Several mutations result in alterations in the distance 
between the N and C-termini in the tertiary structure of the protein, which may 
alter interactions with APP and favour generation of the Aβ42 peptide 
(Berezovska et al., 2005). Some PS1 mutations also cause a concomitant 
reduction in Aβ40 levels, which is not simply a result of a shift in substrate 
preference but rather appears to be a distinct inhibition of Aβ40 generation (Shen 
and Kelleher, III, 2007). However, the precise effect of PS1 mutations on γ-
secretase activity is not currently fully understood. PS2 mutations have been 
shown to alter the ratio of Aβ40/ Aβ42 in a similar manner to PS1. Familial PS2 
mutations must result in a dramatic alteration of PS2 function to produce an 
observable effect, due to the predominant role of PS1 in Aβ generation (Walker 
et al., 2005). 
 
1.3: Molecular pathways of AD 
 
 
AD is a complex disorder and all of the molecular mechanisms which lead to 
disease progression are not yet fully understood. The predominant hypothesis in 
the field is the ‘amyloid cascade hypothesis’ in which elevated levels of Aβ form 
soluble aggregates followed by insoluble plaques. This leads to synaptic 
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dysfunction and eventually neurodegeneration through a number of downstream 
mechanisms such as inflammation and oxidative damage (Fig 1.4). AD is also 
characterised by the activation of a number of protein kinases which result in 
hyperphosphorylation of cellular proteins such as tau, leading to the generation 
of neurofibrillary tangles. An overview of the main events involved in AD 
pathogenesis is given in the following sections. 
 
1.3.1: The amyloid cascade hypothesis 
 
 
This hypothesis proposes that the primary event in the progression of AD is the 
deposition of Aβ, with tau phosphorylation and neuronal death occurring 
subsequent to this event (Hardy and Allsop, 1991). Evidence for the amyloid 
cascade hypothesis comes from the numerous familial mutations in APP and 
PS1/PS2 which increase Aβ generation and subsequently lead to AD (see section 
1.2.1, 1.2.3), while animal models have been generated which overexpress Aβ 
and subsequently develop memory deficits (see section 1.4.1). 
However, the initiating event in sporadic forms of AD is not yet known. It has 
been suggested that a failure of Aβ clearance mechanisms may result in a 
gradually increasing concentration of the peptide in the brain until it reaches a 
level at which it becomes harmful to neuronal function (Mawuenyega et al., 
2010). Alternatively, an increase in β-secretase activity is associated with ageing, 
and so changes in the function of this enzyme could enhance Aβ formation (Cole 
and Vassar, 2007). 
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Figure 1.4: The amyloid cascade hypothesis. Increased levels of the peptide Aβ, in particular Aβ42, occur both in sporadic and familial 
forms of AD. This leads to oligomerisation and aggregation of Aβ and subsequent amyloid plaque formation. A number of harmful 
downstream effects include synaptic dysfunction and loss, the initiation of inflammatory processes and oxidative damage. In addition, 
hyperphosphorylation of tau results in its aggregation and the formation of neurofibrillary tangles. A combination of these factors leads 
to eventual neuronal death which is a contributing factor to dementia. (Modified from Hardy and Allsop, 1991).
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1.3.1.1: The role of oligomeric Aβ 
 
 
There is ongoing debate about the form of Aβ responsible for its toxic 
downstream events. Initially, it was proposed that insoluble plaques were the 
main cause of toxicity but this idea has fallen out of favour as plaque load has 
been shown to correlate poorly with dementia (Giannakopoulos et al., 2003). 
Attention has therefore turned to the role of intraneuronal, oligomeric forms of 
Aβ as the toxic moiety.  
Treatment with oligomeric and fibrillar forms of Aβ causes toxicity in neuronal 
culture (Deshpande et al., 2006) and significantly inhibits the magnitude of long-
term potentiation (LTP) in hippocampal slice preparation (Townsend et al., 2006). 
The field is complicated in this respect by the wide variety of oligomeric 
preparations of Aβ which have been used, including Aβ-derived diffusible 
ligands (ADDLs), dimers/trimers and protofibrils. However, it has been 
suggested that all these forms share conformational similarities which may result 
in a common mechanism of toxicity (Glabe and Kayed, 2006). In addition, a 
number of transgenic mouse models exhibit deficits in memory and reduction in 
LTP well before the development of plaques (see section 1.4). This suggests a 
role for oligomeric Aβ in the production of early cognitive deficits. The exact 
conformation of these oligomers is unknown, but in the Tg2576 model a 56 kDa 
soluble protein known as Aβ*56 has been suggested to impair memory function 
independent of the generation of amyloid plaques (Lesne et al., 2006).   
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1.3.2: Early events in AD progression 
 
 
There are a number of findings which are associated with the early stages of AD 
in human studies and  mouse models. One of the major features thought to 
contribute to the early cognitive deficits in AD is synaptic loss and alterations in 
neuronal synaptic transmission. Other changes observed include mitochondrial 
dysfunction, which contributes to metabolic abnormalities and enhanced 
oxidative stress, and the initiation of low-grade inflammatory processes. 
 
1.3.2.1: Aβ and synaptic dysfunction  
 
 
It is thought that many of the early symptoms in AD may result not from overt 
neuronal death but by more subtle effects of Aβ on synaptic transmission and 
function. Again, a large body of evidence comes from APP transgenic mice 
which show alterations in synaptic plasticity and basal synaptic transmission, 
suggesting that this may be an important mediator of cognitive deficits in models 
of AD. In hippocampal slices from APPSwe mice the processing and secretion of 
Aβ is activity-dependent with the secreted Aβ acting to depress excitatory 
synaptic transmission through an NMDA receptor-dependent mechanism 
(Kamenetz et al., 2003). In support of this, Aβ has been shown to regulate 
NMDA receptor surface expression (Snyder et al., 2005). This suggests that there 
may be a feedback loop between the processing of neuronal Aβ and hippocampal 
excitatory transmission. Hippocampal slice studies have shown that the 
exogenous application of Aβ oligomers results in an impairment of not only LTP 
but also forms of long-term depression (LTD) (Li et al., 2009) which may occur 
through activation of mitogen-activated protein kinase (MAPK) resulting in 
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AMPA receptor phosphorylation and endocytosis (Hsieh et al., 2006). Alteration 
of different forms of synaptic plasticity through regulation of receptor expression 
may underlie the effects of Aβ on excitatory neuronal transmission.  
Synaptic loss is a common feature of AD and synaptic density within the brain 
may correlate with the severity of cognitive symptoms (Scheff et al., 2006). Aβ 
has been shown to cause a loss of dendritic spines and reduction in synaptic 
number in both slice preparations (Wei et al., 2010) and transgenic mouse 
models (Bittner et al., 2010). This is thought to occur through an NMDA 
receptor and Ca2+-mediated pathway in a mechanism similar to that involved in 
the induction of LTD (Shankar et al., 2007). It is likely that a reduction in 
synapse number in AD within regions of the brain such as the hippocampus is 
associated with memory deficits, particularly in the early stages of the disease. 
Therefore, Aβ can affect multiple synaptic mechanisms resulting in a reduction 
of excitatory transmission and structural alterations such as a loss of spine 
density. 
 
1.3.2.2: Glucose hypometabolism 
 
 
Metabolic dysfunction is associated with the early stages of AD, and this has 
been shown in a number of studies in which glucose uptake is regionally reduced, 
particularly in cortical areas, in AD patients (Foster et al., 1984). This glucose 
hypometabolism has marked effects on brain function, as the brain relies on 
glucose as its primary energy source and utilises 20% of the body’s total supply 
(Murray et al., 2011). It has been suggested that this feature occurs prior to 
disease onset in high-risk individuals such as those with mild cognitive 
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impairment (MCI) which may progress to AD, and presymptomatic individuals 
with familial AD mutations (Mosconi et al., 2008), and that it may be prognostic 
of further cognitive decline (Silverman et al., 2001). The major determinant of 
glucose utilisation in the brain is synaptic function, and so it has been suggested 
that synaptic loss, combined with alterations in cerebral blood flow and glucose 
transport, may underlie the observed hypometabolism (Piert et al., 1996).  
 
1.3.2.3: Oxidative stress 
 
 
The major risk factors for AD include increasing age, cardiovascular disease and 
diabetes, and these are all associated with elevated reactive oxygen species 
(ROS), oxidative and inflammatory stress. 
One hypothesis is that the endogenous systems for protection against ROS and 
oxidative stress are somehow compromised or insufficient in early AD. In 
support of this, an increased level of lipid peroxidation, a marker of oxidative 
stress, has been observed in human AD brain (Pratico 2008), while key anti-
oxidant enzymes such as glutathione peroxidise and superoxide dismutase (SOD) 
are depleted in animal models of AD (Resende et al., 2008). Reduction of 
manganese SOD enhances the pathological phenotype of an APP transgenic 
mouse model (Li et al., 2004), which strongly supports the notion that 
impairment of anti-oxidant defence systems enhances AD pathology. In addition, 
a mouse has been generated with reduced levels of nitric oxide (NO) due to the 
knockout of nitric oxide synthase 2 (NOS2), with the expression of the Swedish 
mutant form of APP  (APPswe/NOS2-/-). Nitric oxide is a molecule which is 
involved in neuroinflammation and is also an effective antioxidant. The double 
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transgenic APPswe/NOS2-/- mouse exhibits more severe amyloid and tau 
pathology compared to the single APPswe model and has evidence of neuronal 
loss and behavioural deficits characteristic of AD (Colton et al., 2008) .  
There is also evidence for mitochondrial dysfunction in AD, which can lead to 
oxidative stress. Aβ can enter mitochondria to cause deficits in mitochondrial 
respiration and energy production, and the generation of harmful ROS (Pagani 
and Eckert, 2011). It has been shown that increased ROS production can enhance 
APP processing, Aβ levels and tau phosphorylation. These data suggest that the 
oxidant or anti-/pro-inflammatory balance in the brain modifies AD-like 
pathology.  
 
 
1.3.3: Neuronal death in AD 
 
 
In more advanced cases of AD marked neuronal loss is observed in regions of the 
hippocampus and cortex. This feature is not observed in transgenic mouse 
models of the disease and it is unclear why the human brain is particularly 
vulnerable to age-related neuronal death. This is thought to occur primarily 
though activation of apoptotic pathways and the continued contribution of 
oxidative stress, mitochondrial dysfunction and inflammatory processes.  
Aβ has been shown to interact, either directly or indirectly, with a number of 
cellular signalling proteins. These include components of the apoptotic signalling 
pathway, such as activation of c-Jun N-terminal kinase (JNK) which results in 
downregulation of anti-apoptotic proteins (Yao et al., 2005a), and the activation 
of calpain and caspase-3 through an increase in intracellular Ca2+ concentration 
(Kuwako et al., 2002).  
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Also important in the progression of AD are inflammatory processes, with 
elevated levels of astrocytes and microglia associated with areas of plaque 
deposition. Activation of microglia results in the clearance of Aβ deposits, but 
with the simultaneous release of ROS and proinflammatory mediators such as 
cytokines, chemokines and complement factors (Heneka et al., 2010). This 
perpetuates a cycle resulting in the promotion of further inflammation and 
ultimately leading to cell death.  
The relative contribution of each of these complex factors in the promotion of 
neuronal apoptosis is not currently known. Therefore, it is likely that a number of 
overlapping and interacting factors, each increasing susceptibility to apoptosis, 
are involved in the mechanisms of neuronal cell loss in AD. 
 
1.3.4: Protein kinases in AD  
 
 
Another feature of AD is an alteration of protein kinase activity. Aβ causes the 
aberrant activation of neuronal signalling pathways, which leads to the 
dysregulation of kinase activity and altered phosphorylation of downstream 
target proteins. For example, an increase in phosphorylation of the microtubule 
associated protein tau is a characteristic feature of AD which is discussed in 
section 1.2.2.1. Studies have implicated a number of kinases including glycogen 
synthase kinase 3 (GSK3), cyclin-dependent kinase 5 (Cdk5) and MAPK in the 
pathogenesis of AD. 
The serine-threonine kinase GSK3 is thought to contribute to Aβ-induced 
neurotoxicity and is one of the major contributors to tau hyperphosphorylation in 
AD. Studies of GSK3 levels in human AD have given mixed results, with some 
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reporting an increase in GSK3 activity and some no change, likely due to the 
technical difficulties of measuring enzyme activity in post mortem brain tissue 
(Hooper et al., 2008). In cell models, the activity of GSK3 is increased by Aβ, 
contributing to neurotoxicity (Koh et al., 2008), and in turn GSK3 facilitates the 
processing of Aβ  peptides (Phiel et al., 2003). Further evidence for the role of 
GSK3 comes from transgenic mouse models where conditional overexpression 
results in hyperphosphorylation of tau and neuronal death (Lucas et al., 2001). 
Currently, interest is growing in the use of GSK3 inhibitors such as lithium and 
more selective synthetic compounds as treatments for AD, as GSK3 inhibition in 
transgenic mouse models reduces tau phosphorylation and appears to be 
neuroprotective (Noble et al., 2005). 
In addition to its role in the hyperphosphorylation of tau, GSK3 is involved in the 
phosphorylation of other cellular proteins. For example, phosphorylation of the 
GSK3 target collapsin response mediator protein 2 (CRMP2) has been observed 
in transgenic models of AD and may be one of the early biochemical changes 
associated with the disease (Cole et al., 2007b). This protein plays a role in 
neuronal polarity and axon guidance and promotes the association of tubulin into 
microtubule filaments (Soutar et al., 2009). Therefore, hyperphosphorylation of 
CRMP2 could alter its functional properties and contribute to neurodegeneration. 
Other kinases such as Cdk5 have been suggested to play a role in AD-associated 
neurodegeneration. For example, an increased level of the Cdk5 cofactor protein 
p25 has been reported in AD brain tissue, which results in the prolonged 
activation and altered cellular localisation of Cdk5 (Tseng et al., 2002).  
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Figure 1.5: Protein kinases and phosphorylation in AD. In AD the regulation of a number of protein kinases is altered. The activity of 
GSK3 may be increased; one mechanism by which this occurs is through downregulation of the PI3K-PKB pathway by Aβ, resulting in a 
decrease of the inhibitory phosphorylation of GSK3 at Ser9. Another feature of AD is an increase in levels of the p25 cofactor of Cdk5 which 
results in altered localisation and increased activation of the enzyme. Cdk5 can phosphorylate substrates such as CRMP2 and tau, while 
acting as a priming kinase for further phosphorylation of these proteins by GSK3. Other signalling cascades such as the MAPK cascade may 
also be activated and associated with tau phosphorylation. The result is a hyperphosphorylation of these cellular proteins which is a 
characteristic feature of AD. 
 
Abbreviations: P = phosphorylation. For others, see main text. 
CRMP2 Tau 
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Overexpression of p25 in transgenic mice results in phosphorylation and 
aggregation of tau, associated with neuronal toxicity (Cruz et al., 2003). 
Also implicated in the pathogenesis of AD are members of the MAPK cascades. 
Activation of p38 MAPK in AD has been suggested to contribute to 
inflammatory processes in microglia and astrocytes (Munoz and Ammit, 2010) 
and to be involved in tau phosphorylation (Hanger et al., 2009b). 
Protein kinases have an important role in the regulation of synaptic plasticity (see 
section 1.5.3.4). Aβ treatment of cells reduces the activity of Ca2+/ calmodulin-
dependent protein kinase II (CaMKII) and the phosphoinositide 3-kinase/ protein 
kinase B (PI3K/PKB) pathway (Townsend et al., 2007) and in this way Aβ can 
indirectly modulate LTP. The reduction in the activity of PKB prevents the 
inhibitory phosphorylation of GSK3 leading to its activation (Hernandez et al., 
2010). Recently, GSK3 has been shown to play an important role in synaptic 
plasticity with inhibition of the kinase necessary for the induction of LTP 
(Hooper et al., 2007) and activation required for LTD (Peineau et al., 2007). In 
this way, GSK3 may contribute to the alterations in hippocampal synaptic 
plasticity and subsequent memory deficits which are a feature of mouse models 
of AD. 
 
1.3.5: Insulin signalling in AD 
 
 
Insulin receptors are expressed in many parts of the brain and physiological roles 
for insulin action on the brain are starting to be more clearly defined. In addition, 
exposing primary neuronal cultures to low levels of insulin can be 
neuroprotective, reducing vulnerability to oxidative stress and ischaemic damage 
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(Duarte et al., 2008, Sun et al., 2010), while culturing neurons in high insulin is 
neurotoxic (Noh et al., 1999). This has led to the hypothesis that disrupted 
neuronal insulin action may underlie the link between diabetes and 
neurodegenerative disorders. There are three potential mechanisms proposed, 
firstly that lifestyle factors promote a decline in the insulin sensitivity of the 
brain, in line with the peripheral tissues, leading to loss of protective/vital actions 
of insulin on neurons/synapses (Steen et al., 2005); secondly that the 
hyperinsulinemia that occurs due to insulin resistance reduces insulin transport 
across the blood brain barrier generating insulin deficiency in the brain (Urayama 
and Banks, 2008); and thirdly that hyperinsulinemia in the periphery generates 
hyperinsulinemia in the brain promoting neuronal damage (Cole et al., 2007a). It 
remains to be seen which, if any, of these mechanisms contributes to the 
development of dementia. 
 
1.3.6: The role of tau 
 
 
Although somewhat neglected due to the prominence of Aβ in the study of AD, 
tau plays an important role in the progression of the disease. The best 
pathological correlation of the cognitive deficits present in AD is the extent of 
neurofibrillary tangle deposition within the brain (Giannakopoulos et al., 2003). 
Familial mutations in the tau gene which cause an increase in tau filament 
formation do not result in AD, but in a form of dementia called frontotemporal 
dementia and parkinsonism linked to chromosome 17 (FTDP-17). In transgenic 
mouse models the expression of a familial tau transgene alone results in marked 
neuronal death (discussed in section 1.4.2). This shows that the aggregation of 
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tau is a critical event in the progression of forms of dementia including AD, and 
so AD could be considered a specific form of tauopathy. 
Oligomerisation of tau is enhanced by hyperphosphorylation of the protein which 
increases its propensity to form filaments. This results in not only a loss of the 
normal function of tau in stabilising microtubules but also a toxic gain of 
function as it sequesters normal tau and other microtubule-associated proteins to 
cause further disruption of microtubule function (Alonso et al., 1997). This 
results in compromised axonal function, synapse loss and neuronal degeneration 
(Alonso et al., 2010). It has been suggested that oligomeric tau may have a 
deleterious role on other cellular processes such as actin binding and cellular 
signalling, and cause mitochondrial dysfunction as a result of impaired 
intracellular transport (Gendron and Petrucelli, 2009). However, the exact 
mechanisms by which tau mediates its neurotoxic effects are not currently 
understood. The tau present in neurofibrillary tangles is relatively inert and does 
not appear to cause cellular death, and it is proposed that tangle formation may 
act as a neuroprotective mechanism by removing oligomeric tau forms (Lee et al., 
2005).  
Although tau pathology is widely thought to be downstream of amyloid 
pathology, it may still play a key role in the generation of the cognitive deficits 
observed in the disease. For example, clearance of soluble Aβ by immunization 
does not improve cognitive deficits in the 3xTg mice, with reduction of both Aβ 
and soluble tau required for improvement in performance on a memory task 
(Oddo et al., 2006b). Similarly, the reduction of tau levels in APP-
overexpressing mice leads to an improvement in cognitive symptoms (Roberson 
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et al., 2007). Therefore, it is clear that the contributions of Aβ and tau to the 
progression of AD are closely linked and both should be considered in models of 
the disease. 
 
 
1.4: Transgenic mouse models of AD 
 
 
Multiple different mouse models have been generated using familial AD 
mutations as a basis (see Tables 1.2, 1.3). Although these models do not 
completely replicate all aspects of the disease, they have been useful in 
understanding some of the mechanisms involved in the progression of AD.  
Mice are a particularly attractive model system due to their relatively easy 
genetic manipulation, short lifespan and ease of breeding. They can be 
engineered to develop specific pathological features which closely mimic aspects 
of human AD, and they perform well in cognitive tasks which involve areas of 
the brain affected by AD in humans, such as the hippocampus.  However, there 
are a number of caveats and limitations which must be considered. 
In the majority of mouse models of AD, including the 3xTg and TASTPM 
models, the transgene construct, comprising the gene of interest, enhancer and 
promoter regions, is microinjected into the nucleus of a mouse ovum and 
integrates randomly into the genome. Disadvantages of this approach include the 
insertion of the transgene into other gene sequences potentially altering 
regulation of those sequences, and the influence of surrounding sequence regions 
on transgene expression, with effects such as gene silencing. The insertion of 
multiple transgene copies is common, resulting in different levels of the gene 
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product being produced and the possibility of excessive overexpression (Nature 
Online, Cell Migration Gateway). For this reason, most models are generated 
using multiple founder lines which are individually characterized. Another 
approach, used in the generation of the PS1 M146V knock-in model (Guo et al., 
1999), is the targeted knockin approach. A culture of embryonic stem cells is 
exposed to the vector containing the gene of interest and a neomycin resistance 
gene. In some cells this gene will be taken up and inserted into the mouse 
genome by homologous recombination; these cells can be selected by the use of 
neomycin then injected into a mouse blastocyst. An advantage of this approach is 
the integration of the transgene at a known site, and of a single copy only. 
However, this method is more time consuming and technically difficult (Nature 
Online, Cell Migration Gateway). 
When generating mouse models, the choice of promoter is important as it drives 
the regional expression of pathology. The commonly used promoters are Thy-1, 
platelet-derived growth factor β (PDGF-β) and the mouse or hamster prion 
protein (PrP) promoter which are considered neuron-specific. However, each has 
its own region-specific expression.  For example, Thy-1 is expressed in the 
highest levels in the hippocampus and striatum, followed by the cortex and 
cerebellum (Seki et al., 2002). For a model of AD, it is desirable that the 
promoter produces an expression pattern which mimics that of the protein in the 
human disease. 
The background strain must also be carefully considered as there are biochemical 
and behavioural differences between a number of commonly used inbred mouse 
strains. For example, in the Morris water maze (MWM) task, C57BL/6 mice 
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perform better than DBA2 mice, and use a different search strategy which is 
associated with alterations in hippocampal gene expression (Sung et al., 2008). 
Strain-dependent differences in a range of behavioural tasks, such as the elevated 
plus maze and object recognition tasks, are widely reported (Brooks et al., 2005). 
Linked to this, electrophysiological studies show altered induction and 
maintenance of  LTP between a number of commonly used strains such as 
C57BL/6 and 129/Sv (Nguyen 2006). Unfortunately, the use of one single strain 
is not without its difficulties, as C57BL/6 sub-strains with different genetic 
backgrounds also show behavioural differences (Matsuo et al., 2010). Due to this, 
the choice of transgenic background strain must be carefully considered when 
choosing behavioural readouts, and reported in detail.  
One of the difficulties with transgenic mouse models of this disease is that they 
do not fully replicate all aspects of AD. APP transgenic mice develop plaques, 
cognitive deficits and related pathological changes such as inflammation. 
However, one of the major features of human AD is marked neuronal loss 
resulting in atrophy of the brain (Terry et al., 1981). So far, there is no 
convincing evidence for the presence of this feature in any transgenic models. In 
addition, the marked overexpression of human APP required for plaque 
formation does not result in the generation of tangle pathology in the mouse. 
Only with the presence of both an APP and tau mutation, as in the 3xTg mouse, 
are both plaques and tangles apparent (Oddo et al., 2003).  
All transgenic mouse models that have been generated have focused, by 
necessity, on the familial mutations associated with AD. It is possible that 
although the initiating mechanisms vary between sporadic and familial AD this 
  
55 
results in the same pathogenic endpoint. However, in studies designed to identify 
a treatment to prevent the early development of features of the disease there may 
be critical differences between sporadic and familial AD. For this reason, mouse 
models of the sporadic form of AD are desperately needed, along with a renewed 
focus on gene-environment interactions in transgenic mice, which look at the 
effects of stress, exercise and other ‘lifestyle’ factors on the development of 
pathology. 
Despite their limitations, transgenic mouse models have provided much valuable 
information about the pathology of AD and greatly contributed to the 
advancement of the field. The models available can be broadly divided into three 
groups: single transgenic mice, expressing APP, PS1 or tau, double transgenic 
mice, expressing APP and PS1, and the triple transgenic mouse, expressing all 
three transgenes. The following sections will describe some of the most 
commonly used mouse models, their phenotype, and relevance to the disease. A 
summary table of single transgenic mouse models is presented in Table 1.2 and 
double/ triple transgenic models in Table 1.3. 
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Table 1.2: Selected single transgenic mouse models of AD  
 
Model Mutation Promoter Background Pathology (age 
in months) 
Behavioural 
phenotype (age in 
months) 
Electrophysiology 
studies (age in 
months) 
References 
Tg2576 APP695 
K670N 
/M671L 
(Swedish) 
Hamster 
prion 
C57BL/6SJL 
x C57BL/6 
Soluble Aβ (6) 
Amyloid 
plaques (12-18)  
Impairment in Y-
maze(3) 
and MWM (9) * 
 
 
Reduced basal 
transmission (5) * 
Reduced LTP (5) * 
 
 
Hsiao et al 1996 
Jacobsen et al. 2006 
Lesne et al. 2006 
Westerman et al. 2002 
PDAPP APP(all 
isoforms) 
V717F 
(Indiana) 
PDGF-β C57BL/6 x 
DBA2 
Amyloid 
plaques (6-9) 
Hippocampal 
atrophy (3) 
Impairment in 
MWM (6 – 18) 
Object recognition 
(6) 
Reduced LTP (4) * 
Reduced basal 
transmission (8) 
Chen et al. 2000 
Dodart et al. 1999 
Games et al. 1995 
 
CRND8 APP695 
K670N 
/M671L and 
V717F 
Hamster 
prion 
C3H/HeJ x 
C57BL/6 
Aβ deposition 
(3) 
Amyloid 
plaques (3-5) 
Impairment in 
MWM (3) 
Reduced seizure 
threshold 
Reduced basal 
transmission (5) 
Increased LTP (5) 
Increased synaptic 
excitability 
Chishti et al. 2001 
Del Vecchio et al. 2004 
Jolas et al. 2002 
 
PS1 
knockin 
PS1 M146V  129/Sv x 
C57BL/6 
None None Reduced basal 
transmission (6) 
Increased LTP (6) 
Alterations in Ca2+ 
signalling 
Guo et al. 1999 
Oddo et al. 2003 
Stutzmann et al. 2006  
Wang et al. 2004 
 
JNPL3 Tau P301L Mouse 
prion 
C57BL/6 x 
DBA2 x SW 
Neurofibrillary 
tangles (4-7) 
Progressive motor 
disturbances 
 Gotz et al. 2001 
* Differences reported by other experimental groups (see text) 
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1.4.1: Single transgenic models: APP 
 
 
Single transgenic APP mice express a human APP transgene with one of a 
number of familial AD mutations. There are a vast number of models now 
available using different mutations, promoters or strains; all develop plaque 
pathology and cognitive deficits, but the time course of these events is variable. 
Some of the most commonly studied models have subsequently been used in 
crosses with mice expressing other transgenic proteins in an attempt to replicate 
more fully the pathological features of AD.  
The PDAPP mouse was the first model to be generated, which expresses the 
V717F (Indiana mutation) under the PDGF-β promoter, resulting in a selective 
increase in Aβ42 levels. This mouse develops plaque pathology by 6-9 months in 
the hippocampus and, though it does not show neuronal loss, is one of the few 
models with hippocampal atrophy (Games et al., 1995). It shows age-
independent deficits in the Morris water maze (MWM), a spatial learning task 
which is thought to be hippocampal-dependent, and age-dependent deficits in 
object recognition memory from 6 months, which correlate with the development 
of amyloid plaque pathology (Dodart et al., 1999, Chen et al., 2000). 
Electrophysiological studies have shown a reduction in basal synaptic 
transmission from mice as young as 1 month suggesting there are age-
independent deficits associated with the expression of the transgene (Hsia et al., 
1999). The same study found no impairment in LTP in the hippocampal cornu 
ammonis 1 (CA1) region at 8 months, in contrast with another study which found 
a more rapid decline in LTP from 4 months (Hsia et al., 1999, Larson et al., 
1999). A lack of consensus, particularly in electrophysiological studies, between 
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research groups represents one of the difficulties in working with these 
transgenic models. 
Another widely used model is the Tg2576 mouse, which expresses the APP695 
isoform with the K670N/M671L (Swedish mutation) under the hamster PrP 
promoter. This results in overexpression of both Aβ40 and Aβ42 leading to plaque 
generation. The Tg2576 mouse develops plaques relatively late on in the lifespan, 
from between 12 and 18 months in the cortex and hippocampus (Hsiao et al., 
1996). The large number of studies using this mouse have resulted in a number 
of disparate findings which may in part be due to the use of different behavioural 
tests and electrophysiological protocols. For example, deficits were observed in 
the MWM at 9 months by one group, but this was not replicated in another study, 
although deficits were reported at 3 months in a Y-maze spatial task (Hsiao et al., 
1996, King et al., 1999). In studies of synaptic plasticity, reduced basal synaptic 
transmission has been reported from 5 months, but this was not observed at 15 
months in another study (Chapman et al., 1999a, Jacobsen et al., 2006), while 
LTP in aged mice (over 12 months) is reduced in several studies (Chapman et al., 
1999a, Mitchell et al., 2009) but unimpaired in another (Fitzjohn et al., 2001). In 
the Tg2576 mouse, the late onset of plaque deposition and the lack of correlation 
between memory deficits and insoluble amyloid (Westerman et al., 2002) has 
been used to provide evidence for the toxicity of soluble, oligomeric forms of Aβ 
in AD.  
Finally, the CRND8 mouse model expresses the APP695 isoform with both the 
K670N/M671L (Swedish) and V717F (Indiana) mutations. Due to the 
combination of two familial mutations this mouse develops early and marked Aβ 
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deposition from the age of 3 months which is accompanied by premature 
mortality (Chishti et al., 2001). In addition, cognitive deficits in the MWM are 
observed at this early age (McCool et al., 2003). Interestingly, although reduced 
basal synaptic transmission is observed in these mice, LTP is increased in 
magnitude at 5 months of age. This has been linked to altered neuronal 
excitability, with a reduction in GABAergic and enhancement in glutamatergic 
function (Jolas et al., 2002). In support of this, CRND8 mice show an enhanced 
susceptibility to seizures induced by pentylenetetrazole, a GABA receptor 
antagonist (Del Vecchio et al., 2004). This suggests that changes in hippocampal 
network function and an alteration of the balance between excitatory and 
inhibitory transmission may occur in APP transgenic mice. 
 
1.4.2: Single transgenic models: tau 
 
 
There are several transgenic models developed which express familial tau 
mutations. However, mutations in tau are not observed in human AD, but in 
other forms of dementia such as frontotemporal dementia (Hutton et al., 1998). 
In addition, tangle pathology is observed in a number of neurodegenerative 
conditions (classified as ‘tauopathies’) such as corticobasal degeneration and 
progressive supranuclear palsy which generally involve a component of 
movement disorder. 
Tau mutant mice develop marked motor deficits, a feature characteristic of other 
tauopathies and not generally observed in AD. For example, the JNPL3 mouse, 
which expresses the tau P301L mutation under the mouse PrP promoter, shows 
degeneration of motor neurons in the spinal cord, neuropathy and muscular 
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atrophy. Neurofibrillary tangles are apparent in regions not widely affected in 
AD such as the brainstem and cerebellum (Lewis et al., 2000). Severe motor 
impairments occur from the age of 6 months which progress rapidly to a terminal 
state within 4-5 weeks.  
The JNPL3 mouse does however develop several features which mimic those 
observed in AD. Hyperphosphorylation of tau occurs at several AD-related 
epitopes, such as the AT8 epitope, and tau deposition is observed in the cortex, 
hippocampus and amygdala (Gotz et al., 2001). This suggests that tau mutant 
mice might be useful for studying aspects of AD pathology; for example the 
JNPL3 mouse has been used in the study of tau filament formation (Sahara et al., 
2002). 
The primary value of tau transgenic mice in AD research has been to study the 
interactions between Aβ and tau. For example, injection of Aβ fibrils exacerbates 
pathology in the JNPL3 mouse, resulting in a fivefold increase in tangles in the 
amygdala (Gotz et al., 2001). In another study, a cross between Tg2576 and the 
JNPL3 mouse results in an enhancement of neurofibrillary tangle pathology 
when compared to the tau mutants alone (Lewis et al., 2001), showing that Aβ 
overexpression can interact with tau protein to cause an enhancement of tangle 
pathology. 
 
1.4.3: Single transgenic models: presenilin 
 
 
Mouse models have been generated using a number of mutations in the PS1 gene 
such as M146V or M146L, PS1∆e9 (exon 9 deleted), and A246E. Although 
human mutant PS1 expression in mice causes a selective increase in the levels of 
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Aβ42 (Sudoh et al., 1998),  this does not result in the development of plaque or 
tangle pathology. The homozygous PS1 M146V knockin mouse shows no overt 
biochemical or cognitive phenotype (Guo et al., 1999). However, these mice 
appear to have an enhanced susceptibility to excitotoxicity, with an increased 
vulnerability to seizure-induced neurodegeneration in vivo and glutamate-
induced toxicity in hippocampal culture (Guo et al., 1999). In addition to this, 
they have been shown to possess alterations in intracellular Ca2+ signalling 
(Stutzmann et al., 2006). Studies of synaptic function have shown a reduction in 
basal synaptic transmission at 6 months, but an enhancement in PPF and the 
initial phase of LTP, which involve Ca2+-mediated signalling (Oddo et al., 2003). 
A similar phenotype of facilitated LTP and enhanced excitotoxicity is observed 
in another PS1 model, A246E (Schneider et al., 2001). Therefore, PS1 mutant 
mice may be useful for studying the role of Ca2+ in the pathogenesis of AD.  
In addition to this PS1 transgenic mice have been used in the generation of 
multiple other models, including the 3xTg mouse, and these are discussed in the 
following sections. 
 
1.4.4: Double transgenic models  
 
 
The two most commonly used APP x PS1 mice are the PSAPP and the TASTPM 
models. Biochemical and electrophysiological characterisation of the TASTPM 
mouse is a focus of this thesis. 
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Table 1.3: Selected double/triple transgenic mouse models of AD  
 
Model Mutation Promoter Background Pathology (age in 
months) 
Behavioural 
phenotype (age 
in months) 
Electrophysiolog
y studies (age in 
months) 
References 
PSAPP APP695 
K670N/ 
M671L x 
PS1M146V 
PDGF-β/ 
prion 
promoter 
C57BL/6 x 
DBA2 
Amyloid plaques 
(3-6)  
Impairment in 
radial arm water 
maze (15) 
 Holcomb et al. 
1998 
Gordon et al. 2001 
McGowan et al. 
1999 
 
TASTPM APP695 
K670N/ 
M671L 
(TAS10 
line) x PS1 
M146V 
Thy-1 C57BL/6 x 
C3H 
backcrossed 
to C57BL/6 
Aβ deposition (3) 
Amyloid plaques 
(6) 
Deficits in object 
recognition (6) 
Aggression 
Premature 
mortality 
Alterations in 
intracellular Ca2+ 
signalling 
Goussakov et al. 
2010 
Howlett et al. 2004 
Howlett et al. 2008 
Pugh et al. 2006 
3xTg APP695 
K670N/ 
M671L, 
TauP301L x 
PS1M146V 
Thy-1 C57BL/6 x 
129X1/SvJ 
x 129S1/Sv 
Soluble Aβ(3-9)* 
Amyloid plaques  
(6-12)* 
Tau 
hyperphosphory-
lation (6-12)* 
Tangles (18) 
Deficits in 
MWM (4-6)* 
Increased 
contextual fear 
conditioning (6) 
Reduced basal 
transmission (6)* 
Reduced LTP 
(6)* 
Billings et al. 2005 
Espana et al. 2010 
Hirata-Fukae et al. 
2008 
Mastrangelo et al. 
2008 
Oddo et al. 2003 
 
* Differences reported by other experimental groups (see text) 
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The cross of an APP and PS1 transgenic mouse results in the acceleration of Aβ 
pathology. For example, the PSAPP mouse, generated by crossing the Tg2576 
(APPSwe) with the PS1 M146V model, shows the onset of plaque deposition at 3 
months in the cortex and hippocampus, with extensive deposition by 6 months, 
(McGowan et al., 1999). This is markedly faster than in the single transgenic 
Tg2576, and the PSAPP mice show a four- to six-fold elevation of Aβ42 levels 
due to the presence of the PS1 mutation (Holcomb et al., 1998). 
The TASTPM mouse was generated by a cross of the PS1 M146V mouse with 
the previously generated TAS10 line, which expresses the APP695 
K670N/M671L (Swedish) mutation under the Thy-1 promoter on a C57BL/6 
background. The TAS10 mouse shows Aβ deposition from the age of 12 months 
in hippocampus and cortex, which increases progressively to the age of 24 
months. Cognitive deficits are present in the MWM from 6 months, when initial 
structural changes are observed such as dystrophic neurites and activated 
microglia (Richardson et al., 2003). In electrophysiological studies at 12 months, 
these mice show impaired basal synaptic transmission but normal LTP induction, 
with altered synchronous activity suggesting a disruption of neuronal network 
function in the hippocampus (Brown et al., 2005). 
The development of Aβ deposition occurs more rapidly in the TASTPM model 
than in the parent TAS10 line. At 3 months of age, amyloid deposition is 
apparent in the cortex, with mature plaques developing by 6 months; by 6-8 
months the plaque levels are similar to those observed in 16 month TAS10 mice. 
There is a gender-dependent difference, with Aβ load higher in female mice at all 
ages studied (Howlett et al., 2004). Other pathological features include neuronal 
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loss in the vicinity of amyloid plaques and hyperphosphorylated tau associated 
with dystrophic neurons (Howlett et al., 2008a); this shows that in mice 
overexpression of mutant APP in combination with mutant PS1 can induce 
biochemical changes in wild type tau. 
In comparison to the widely studied 3xTg model there have been relatively few 
electrophysiological or behavioural studies of the TASTPM mice. These mice 
show a marked behavioural phenotype characterised in males by a high level of 
aggression which requires individual housing. They also exhibit weight loss, 
despite a higher food intake, and premature mortality which is particularly 
apparent in female mice.  In addition, they show alterations in circadian rhythm, 
disinhibition and locomotor hypoactivity (Pugh et al., 2007). This has been 
suggested to replicate some of the behavioural alterations in human AD, such as 
a fragmented sleep-wake cycle and personality changes such as irritability and 
aggression, however it is difficult to make correlations between mouse and 
human behaviour. 
Studies of cognitive behaviour in the TASTPM mouse have shown deficits in the 
hippocampal and cortical-dependent novel object recognition task from the age 
of 6 months (Howlett et al., 2004). At this age, there is marked amyloid 
deposition with mature plaque formation, suggesting these mice require a 
significant Aβ load before cognitive deficits are observed in this task. 
Electrophysiological studies have shown a marked reduction in basal synaptic 
transmission in the TASTPM mice at the age of 8 months (Spencer et al., 2004) 
similar to that observed in the parent TAS10 line (Brown et al., 2005). In 
addition, these mice show an alteration in intracellular Ca2+ signalling, likely due 
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to the presence of the PS1 mutation (Goussakov et al., 2010). This suggests that 
there are alterations in synaptic function in the TASTPM mice which have not 
been fully characterised. 
 
1.4.5: The triple transgenic (3xTg) mouse 
 
 
The triple transgenic (3xTg) mouse is the primary mouse model investigated in 
this thesis. It was generated at the University of California, Irvine, by a group led 
by Dr. Frank LaFerla. A homozygous PS1M146V mutant mouse was used which 
was developed from a hybrid C57BL/6 x 129/Sv strain. cDNA constructs 
containing an hAPP K670N/M671L Swedish mutation and a P301L tau mutation 
were microinjected into the embryos of these mice and expressed using the 
Thy1.2 neuronal-specific promoter to produce a triple APPK670N/M671L, TauP301L 
and PS1M146V mouse. In the founder line, these integrated at the same locus, 
allowing co-transmission of the transgenes. The homozygous mouse shows a 3-4 
fold increased steady state level of APP and a 6-8 fold increased level of tau 
above endogenous levels in the brain (Oddo et al., 2003). 
 
1.4.5.1: Pathological features of the 3xTg mouse: amyloid pathology 
 
 
The pathology in these mice has been extensively characterised, but there are 
some discrepancies in the findings, in particular between studies from distinct 
groups. It was originally reported that intraneuronal Aβ reactivity was present at 
3-4 months in the cortex and by 6 months in the CA1 region of the hippocampus. 
Within the hippocampus the majority of neurons expressing intraneuronal Aβ 
may be outside the pyramidal layer and instead within the stratum oriens, 
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subiculum and corpus callosum (Mastrangelo and Bowers, 2008). The 
intraneuronal Aβ is monomeric until around 4-6 months of age, at which stage it 
may begin to oligomerise within the neurons (Oddo et al., 2006a). However, a 
recent paper has suggested that the intraneuronal Aβ is not present as a free 
peptide but as the uncleaved peptide within the APP protein, which the majority 
of antibodies are unable to distinguish between (Winton et al., 2011), and that 
free Aβ may not be required for pathogenesis in these mice. Extracellular plaques 
begin to develop at 6 months in the frontal cortex and are clearly apparent by 12 
months, when plaques begin to develop in other regions of the cortex and 
hippocampus (Oddo et al., 2003); plaque pathology initiates at the interface 
between the subiculum and CA1 region before spreading to involve the entire 
hippocampus (Mastrangelo and Bowers, 2008). España et al., (2010) also 
observed intraneuronal Aβ at 6 months in the cortex and hippocampus, with 
plaques present by 12 months. Interestingly, they highlight the importance of the 
basolateral amygdala in the pathological staging as this region shows the highest 
levels of intraneuronal Aβ at 6 months. Intraneuronal Aβ is also present within 
midbrain and brainstem regions from the age of 2 months (Overk et al., 2009).  
The development of pathology is reported by others to occur more slowly than 
originally reported. Hirata-Fukae et al. (2008) observed intraneuronal Aβ at 6 
months in the cortex and 9 months in the hippocampus, a full 3 months later than 
the original report. Mastrangelo et al. (2008) observed the early development of 
intraneuronal Aβ from the age of 2 months but report no plaque pathology within 
the hippocampus until mice are older than 15 months of age, and none within the 
cortex until 18 months of age. 
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The late onset of plaques was also observed by Hirata-Fukae et al. (2008) who 
did not report their development until the age of at least 14 months, and initially 
only in female mice, in contrast with the original study by Oddo et al. (2003) 
who observed no gender-dependent differences in brain pathological features. 
More pronounced pathology in female mice has also been reported by Overk et 
al., (2009) who observed plaques in the pons of female mice only at the age of 9 
to 12 months. Hirata-Fukae et al. (2008) suggest that an upregulation of Aβ 
production, as measured by soluble levels, and a reduction in the activity of the 
Aβ degrading enzyme neprilysin may be the cause of the more severe 
pathological features in females.  
Although the exact time course remains unclear, it is therefore evident that 
intraneuronal Aβ accumulation precedes plaque deposition by a number of 
months with plaque formation a relatively late event in the lifespan of this model. 
In addition, the amyloid pathology shows a region-specific progression within 
the mouse brain, affecting the cortex first and followed by the hippocampus.  
 
1.4.5.2: Pathological features of the 3xTg mouse: tau pathology 
 
 
Tau pathology occurs initially with somato-dendritic accumulation (Clinton et al., 
2007) and sequential phosphorylation of multiple residues, which can be shown 
using antibodies raised against the different phosphorylatable sites on the tau 
protein. At 6 months, increased phosphorylation is present at sites recognised by 
the AT100 and 12E8 sites (Thr 212/Ser 214 and Ser262) but the AT8 (Ser 202, 
Thr 205) and AT180 (Thr 231) sites are not phosphorylated until 12-15 months, 
along with conformational changes detected by the MC1 antibody (Oddo et al., 
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2003). Neurofibrillary tangles, to which the PHF-1 antibody reacts, are not 
evident until 12 - 18 months of age. In contrast to the APP pathology, which 
initiates in the cortex and then spreads to the hippocampus, the tau pathology is 
first apparent in the hippocampus, in particular the neurons of the CA1 region, 
and develops to involve the cortex (Oddo et al., 2003, Oddo et al., 2007). The 
development of biochemical changes in tau is not thought to show any gender-
dependent differences (Hirata-Fukae et al., 2008). It is generally accepted that 
tau hyperphosphorylation and tangle generation occurs much later than the 
development of amyloid pathology, but again there are some discrepancies 
between groups. Mastrangelo et al. (2008) observed AT180 staining suggesting 
phosphorylation of Thr231 as early as six months of age in the hippocampus, in 
contrast with Oddo et al. (2007) who observed such phosphorylation at 12 
months. This group also failed to observe substantial tangle pathology until the 
late age of 23 months although they did detect some PHF-1 reactivity at 15 
months within the hippocampus, a similar age to Oddo et al. (2007).  One group 
has detected multiple phospho-tau isotopes, including AT180, as early as three 
weeks of age in the amygdala and cortex, although tangles do not appear until the 
age of 23 months (Oh et al., 2010). There is a general consensus that the tangle 
pathology appears late in the lifespan of the mouse but the expression of 
phosphorylated tau epitopes may be time and brain-region specific and vary 
between individual colonies of 3xTg mice.  
 
1.4.5.3: Pathological features of the 3xTg mouse: other alterations 
 
 
An important feature that should be replicated in a mouse model of AD is the 
presence of an inflammatory response at sites adjacent to amyloid deposition. 
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Localised inflammation surrounding plaques is observed in AD and is 
characterised by the presence of activated microglia and astrocytes. In the 3xTg 
mouse there is a progressive increase in activated microglia with age, although 
this occurs relatively late in the lifespan from the age of 12 months (Kitazawa et 
al., 2005). However, there is no alteration in the levels of activated astrocytes 
with age (Mastrangelo and Bowers, 2008). This shows that in the 3xTg model 
there is a limited inflammatory response; however, this may still mirror some 
aspects of this feature of human AD.  
Alterations in adult neurogenesis (Rodriguez et al., 2008, Hamilton et al., 2010), 
serotonergic function (Noristani et al., 2010), and the presence of dendritic spine 
loss (Bittner et al., 2010) have also been observed in this model. However, 
further studies are required to understand the relevance of each of these features 
and how they relate to the cognitive and electrophysiological deficits observed. 
Also widely reported are alterations in neuronal Ca2+ homeostasis, with an 
increase in resting Ca2+ levels and enhanced ryanodine receptor (RyR)-mediated 
Ca2+ release (Stutzmann et al., 2006, Lopez et al., 2008). This may be due to the 
presence of the PS1M146V mutation and may result in modulation of synaptic 
plasticity, which is discussed further in Chapter 3. 
 
1.4.5.4: Behavioural phenotype of the 3xTg mouse 
 
 
A number of studies have analysed the learning ability and general behaviour of 
3xTg mice in an attempt to correlate deficits in these measures with the time 
course of the development of pathology. 
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3xTg mice, unlike the TASTPM strain, do not show abnormally aggressive 
behaviour and are reasonable docile and easy to handle. Young 3xTg mice 
appear healthy, with no apparent increase in premature mortality. At the age of 6 
months, 3xTg mice have a significantly higher body weight than their control 
counterparts and this is accompanied by an increased food intake. In contrast, 12 
month mice, despite an increased food intake, show reduced body weight and an 
increase in metabolic rate (Knight et al., 2010). There are also circadian rhythm 
changes prior to 6 months of age, with both male and female mice showing 
decreased nocturnal behaviour compared with control. Males show greater 
locomotor activity during the day and females a decrease in activity levels during 
their normal active phase (Sterniczuk et al., 2010b). These behavioural 
abnormalities occur at ages before the development of major plaque and tangle 
pathology.  
 
1.4.5.5: Cognitive testing of 3xTg mice 
 
 
3xTg mice show no impairment of performance in the MWM at 2 months but at 
4 months show retention deficits from day to day during acquisition training and 
deficits in a 24 hour probe trial, showing impaired long-term memory. By 6 
months the mice also have impairment in a 1.5 hour probe trial, showing that by 
this age they have marked deficits in spatial reference memory (Billings et al., 
2005). There is a gender-dependent effect on this task, with females showing 
poorer performance than males, possibly linked to an increased stress response 
and corticosterone levels (Clinton et al., 2007). A further study has shown that 
previous experience of testing at 2, 6 and 9 months can markedly improve 
performance in the MWM of 12 month 3xTg mice, with experienced mice 
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showing a reduced plaque load at 12 months and decreased phosphorylation of 
tau compared with naïve mice (Billings et al., 2007). In the novel object 
recognition task the 3xTg mice show impaired performance at the age of 12 
months (Arsenault et al., 2011), an age at which amyloid deposition should be 
well established within the hippocampus. 
3xTg mice have also been tested in a contextual fear conditioning task, in which 
a freezing response is elicited from a tone or light which was previously paired 
with a footshock; this involves both the hippocampus and amygdala. At 6 months, 
3xTg mice show improved performance when compared to control, characterised 
by an increased freezing response when tested 24 hours after the initial footshock. 
This may be associated with the increased anxiety behaviour observed in these 
mice (see Chapter 5), as they also show enhanced freezing behaviour when first 
placed in the test chamber (Espana et al., 2010).  
Finally, a recent study has used a five-choice serial reaction time test, which 
involves the mouse reacting to a light stimulus by pressing a touchscreen to 
subsequently receive a food reward (Romberg et al., 2011). 9 month old 3xTg 
mice are impaired in this task and this may represent a deficit in attention, 
mediated by cholinergic inputs to the frontal cortex, as these effects are rescued 
by the cholinesterase donepezil. In addition, 3xTg mice show a higher rate of 
perseverative responses (i.e. the continued repetition of behaviour in the absence 
of the stimulus). It has been suggested that alterations in behavioural measures 
such as attention may also influence the performance of 3xTg mice on other 
cognitive tasks. 
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In summary, the behavioural phenotype of this model has been extensively 
examined but these studies did not attempt to link synaptic or 
electrophysiological deficits to the appearance of behavioural deficits. 
 
 
1.5: The hippocampus 
 
The hippocampus is a region of the brain important in memory processes, 
including the retention of spatial information and memory for recent events. It is 
also one of the earliest regions to be affected by tau pathology in AD and is 
thought to contribute to the early memory deficits which are a symptom of the 
disease. Forms of synaptic plasticity such as long-term potentiation (LTP), 
thought to be a cellular correlate of memory, have been widely studied, with 
alterations in the magnitude of LTP associated with cognitive deficits in mouse 
models of AD. The following sections describe the anatomy of the hippocampus, 
its role in memory processes and the molecular mechanisms of synaptic plasticity. 
 
1.5.1: Structure and anatomy of the hippocampus  
 
 
The hippocampus is a paired structure located within the medial temporal lobe of 
the brain. It has a curved appearance, resembling the body of a seahorse, which 
gives the region its name. This structure is unique within the brain as it possesses 
a mainly unidirectional neuronal circuit which lies within the same orientation, 
allowing the experimental preparation of hippocampal slices in which the 
synaptic contacts are largely preserved. A diagram of the hippocampus (sagittal 
orientation) is shown in Fig. 1.5.  
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Figure 1.6: Sagittal section of the rodent hippocampus. Input comes from the 
EC via the perforant path where it synapses with DG granule cells. The granule 
cells project to the CA3 region via the mossy fibres and synapse with the 
pyramidal cells in this region. CA3 pyramidal cells then project to the CA1 
pyramidal cells via the Schaffer collateral-commissural pathway. This pathway is 
primarily unidirectional and is so often called the ‘trisynaptic pathway’.  
 
Abbreviations: EC (entorhinal cortex), DG (dentate gyrus), CA3 (cornu ammonis 
3), CA1 (cornu ammonis 1). 
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 The primary input pathway to the hippocampus occurs through the entorhinal 
cortex (EC) which projects to the dentate gyrus (DG) through the perforant 
pathway. In addition, the EC provides an output pathway for information leaving 
the hippocampus through the subiculum. The EC projects widely to a number of 
other cortical regions, including the piriform, temporal and frontal cortex 
(Burwell and Amaral, 1998) and also to other brain regions such as the amygdala 
and thalamus (Amaral and Lavenex, 2007).   
From the DG to the CA1 region the pathway is unidirectional and is often called 
the ‘trisynaptic circuit’ i.e. EC to DG, DG to CA3, CA3 to CA1. The principal 
neurons of the DG, the granule cells, project via the mossy fibre pathway to the 
CA3 (cornu ammonis 3) region where they synapse with CA3 pyramidal neurons. 
From this region, the CA3 neurons project to the CA1 pyramidal neurons via the 
Schaffer-collateral commissural pathway. The CA1 region projects both to the 
hippocampal subiculum which is linked to the EC, and the EC directly to allow 
information to leave the hippocampus. Although the primary granule cells and 
pyramidal neurons are glutamatergic, the hippocampus also contains a network 
of GABAergic interneurons which modulate neuronal transmission (Amaral and 
Lavenex, 2007).   
 
1.5.2: Function of the human hippocampus  
 
 
Studies involving patients with hippocampal lesions have shown unequivocally 
that the human hippocampus plays a critical role in aspects of memory. However, 
the concept of ‘memory’ is complex and can be divided into a number of 
subtypes, the most basic being the division between short-term and long-term 
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memory. Within the category of long-term memory are procedural memory 
(carrying out skills or motor tasks) and declarative memory (recollection of facts 
and events). It is in this latter process the hippocampus is thought primarily to be 
involved. This theory was first developed using the case of the famous patient 
H.M., who underwent bilateral removal of the medial temporal lobe as a 
treatment for intractable epilepsy. Following the procedure, he was unable to 
retain memory for new events (anterograde amnesia) or recent previous events 
(retrograde amnesia) although his short term and procedural memory were 
unaffected, along with his memory of early life events (Corkin et al., 1997). 
Short-term memory and the prolonged storage of declarative memories are 
thought to involve regions of the brain distinct from the hippocampus, such as 
the cerebral cortex (Squire and Zola-Morgan, 1991). Similar amnesia is observed 
in a number of individuals who have experienced ischaemic damage to the 
hippocampal formation (Rempel-Clower et al., 1996).  
Overall, data supports the existence of a ‘medial temporal lobe memory system’ 
consisting of the hippocampus, EC and adjacent parahippocampal cortex, 
involved in the acquisition of facts (semantic memory) and events (episodic 
memory (Squire and Zola-Morgan, 1991)). Another widely studied function of 
the hippocampus is its role in spatial memory and processing. The existence of 
hippocampal place cells, which encode spatial location, has been demonstrated 
and widely studied in the mouse and rat. Performance in tasks such as the Morris 
water maze (MWM), in which the animal must form a spatial representation of a 
pool, is impaired in rats with hippocampal lesions (Morris et al., 1990). In 
humans, a subset of neurons within the hippocampus fire in response to specific 
spatial locations (Ekstrom et al., 2003) suggesting the existence of place cells 
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within this structure. However, it has been suggested that the role of the 
hippocampus in human spatial memory is more complex and involves the 
integration of aspects such as episodic memory and contextual information 
(Good et al. 2002). 
The divergent roles of the hippocampus are consistent with damage in this region 
leading to some of the cognitive deficits observed in human AD. The EC and the 
hippocampus are one of the earliest regions to be affected by pathological 
changes such as tangle deposition (Braak and Braak, 1991). Early AD is 
primarily characterised by deficits in declarative memory, with an inability to 
learn new information and remember recent events, and this has been shown to 
correlate with the degree of hippocampal atrophy (Walker et al. 2007). Another 
early symptom is disorientation, with individuals ‘getting lost’ initially in 
unfamiliar environments but subsequently in their own homes. Damage to the 
hippocampal regions may result in an impaired memory for relevant places 
which may result in difficulties with spatial navigation. Therefore, neuronal 
damage and atrophy within the hippocampus and EC is likely to explain the 
impairments in spatial processing and anterograde amnesia in AD.  
A number of other memory impairments are also reported in AD, and this is 
reflected in the varied cognitive tests required to form a preliminary diagnosis. 
An inability to recognise objects (visual agnosia), difficulties in performing tasks 
or movements (apraxia) and language difficulties may reflect increasing cortical 
involvement in the disease (Walker et al. 2007). This shows that, although the 
hippocampus plays a critical role in human memory, a number of other brain 
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regions are damaged in AD leading to the cognitive deficits observed, 
particularly in the later stages of the disease. 
 
1.5.3: Synaptic plasticity in the hippocampus 
 
 
There are several activity-dependent forms of synaptic plasticity in the 
hippocampus which last from milliseconds to several hours, days or longer. 
Synaptic plasticity is an alteration of the efficiency of synaptic transmission, 
which may involve both increases and decreases in synaptic strength and is 
characterised by biochemical and morphological alterations of the synapse. 
Short-term forms of plasticity include paired-pulse facilitation (PPF) which 
occurs on the scale of several hundreds of milliseconds, and post-tetanic 
potentiation (PTP) which may last several minutes, while long-term potentiation 
(LTP) and depression (LTD) result in sustained changes in synaptic strength 
which may last for several hours or longer.  
 
1.5.3.1: Paired-pulse facilitation (PPF) 
 
 
Facilitation is a form of short-term synaptic enhancement which occurs over a 
period of several hundreds of milliseconds and results in an enhanced probability 
of neurotransmitter release. PPF occurs at CA1 hippocampal synapses when two 
stimuli are given within around 50 – 500ms of each other. The amplitude of the 
second synaptic response recorded is typically greater than that of the first 
stimulus. PPF is largely due to presynaptic mechanisms, in particular the 
transient increase in Ca2+ generated by an incoming action potential. The residual 
Ca2+ present in the terminal following the first stimulus is combined with the 
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Ca2+ influx occurring from the second stimulus to cause an enhancement of the 
magnitude of the second synaptic response. It has been shown that the level of 
PPF is linearly related to the concentration of residual Ca2+ within the terminal 
(Wu and Saggau, 1994).  
 
1.5.3.2: Induction of LTP 
 
 
Following an initial stimulus, an activity-dependent increase in the strength of 
synaptic transmission is observed which can be maintained for several hours or 
indeed many days in vivo. This was first observed in the anaesthetised rabbit, 
where brief high-frequency stimulation resulted in a long-lasting potentiation of 
the synaptic response obtained by stimulation of the perforant path (Bliss and 
Lomo, 1973). The clear laminar structure of the hippocampus lends itself well to 
such experiments, and over several decades the mechanisms of hippocampal LTP 
have been extensively studied. These are discussed in the following sections and 
summarised in Fig. 1.6. 
In the two most commonly studied pathways, the Schaffer collateral-
commissural pathway to CA1 pyramidal synapses and the perforant path to DG 
granule cell synapses, induction of LTP is dependent upon the activation of the 
NMDA receptor (Collingridge et al., 1983). This receptor is subject to a voltage-
dependent Mg2+ block under conditions of basal synaptic transmission. However, 
in the presence of enhanced glutamate release, Na+ influx through postsynaptic 
AMPA receptors results in a sustained depolarisation of the postsynaptic spine. 
This relieves the Mg2+ block of the NMDA receptor, allowing Ca2+ influx and the 
activation of Ca2+-dependent enzymes. Inhibitory GABAergic interneurons 
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which act on the postsynaptic spine usually act to limit depolarisation, however 
sustained depolarisation (as delivered by a LTP induction protocol) results in the 
fatigue of these interneurons through the activation of inhibitory GABAB 
autoreceptors. For this reason stimulation protocols such as the theta burst have 
been developed which deliver stimuli at the time of maximal presynaptic 
GABAB autoreceptor activation, leading to a reduction in GABA-mediated 
hyperpolarisation of the postsynaptic cell (Davies and Collingridge, 1996).  
 
1.5.3.3: Post-tetanic (PTP) and short-term (STP) potentiation  
 
 
Immediately following the induction stimulus there is an increase in synaptic 
strength which is often substantial and characteristic of PTP. This is a short term 
form of plasticity which declines within several minutes and, similar to PPF, is 
thought to depend upon the presynaptic Ca2+ concentration. Following this, the 
amplitude of the synaptic response should become stable and elevated for at least 
40-60 minutes to be considered as LTP. A return to basal synaptic strength prior 
to this period is usually considered STP, but the cutoff points vary between 
groups, as the two forms of plasticity overlap and cannot be distinguished 
without pharmacological means. STP can be generated by performing the 
stimulation protocol in the presence of broad spectrum protein kinase inhibitors 
which prevent the kinase activity necessary for LTP induction (Malenka et al., 
1989). It is thought to be a presynaptic phenomenon which decays in an activity-
dependent manner (i.e. if the input stimulation is stopped for any period of time, 
STP will resume at the same magnitude when it is restarted) and the level of STP 
varies with the strength of induction protocol used (Volianskis and Jensen, 2003). 
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1.5.3.4: Early phase LTP (E-LTP) 
 
 
The initial phase of LTP occurs as a result of the marked rise in intracellular Ca2+ 
caused by influx though NMDA receptors and other mechanisms such as 
voltage-gated Ca2+ channel activation and release of Ca2+  from internal stores 
(Alford et al., 1993). Studies of the molecular mechanisms of this process has 
been largely determined by the availability of selective inhibitors and transgenic 
models. A number of kinases have been implicated in this mechanism, although 
most play a regulatory rather than an essential role. 
Thought to be most important in LTP expression is Ca2+ /calmodulin-dependent 
protein kinase (CaMKII) which undergoes autophosphorylation when associated 
with the Ca2+ -associated form of the protein calmodulin. This results in the 
persistent activation of the enzyme despite the reduction in intracellular Ca2+ 
which occurs subsequent to LTP induction. Evidence for the role of CaMKII 
comes from studies in which a peptide inhibitor blocks LTP induction (Malinow 
et al., 1989). In addition, a transgenic mouse with a point mutation in which 
autophosphorylation of CaMKII is prevented shows a reduction of LTP in the 
CA1 region (Giese et al., 1998). Activation of CaMKII results in a cascade of 
downstream events which allow the persistent expression of LTP and are 
discussed in the following section. 
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Figure 1.7: Mechanisms of LTP. Sustained glutamate release from the 
presynaptic terminal and depolarisation of the postsynaptic terminal mediated 
by AMPA receptor activation is sufficient to relieve the Mg2+ block of the 
NMDA receptor and allow Ca2+ influx. This is subsequently enhanced by the 
entry of Ca2+ through voltage dependent Ca2+ channels and release from 
intracellular stores. Ca2+ bound to calmodulin activates the kinases CaMKII and 
PKC, which phosphorylate existing AMPA receptors and initiate the 
translocation of new receptors to the synapse. Activation of PKA and MAPK 
results in phosphorylation of the transcription factor CREB which translocates 
to the nucleus and initiates gene transcription, promoting the synthesis of new 
proteins essential for the maintenance of LTP.   
 
Abbrevations: Glu (glutamate), AMPAR (AMPA receptor), NMDAR (NMDA 
receptor), VGCC (voltage gated Ca2+ channels), P (phosphorylation). 
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A number of other kinases are thought to have a regulatory role in E-LTP. 
Protein kinase C (PKC), in particular the PKCγ isoform, may be persistently 
activated following LTP induction and may initiate an alternative kinase cascade 
in parallel with CaMKII. Inhibitors of PKC applied into the postsynaptic neuron 
can inhibit both the induction and  maintenance of LTP (Wang and Feng, 1992). 
Also implicated in LTP are protein tyrosine kinases such as fyn (Grant et al., 
1992), MAPK (English and Sweatt, 1997) and protein kinase A (PKA), although 
these are thought to have a greater role in L-LTP. 
In conclusion, there are a number of protein kinases which modulate the 
expression of E-LTP. However, the exact role of each kinase and its downstream 
effects are not fully understood. It is likely that there are multiple and 
overlapping cascades which result in a number of downstream mechanisms 
allowing the prolonged maintenance of synaptic potentiation.  
 
1.5.3.5: Postsynaptic expression mechanisms 
 
  
The most important postsynaptic expression mechanisms in E-LTP involve the 
alteration of AMPA receptor function. This occurs both through the modification 
of existing receptors and the trafficking of new receptors into the synapse. 
Activation of CaMKII results in the phosphorylation of the GluR1 subunit 
membrane AMPA receptors at Ser831. This alters the single-channel 
conductance of the receptor to increase its permeability to Ca2+ (Lee et al., 2000). 
In addition, it has been suggested that there are alterations in the subunit 
composition of these AMPA receptors, with the transient expression of GluR2-
lacking (Ca2+-permeable) receptors prolonging the rise in intracellular Ca2+ (Plant 
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et al., 2006). New AMPA receptors enter the synapse through two distinct 
mechanisms: trafficking from intracellular compartments and lateral diffusion 
from perisynaptic regions (Makino and Malinow, 2009). This may result in the 
activation of previously ‘silent’ synapses which lack functional AMPA receptors 
at resting membrane potential (Kullmann 2003). The subunit composition of 
these AMPA receptors varies and this may regulate the insertion or replacement 
of existing receptors through interactions with intracellular proteins (Shi et al., 
2001). The overall increase in cell surface AMPA receptor number as a result of 
these mechanisms is responsible for maintaining a sustained increase in synaptic 
strength. 
 
1.5.3.6: Late phase LTP (L-LTP) 
 
 
The second stage of LTP is known as late LTP (L-LTP) and commences from 
roughly one to five hours after LTP induction, although there is substantial 
overlap with E-LTP. L-LTP is protein-synthesis dependent and can be prevented 
by the application of protein synthesis or transcriptional inhibitors (Nguyen et al., 
1994). Activation of protein kinases initiate signalling cascades which result in 
the recruitment of nuclear transcription factors. Particularly important in this 
process is PKA, as inhibition of this kinase blocks L-LTP (Frey et al., 1993) but 
the MAPK cascade is also involved in nuclear signalling (English and Sweatt, 
1997). One of the most important downstream targets of PKA (and members of 
the MAPK family) are cAMP response element binding (CREB) proteins, which 
bind to cAMP response elements (CREs) in the regulatory region of genes to 
modulate transcription. This results in the activation of immediate early genes 
such as zif268 and arc which encode proteins associated with synaptic 
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scaffolding complexes and influence receptor trafficking and cytoskeletal 
function. These and other newly synthesised proteins contribute to structural 
remodelling of dendritic spines and the enlargement and growth of new synapses 
(Okuno 2011). Such morphological alterations allow the prolonged maintenance 
of synaptic potentiation in hippocampal neurons. 
 
1.5.3.7: LTP and memory 
 
 
Although LTP has been primarily studied in the hippocampus, it is also apparent 
in other regions of the brain such as the cortex and cerebellum, and has been 
linked to motor learning in these areas (Rioult-Pedotti et al., 2000, Coesmans et 
al., 2004). It is hypothesised that LTP may be a cellular correlate of certain types 
of memory. A number of studies in mice have correlated deficits in spatial 
memory with reductions in LTP both in vitro and in vivo,  including in transgenic 
models of AD (see section 1.4). These have attempted to link the induction and 
maintenance of LTP within individual neuronal populations more closely to 
particular behavioural tasks although this is technically challenging. Ideally, 
blocking LTP generation should impair the formation of new memories, and 
reversal of established LTP should induce amnesia. A pioneering study has 
shown the latter, as an inhibitor of the atypical PKC isoform PKMζ that reverses 
established LTP results in the loss of previously obtained place-avoidance 
memory (Pastalkova et al., 2006). This is consistent with LTP having a role in 
encoding subtypes of hippocampal-dependent memory. Overall, evidence 
suggests that it is valid to link alterations in LTP, such as those observed in 
transgenic models of AD, with observable memory deficits in hippocampal-
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dependent tasks. It is also probable that LTP and other forms of synaptic 
plasticity occur in the human brain and interest is growing in how alterations in 
these processes may result in the cognitive symptoms of AD. 
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1.6: Aims and objectives of this thesis 
 
1.6.1: Background 
 
 
The 3xTg mouse is one of the most commonly used transgenic models of AD 
and is unique as it is the only available model to develop both plaque and tangle 
pathology, due to the presence of three transgenes: APPSwe, PS1M146V and 
TauP301L. Previous studies of this mouse are described in detail in section 1.4.5, 
however in brief, the original paper by Oddo et al. described deficits in 
electrophysiological studies of LTP at the age of 6 months, accompanied by Aβ 
accumulation (4-6 months) and subsequent plaque deposition (6-12 months). Tau 
hyperphosphorylation is present at the age of 6 months onwards, while tangle 
formation occurs later in the lifespan, from around 12 months of age. A number 
of published biochemical studies have replicated the presence of these 
pathological features in the model, although the time course of their development 
varies widely between reports. Behavioural studies of this mouse have shown the 
presence of cognitive deficits in a water-maze paradigm from 4 - 6 months, 
which may be linked to the rising intraneuronal Aβ levels apparent with age 
(Billings et al., 2005).  
The TASTPM mouse, described in section 1.4.4, carries both the APP K670N/M671L 
and PS1M146V  mutations but does not possess a tau transgene, so develops only 
plaque-like structures in the brain. This mouse possesses an earlier onset of the 
biochemical phenotype, with elevated Aβ present at 3 months of age and plaque 
deposition at 6 months. Few electrophysiological studies have been carried out in 
these mice and LTP has not previously been characterised, however reduced 
basal synaptic transmission is reported at the age of 8 months (Spencer et al., 
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2004). Behavioural studies have shown deficits in the novel object recognition 
test, along with a phenotype of markedly aggressive behaviour and premature 
death (Howlett et al., 2004).  
 
1.6.2: Aims 
 
 
Although there are a number of published studies of the 3xTg mouse, the 
majority have carried out biochemical analysis alone, or linked this to either 
electrophysiological or behavioural studies. In addition, there are a number of 
discrepancies between groups regarding the rate at which the pathological 
features develop in this model. One of the major aims of this thesis is to 
systematically characterise the time course of development of the phenotype 
using electrophysiological, behavioural and biochemical studies in the same 
colony of 3xTg mice, with a particular focus on any early phenotypic changes 
which could be relevant to the initial stages of AD development. There are fewer 
published studies on the TASTPM mouse, and in particular as LTP has not 
previously been reported in this model an aim of the thesis is to carry out 
electrophysiological studies to observe if, similar to the 3xTg mouse, reductions 
in synaptic plasticity or basal synaptic transmission become apparent with age. 
Another primary aim of this thesis is the comparison of the 3xTg and TASTPM 
models. The predominant hypothesis in the field, the amyloid cascade hypothesis 
(see section 1.3.1) states that the generation of Aβ through the abnormal 
processing of APP is a key initiating factor in the development of AD. Therefore, 
as both these models possess the human APPSwe transgene, any molecular or 
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electrophysiological changes which are observed in both could represent a 
common mechanism of disease progression.  
The key difference between the 3xTg and TASTPM models is the presence of 
the TauP301L  transgene in the 3xTg mouse which results in tau 
hyperphosphorylation and subsequent tangle generation. An aim of this thesis is 
to observe the contribution of the tau transgene, and particularly early changes 
such as tau hyperphosphorylation, to the development of the phenotype in 3xTg 
mice. It is hoped that by comparison of the 3xTg and TASTPM mice the role of 
tau in early biochemical or electrophysiological deficits can be assessed. 
 
1.6.3: Summary  
 
 
 
1.  Characterise the development of any electrophysiological, biochemical or 
behavioural changes in the 3xTg or TASTPM mouse models of AD. 
 
2. Link any observed alterations in synaptic function with the development 
of pathology in these models. 
 
3. Observe any early features of these models that might be associated with 
the initial stages of AD. 
 
4. Compare the 3xTg and TASTPM models to observe the role of tau in the 
development of AD pathology. 
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Chapter 2 
 
Materials and Methods 
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2.1: Materials 
2.1.1: Antibodies  
 
Primary antibody Source Species 
 
Actin Sigma Rabbit 
6E10 Covance Mouse 
Total CRMP2 DSTT, University of 
Dundee 
Sheep 
CRMP2 pSer509/514 DSTT, University of 
Dundee 
Sheep 
CRMP2 pSer522 DSTT, University of 
Dundee 
Sheep 
Total GSK3β BD Biosciences Mouse 
GSK3α/β pSer21/9 Cell Signalling Rabbit 
Total MAPK Cell Signalling Rabbit 
MAPK pThr202/Tyr204 Cell Signalling Rabbit 
Total PKB Cell Signalling Rabbit 
PKB pSer 473 Cell Signalling Rabbit 
Tau5 Millipore Mouse 
Tau AT8 (Ser202/Thr205) Autogen Bioclear Mouse 
Tau pSer396 Cell Signalling Mouse 
Tau pSer404 Millipore Rabbit 
Synaptophysin Abcam Rabbit 
p35 Cell Signalling Rabbit 
 
All primary antibodies were diluted 1/1000 in TBST containing 1% milk with the 
exception of actin which was diluted 1/5000. 
 
Secondary antibodies: HRP-conjugated anti-mouse, rabbit and sheep (Pearce) 
were diluted 1/10 000. Infrared-dye conjugated anti-mouse (Rockland) was 
diluted 1/5000 while Infrared-dye conjugated anti-sheep (Rockland) was diluted 
1/10 000. 
 
2.1.2: Buffer composition 
 
Buffer Ingredients 
aCSF 124mM NaCl, 3mM KCl, 26mM NaHCO3, 1.25mM 
NaH2PO4, 1mM MgSO4, 10mM D-glucose, 2mM CaCl2 
 
RIPA buffer  50mM Tris base, 0.1mM EGTA, 1mM EDTA, 1% Triton-
X 100, 1mM Na3VO4, 50mM NaF, 5mM Na4P2O7, 0.27M 
sucrose, 0.1% β-mercaptoethanol, 1 Complete Protease 
Inhibitor Cocktail tablet (Roche) 
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NuPage LDS 
sample buffer 
(Invitrogen) 
10% glycerol, 141mM Tris base, 2% LDS, 0.51mM 
EDTA, 0.22mM SERVA Blue G250, 0.175mM Phenol 
Red (pH 8.5) 
 
NuPage MOPS 
SDS running buffer 
(Invitrogen)               
50mM MOPS, 50mM Tris base, 0.1% SDS, 1mM EDTA 
(pH 7.7) 
NuPage transfer 
buffer (Invitrogen) 
25mM glycine, 50mM Tris base, 0.1% SDS, 1mM EDTA, 
20% methanol 
 
Tris-buffered saline 
with Tween 
(TBS-T) 
50mM Tris base, 150mM NaCl, 0.1% v/v Tween 20 
Laemmli sample 
buffer 
63mM Tris base, 10% glycerol, 2% SDS, 0.0025% 
bromophenol blue (pH 6.8) 
Running buffer 250mM Tris base, 1.92M glycine, 1% SDS, pH 8.3 
Transfer buffer 48mM Tris base, 39mM glycine, 20% methanol 
 
 
2.1.3: Chemicals  
 
Chemical Supplier 
β-mercaptoethanol, CaCl2, D-glucose, 
KCl, NaCl, NaHCO3 , NaH2PO4, 
MgSO4 
 
VWR 
Bromophenol blue, EDTA, EGTA, 
kynurenic acid, NaF, Na4P2O7, Na3VO4, 
SDS, Tris base, Triton X, Tween  
 
Sigma 
Methanol, sucrose Fisher 
Glycine Melford 
 
 
2.1.4: Transgenic mice 
 
 
 
3xTg mice were originally generated at the University of California (Irvine, USA) 
by the insertion of a transgene containing the human APP695 isoform with the 
Swedish (K670M, N671L) double mutation and human 4R0N tau with the P301L 
mutation, under the Thy1.2 promoter, into PS1M146V mice (Oddo et al., 2003). 
The generation of PS1
 M146V mice from a C57BL/6 x 129/Sv background has 
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been previously described (Guo et al., 1999).
 
Male and female 3xTg founder 
mice for our colony were provided by Stuart Allan (Manchester). Additional 
female mice were provided by Karen Horsburgh (Edinburgh); these were 
maintained separately and not used for breeding purposes. Genotyping was 
carried out from ear punch biopsy in several 3xTg mice to confirm the presence 
of the transgenes (performed by Linda Gallacher). Control mice were generated 
from a mixed C57/BL6 x 129/Sv background and were initially provided by 
Stuart Allan (Manchester). 
TASTPM mice were generated at GlaxoSmithKline (Harlow, UK) by the cross 
of two previously available lines, TAS10 and TPM (Howlett et al., 2004). 
TAS10 mice were generated by the insertion of a transgene containing the human 
APP695 isoform with the Swedish (K670M, N671L) double mutation, under the Thy1 
promoter, into C57BL/6 mice (Richardson et al., 2003). TPM mice were 
generated by the insertion of a transgene containing the human PS1 gene with the 
M146V mutation, under the Thy1 promoter, into C57BL/6 mice (Howlett et al., 
2004). Following this, TAS10 mice were backcrossed onto a pure C57BL/6 line 
and then crossed with TPM to produce TASTPM mice with the double APPSwe 
and PS1M146V mutations.  
All mice were maintained on a 12 hour light/dark schedule with free access to 
food (RM1, Special Diet Services) and water, and were group housed with the 
exception of a number of male TASTPM which had to be separated due to 
aggressive behaviour. All animal procedures were carried out under the Animals 
(Scientific Procedures) Act 1986. 
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2.2: Methods 
2.2.1: Electrophysiology methods 
 
2.2.1.1: Hippocampal slice preparation 
 
 
Each mouse was killed by cervical dislocation under Schedule 1 of the Animals 
(Scientific Procedures) Act 1986, the brain was removed and placed in a dish of 
artificial cerebrospinal fluid (aCSF) at room temperature. The cerebellum and 
lateral portion of the temporal lobes were removed, and the brain was halved 
down the midline and glued by its flat edge to a metal plate with cryanoacrylate. 
400µM thick sagittal brain sections were then cut using a Vibratome (Intracel, 
Herts, UK) with the brain submerged in room-temperature aCSF and oxygenated 
with a 95% O2/ 5% CO2 mixture. Following sectioning the slices were placed on 
netting in a glass chamber containing oxygenated aCSF which was able to flow 
freely around the tissue. They were then allowed to recover for at least one hour 
before use in electrophysiological recording.  
 
2.2.1.2: Extracellular recording 
 
 
The slice was placed in an electrophysiological recording chamber (Scientific 
Systems Design, Mississauga, Ontario, Canada) which allowed extracellular 
submerged recording from the hippocampus. The aCSF within the chamber was 
maintained at 31-32°C using a temperature controller (Digitimer, Hertfordshire, 
UK) with an oxygenated water chamber which circulated the warmed water 
beneath the slice. The slice itself was oxygenated in the perfusion system with a 
95% O2/ 5% CO2 mixture at a flow rate of approximately 2ml/min. 
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Electrical stimulation was given using a stimulator box (Digitimer, Hertfordshire, 
UK) which was electrically isolated to prevent interference from mains electrical 
noise. A bipolar stimulating electrode either hand-made from twisted Teflon 
coated tungsten wire (Advent Research Materials, Oxford, UK) or a commercial 
electrode (World Precision Instruments, Florida, USA) with a resistance of 1 MΩ 
was used; responses were comparable using both types of electrode.  
Recordings were made using an electrode made of borosilicate glass (King 
Precision Glass, California, USA) which had a resistance of 3-4 MΩ and was 
filled with aCSF. In the centre of the electrode was a silver wire (Advent 
Research Materials, Oxford, UK) and this, along with a ground electrode of 
silver wire, was attached to an isolated differential amplifier where the signal 
was amplified and filtered (Warner Instrument Corporation, Conneticut, USA). 
Both the stimulating and ground electrodes were electrically chlorided by 
immersion in 1M KCl solution.  The output from the amplifier was fed through 
an oscilloscope (Tektronix, Oregon, USA) and digitised through an acquisition 
board (BNC-2090, National Instruments, Berkshire, UK). A schematic diagram 
of the setup is shown in Fig. 2.1. The responses evoked from the slice were 
visualized using a computer running WinLTP software (v. 0.95b, Anderson, 
www.winltp.com). 
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Figure 2.1: Diagram of the electrophysiology setup. The pump-controlled 
perfusion system provides oxygenated aCSF to the slice in the tissue bath, 
while a controller maintains the temperature at 32°C. A stimulating electrode 
is placed in the slice which is connected to an isolated stimulator unit to allow 
electrical pulses to be given to the tissue. The recording electrode is connected 
to an amplifier which enhances the output signal, then a data acquisition board 
via an oscilloscope. The acquisition board feeds into a PC running WinLTP 
software which allows visualisation of the evoked electrical responses from 
the tissue.  
  
96 
2.2.1.3: Measurement of the fEPSP 
 
 
In the hippocampus, the presence of well-defined synaptic layers facilitates the 
measurements of field extracellular postsynaptic potentials (fEPSPs). These are 
generated by electrical stimulation of the Schaffer collateral fibres which project 
from the CA3 region to pyramidal neurons in the CA1 region. Stimulation of 
these presynaptic fibres results in glutamate release at the synapse between the 
axons of the CA3 region and dendrites of the CA1 neurons. This results in a 
synchronous postsynaptic depolarisation which occurs as a result of ionotropic 
receptor activation (primarily AMPA receptors) and influx of positive ions into 
the postsynaptic terminal. This can be detected by placing a recording electrode 
within the CA1 dendritic layer (stratum radiatum). 
The WinLTP software provides a visual representation of the evoked fEPSP and 
can also be used to alter the stimulation protocol (e.g. the number or duration of 
pulses) or the parameters of the fEPSP recording (e.g. the length of recording or 
amplitude and slope detection values). All pulses given were 0.1ms in length. 
During the experiment stimulation was given at thirty second intervals to record 
dynamic changes in the fEPSP. 
The fEPSP has a number of characteristic features (shown in Fig. 2.2). The two 
main measurements which are recorded are the amplitude and slope of the fEPSP 
which can be measured to give an indication of synaptic activity within the 
neuronal population. The slope is most commonly measured as it is less subject  
to interference by other sources of current flow such as feedforward GABAergic 
inhibition or action potential firing.  
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Figure 2.2: A field extracellular postsynaptic potential (fEPSP). The 
amplitude is calculated as the measurement from the baseline to the peak of 
the fEPSP while the slope is 20-80% of the initial phase. The stimulus artefact 
appears as a spike immediately before the fEPSP. An increase in the slope and 
amplitude values of the fEPSP is characteristic of LTP. The fEPSP represents 
the simultaneous depolarisation of a population of CA1 pyramidal neurons, 
which is recorded as a negative voltage deflection due to the flow of positive 
ions away from the recording electrode into the postsynaptic terminals. 
  
98 
The peak amplitude was usually measured 4-15 ms after the pulse and the slope 
was taken as 20-80% of the peak, with a baseline of at least 8-2ms before the 
pulse. An increase in the amplitude and slope is characteristic of LTP. However, 
the baseline fEPSP measurements can be used as a measure of the synaptic 
strength within the neuronal population. This is the likelihood of a synaptic 
response following an input stimulus and involves both presynaptic components 
(e.g. release probability, quantal size) and postsynaptic components (e.g. receptor 
function and density). For LTP experiments, a baseline fEPSP of  approximately 
40% of the maximum fEPSP was established to ensure that synaptic potentiation 
following theta burst was possible.  
 
2.2.1.4: Input-output function 
 
 
Basal synaptic transmission can be studied more systematically with an input-
output curve. This is a measure of synaptic recruitment, which increases with the 
input stimulus due to the activation of a greater population of neurons.  Input-
output response can vary due to differences in synaptic density and the strength 
of individual synapses within the population (Usdin et al., 1999). Curves were 
generated using an increasing stimulus intensity and recording the slope and 
amplitude of each evoked fEPSP. The intensity was initially set at 0.2mA and 
manually increased in 0.1mA increments which provided a sigmoidal shaped 
input-output response. Three slope and amplitude readings were recorded for 
each stimulation intensity at thirty second intervals and averaged. The slope of 
the fEPSP was then plotted as a function of stimulus strength. The curve was 
completed when a plateau phase was reached with the amplitude and slope of the 
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field remaining similar at several increasing stimulus intensities (usually 1-
1.2mA). 
 
2.2.1.5: Paired-pulse facilitation 
 
 
PPF was recorded at interstimulus intervals of 20ms, 50ms, 100ms, 200ms, 
300ms, 400ms and 500ms. The optimum interstimulus interval was 50ms, with 
shorter intervals causing reduced PPF or even synaptic depression likely due to 
Ca2+ depletion, and longer stimulus intervals less effective at inducing PPF due 
to a gradually decreasing concentration of Ca2+ in the presynaptic terminal.  
PPF was graphed using the paired pulse ratio, which is the amplitude of the 
second fEPSP divided by the amplitude of the first. Values of greater than 1.0 
indicate facilitation. 
 
2.2.1.6: Stimulation protocols for the induction of LTP 
 
 
There are a number of stimulation protocols which have been used to induce LTP 
in the hippocampal slice preparation. The appropriate choice of stimulation 
protocol is important as different protocols are thought to work through diverse 
cellular signalling mechanisms, which may be initiated by the dynamics of Ca2+ 
release (Smith et al., 2009). 
The theta burst protocol is characterised by an interburst interval of 200ms, and 
is thought to be relatively physiological as a hippocampal theta rhythm (6-10 Hz) 
is commonly observed in living animals. It is generally involved with states of 
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attention and movement but has also been associated with learning (Otto et al., 
1991). 
The theta burst protocol used in these experiments was a four-pulse theta burst 
consisting of 4 pulses at a frequency of 100 Hz, repeated 10 times with an 
interburst interval of 200ms. 
 
2.2.1.7: Measurement of LTP 
 
 
A typical LTP experiment has several characteristic features (Fig. 2.3) which 
allows for several parameters to be compared between experiments. The 
measurement of LTP is complicated by the existence of several mechanisms of 
potentiation which superimpose and overlap. Following the theta-burst 
stimulation there is an immediate and often dramatic increase in both the slope 
and the amplitude of the fEPSP, which usually reaches its peak in the 30 seconds 
following LTP induction. This is related to an initial phase of post-tetanic 
potentiation (PTP) which decays rapidly, causing a steep decrease in the slope 
and amplitude of the fEPSP, typically over the first 10-15 minutes following 
theta burst. PTP is thought to be presynaptic and caused by an increase in the 
intra-terminal Ca2+ concentration causing enhanced neurotransmitter release 
(Delaney and Tank, 1994). 
This initial phase is followed by a plateau phase in which the amplitude and 
slope of the fEPSP remain stable for at least 60 minutes following theta burst 
stimulation. Experiments which decay to baseline before this time (<5% of total) 
are described as showing short-term potentiation only and were discarded. The 
plateau phase corresponds to early LTP (E-LTP), characterised by protein-
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synthesis independent mechanisms such as receptor phosphorylation and 
trafficking, and generally thought to persist over several hours (see Chapter 1). 
Late phase LTP (L-LTP), which involves gene transcription and protein 
synthesis, allows the prolonged expression of potentiation over many hours and 
shows overlap with early LTP (Frey and Morris, 1997). However, without using 
pharmacological treatments such as protein synthesis inhibitors, it is impossible 
to dissociate the phases of LTP; based on the time scale of these experiments it is 
likely that the majority of LTP recorded is E-LTP. 
The peak potentiation following theta burst was used as a measure of PTP, and 
LTP was measured using the average potentiation of the plateau phase, taken as 
50-60 minutes following theta burst stimulation. The mean value was calculated 
firstly for each individual mouse then for the group as a whole at all time points. 
The average potentiation of the graph during the complete experiment from 0-60 
minutes was also used for statistical comparison between groups. LTP was 
plotted either conventionally using the normalised fEPSP slope values, which 
standardises differences in the size of the fEPSP between experiments, or as a 
non-normalised graph to show the actual recorded values of the fEPSP. 
 
2.2.1.8: Statistics and analysis 
 
 
All electrophysiology graphs were created using Origin software version 7 
(www.originlab.com). Statistical analysis was carried out using SPSS version 17 
(www.spss.com). For input-output curves, an unpaired t-test was used to 
compare groups at each stimulus intensity. Paired-pulse facilitation was analysed 
using repeated measures ANOVA, followed by unpaired t-test at individual 
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interstimulus intervals to establish those which were statistically significant. LTP 
measurements were analysed using repeated measures ANOVA with strain as the 
between subjects factor and time as the within subjects factor. Post hoc analyses 
for time were only performed if the interaction between mouse strain and time 
was statistically significant. The analysis used for each experiment is indicated in 
the text where appropriate, and values are expressed as ± standard error of the 
mean (s.e.m.). A p value of < 0.05 was considered to be significant. 
  
103 
 
 
 
 
 
0 20 40 60 
0 
50 
100 
150 
200 
250 
300 
350 
400 
Time (min) 
THETA BURST 
PEAK PHASE 
PLATEAU PHASE 
N
o
rm
a
lis
e
d 
fE
PS
P 
sl
o
pe
 
(%
) 
A 
B 
C 
 
  A                           B                            C 
 
Figure 2.3: Long-term potentiation. Following at least ten minutes of stable 
baseline, a four-pulse theta burst stimulation is given. This causes a marked 
increase in the slope of the fEPSP which immediately reaches its peak and then 
declines to a sustained plateau phase. The peak value was used as a measure of 
PTP and the average from 50-60 minutes when the slope of the fEPSP has 
plateaued as a measure of LTP. Typical fEPSPs obtained at the labelled points 
of the experiment are represented below the graph. 
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2.2.2: Biochemical methods 
 
2.2.2.1: Brain lysate preparation 
 
 
Samples were prepared using a method to separate soluble and insoluble tissue. 
RIPA buffer was added at approximately double the volume of the sample and 
the tissue was homogenized using a pellet mixer. The lysate was then centrifuged 
in a chilled desktop centrifuge (Fisher Scientific, Leicestershire, UK) at 12 000 
rpm for ten minutes and the supernatant removed and retained as the soluble 
protein fraction. Half the volume of RIPA buffer was then added to the pellet, the 
process repeated and the supernatants combined; the insoluble material was 
discarded. The soluble fraction was again centrifuged to remove any remaining 
insoluble material and then frozen at -80°C for future use. 
The concentration of protein in each brain lysate was determined using the 
Bradford method (Bradford 1976). This uses the Coomassie Blue G-250 dye, 
which shifts absorbance from 465nm to 595nm when bound to proteins within a 
sample. 980 µl of reagent (Bio-Rad, California, USA) was added to 20µl of an 
appropriate dilution of brain lysate (e.g. 1/10, 1/20), triturated and incubated at 
room temperature for 10 minutes and the absorbance read using a 
spectrophotometer (Pharmacia Biotech, Uppsala, Sweden). The values obtained 
were compared against a standard curve generated using serial dilutions of 
bovine serum albumin to determine the protein concentration within each sample. 
  
105 
2.2.2.2: Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
 
 
Samples were diluted in RIPA buffer to a known concentration (i.e. 0.5 or 
1mg/ml). Two methods were used for SDS-PAGE due to a change in laboratory 
protocol. NuPAGE SDS sample buffer (Invitrogen, California, USA) or LDS 
sample buffer was added to each sample; the negatively charged SDS/LDS 
within the sample buffer binds to the protein to provide a uniform charge density 
which allows each protein to migrate through the gel based solely on its 
molecular weight. The sample buffer also contained 10mM of the reducing agent 
dithiothreitol (DTT) to break up the native structure of the protein. As each 
sample was of known concentration an equal weight of protein could be loaded 
onto the gel. Samples were then loaded and run using either the Novex or 
BioRad systems. 
Using the NuPage Novex system, (Invitrogen, California, USA) a current of 
180V was applied for one hour through a graded 4-12% polyacrylamide gel, with 
a prestained molecular weight marker run alongside to provide bands of known 
molecular weight for comparison (SeeBlue, Invitrogen, California, USA). 0.5ml 
of antioxidant was added to the upper buffer chamber to prevent reoxidisation of 
the samples during electrophoresis.    
Using the BioRad system, a current of 120V was applied for one and a half hours 
through a graded 4-15% polyacrylamide gel, with Plus Protein Dual Colour 
Standard, (BioRad, California, USA) used as the molecular weight marker. 
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2.2.2.3: Western blotting 
 
 
Following SDS-PAGE, a 0.45mm nitrocellulose membrane (Hybond-C, GE 
Healthcare, Buckinghamshire, UK) was placed on top of the gel to allow for 
protein transfer. The gel and membrane were then sandwiched between filter 
paper and placed in a transfer cassette containing nylon sponges soaked in 
transfer buffer (Invitrogen, California, USA), dehydrated with 20% methanol to 
allow for more efficient transfer. The cassette was placed in a chamber filled 
with transfer buffer and a current of 35V was applied for 2 hours, causing the 
proteins within the gel to migrate onto the nitrocellulose membrane.  
Following transfer, the membrane was stained with the reversible protein dye 
Ponceau-S (Sigma-Aldrich, Missouri, USA), to assess efficiency of transfer and 
allow cutting of the membrane, and was then washed off. 
For use with the enhanced chemiluminescence (ECL) development method, 
membranes were blocked with 5% milk powder in TBS-T for one hour to 
prevent non-specific binding of the primary antibody to the membrane. They 
were then incubated overnight at 5ºC with the appropriate primary antibody. 
Following multiple washes, the membrane was incubated with a horseradish 
peroxidase (HRP)-conjugated secondary antibody for one hour at room 
temperature. 
The membrane was then washed several times in TBS-T and 1ml of ECL reagent 
(GE Healthcare, Buckinghamshire, UK) was added to the surface of the 
membrane for one minute. This causes a chemiluminescent reaction with the 
secondary antibody that can be detected using photographic film. In a dark room, 
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either X-ray Film (CL-EXposure, Thermo Scientific, Illinois, USA) or high-
sensitivity film (Hyperfilm, GE Healthcare, Buckinghamshire, UK) was used in a 
film cassette (Kodak, New York, USA) to develop multiple exposures of each 
membrane dependent on the strength of the signal. 
For use with the Li-Cor Odyssey system, membranes were blocked in 3% bovine 
serum albumin for one hour and a primary antibody in 1% milk powder in TBS-
T was then added overnight at 5ºC. Following washing of the membrane, the 
infrared dye-conjugated secondary antibody was added for one hour at room 
temperature. Membranes were then developed using the Li-Cor Odyssey. 
 
2.2.2.4: Densitometry and analysis 
 
 
Densitometry of LiCor Odyssey-developed films was carried out using the 
Odyssey software (version 2.1). Actin was used as a loading control for each 
protein except the phosphorylated forms of tau and CRMP2 which were 
normalised to the total protein levels. All graphs were created using Origin 
software version 7 (www.originlab.com). Statistical analysis was carried out 
using SPSS version 17 (www.spss.com) and consisted of unpaired t-test, one-
way ANOVA and two-way ANOVA dependent on the number of groups and 
number of variables (detailed in results where appropriate). All values are 
expressed as ± standard error of the mean (s.e.m.).  Post-hoc analysis was carried 
out using Student-Newman-Keuls testing and a p value of < 0.05 was considered 
to be significant. 
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2.2.3: Behavioural methods 
 
 
All behavioural experiments were carried out under license PPL 60/3766 from 
the Home Office under the Animals (Scientific Procedures) Act 1986. 
2.2.3.1: Rewarded alternation T-maze  
 
 
The T-maze consists of three arms: the start arm and two goal arms arranged in a 
T shape, with two removable doors that can be used to block the arms. A food 
reward is placed in a well at the end of each goal arm. 
Mice were placed in the T-maze with their littermates for ten minutes on at least 
five days, with all arms open and a 1:1 solution of condensed milk (Carnation, 
Nestlé) placed within the food well at the end of each goal arm. At the same time, 
mice were provided with several drops of condensed milk in a food well 
overnight within their home cage to allow habituation to the apparatus and to the 
reward. 
During the testing phase, mice were maintained at 85-90% free-feeding weight to 
increase motivation for the task. Mice were tested in squads of equal numbers 
(six to eight), with all mice having run the first trial before commencing the 
second trial which provided a similar inter-trial interval for each mouse. The 
apparatus was cleaned with 70% ethanol solution between individual mice. Four 
trials were carried out each day for nine or ten consecutive days. 
The mouse was placed at the far end of the start arm, with access to the rest of 
the maze blocked by a removable door. After five seconds, the door was lifted 
and the mouse allowed to run down one of the goal arms and consume the 
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reward, with the other blocked by the second removable door. This forced 
direction was chosen in a pseudorandom manner, with no more than two 
consecutive left or right presentations to prevent the development of place 
preference. Following consumption of the condensed milk reward, the mouse 
was again placed in the start arm for five seconds. The doors blocking access to 
the rest of the start arm and to one of the goal arms were then lifted, allowing 
free access to all arms. The mouse was allowed to run down a goal arm; if the 
choice was correct it obtained another reward, if incorrect the door was lowered 
and it was ensured that the mouse had found the food well was empty before 
being removed from the maze. Each mouse was returned to its home cage 
between trials. Mice which were reluctant to run were encouraged initially by 
several drops of condensed milk placed in the start arm; if a mouse failed to 
complete the task within three minutes on either the forced or choice element of 
the trial they were returned to the home cage. 
Where a delay was introduced, the mouse was placed in the start box for 0, 30 or 
60 seconds following the forced element of the trial. The length of delay was 
varied and spread equally between left and right presentations. Trials in which 
the mouse failed to choose a goal arm within the first 30 seconds of the choice 
element were excluded from analysis. 
 2.2.3.2: Activity box 
 
 
The activity box used was a clear Perspex box of diameter 32 x 20 x 19 cm with 
a wire lid. An activity monitor (Benwick Electronics, Norfolk, UK) consisting of 
a 1 inch grid of infrared beams was used, with two sets of beams spaced 2cm 
vertically apart to measure both horizontal movement and rearing behaviour. 
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When the animal moved either horizontally or vertically the beam was broken 
and an activity count was recorded electronically. The break of two consecutive 
beams was considered a count to minimise the effect of static movements such as 
grooming. The parameters which were recorded were fast and slow mobile 
counts, fast and slow rearing counts and the percentage and time the mouse spent 
mobile. 
Mice were placed in the box for fifteen minutes and allowed to explore freely, 
with measurements being recorded every five minutes. This was carried out on 
four consecutive days to allow both intra-trial and inter-trial habituation to be 
measured.   
2.2.3.3: Statistical analysis 
 
 
All behavioural graphs were created using Origin software version 7 
(www.originlab.com). Statistical analysis was carried out using SPSS version 17 
(www.spss.com). The appropriate statistical test was carried out for each 
experiment and is noted in the results chapter. A p value of < 0.05 was 
considered to be significant. 
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Chapter 3 
 
Electrophysiology 
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3.1: Introduction 
 
Studies using electrophysiological techniques have given an important insight 
into synaptic transmission and plasticity in mouse models of AD. In this chapter, 
I have used extracellular recording in the hippocampal slice preparation to 
examine basal synaptic function and LTP in the 3xTg and TASTPM mouse 
models. 
It has previously been reported that the 3xTg mouse shows a reduction in basal 
transmission as shown by a smaller fEPSP, accompanied by deficits in LTP at 
the age of 6 months associated with an increase in intraneuronal Aβ (Oddo et al., 
2003). For this reason, I studied measures of synaptic function in this model at a 
range of ages from 2 – 17 months when the pathological features such as Aβ 
accumulation should be present in our colony of 3xTg mice. I have measured 
both LTP, basal synaptic transmission and other forms of short-term plasticity 
such as PPF.   
There is currently no published hippocampal slice electrophysiology data on the 
TASTPM model. I therefore studied synaptic function in this model including 
basal transmission, PPF and LTP to observe any alterations in these measures 
that might be associated with the biochemical changes in these mice. 
The final section of this chapter describes treatment of both 3xTg and TASTPM 
slices with the glutamate receptor antagonist kynurenic acid during slicing to 
reduce excitotoxicity and improve slice viability. It has previously been reported 
that deficits in fEPSP amplitude in APP-overexpressing mice can be reversed by 
incubation with this compound (Fitzjohn et al., 2001). I have observed the effects 
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of kynurenic acid treatment in the 3xTg and TASTPM mice to determine 
whether an increased susceptibility to excitotoxicity is a feature of these models.  
 
 
3.2: Results 
 
 
In the 3xTg, TASTPM and control mice a number of parameters were measured 
to give a measure of synaptic function. These experimental approaches are 
discussed in more detail in the methods section (Section 2.2.1) and include: 
input-output function and fEPSP amplitude/slope measurements, PPF and LTP. 
Briefly, an input-output curve was generated by measuring the slope of the 
fEPSP at gradually increasing stimulus intensities to give a measure of basal 
synaptic transmission. PPF, a form of short-term plasticity, was also recorded to 
test presynaptic function Finally, LTP was induced using a four pulse theta burst 
protocol, with the change in the slope of the fEPSP (quantified as mV/ms) used 
as a measure of synaptic plasticity.  
The notation (n = x / y) following a group indicates the number of brain slices 
used and the number of mice from which these slices came i.e. (n = 6/4) denotes 
six slices obtained from four mice. All experiments were carried out on 
hippocampal slices from at least three individual mice in each group. 
 
 
3.2.1: Control data 
 
 
LTP was reliably obtained in slices from control mice at ages up to 17 months 
maintained for up to eight hours in vitro following initial slice preparation. LTP 
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could be induced and maintained for 60 minutes post-theta burst in control mice, 
and in some slices for up to 120 minutes (data not shown) although this was 
difficult due to technical limitations (e.g. the formation of air bubbles underneath 
the slice). This shows that the slices remain viable throughout the duration of the 
experiments reported in this thesis.  
 
 
3.2.2: Electrophysiological characterisation of 2 month old 3xTg 
mice 
 
3.2.2.1: Input-output function  
 
 
Input-output curves were generated and compared for 2 month old 3xTg mice 
and 2 month old control mice of both genders. A normalised input-output curve, 
where the maximum field slope is set to 100%, was generated, along with a non-
normalised input-output curve using the actual values (mV/ms) obtained. 
In 2 month old control mice, there is no significant difference (p > 0.05, unpaired 
t-test) between the normalised input-output curve of male (n = 5/3) and female (n 
= 8/3) mice (Fig. 3.1A). Similarly, for the 2 month 3xTg mice, there is no 
significant difference (p > 0.05, unpaired t-test) between the normalised input-
output curve for male (n = 5/3) and female (n = 8/3) mice (Fig. 3.1B).  
Given these findings the male and female data was pooled together. When the 
two groups are compared, there is no significant difference (p > 0.05, unpaired t-
test) between the normalised input-output curve of the control mice (n = 12/7) 
and the 3xTg mice (n = 13/8) (Fig. 3.2A).  
  
115 
For the non-normalised input-output curve, the control mice exhibit an fEPSP 
slope at 1 mA of 0.46 ± 0.11 mV/ms, while the 3xTg mice exhibit an fEPSP 
slope at 1 mA of 0.71 ± 0.14 mV/ms (Fig. 3.2B). There is no significant 
difference (p > 0.05, unpaired t-test) between the two groups. The large error 
bars are due to the marked variability in the size of the fEPSP between individual 
slices, which occurs even in tissue from the same mouse.  
 
 
3.2.2.2: Paired-pulse facilitation  
 
 
Paired-pulse facilitation was compared between 2 month old 3xTg mice and 2 
month old control mice, and the effect of gender was also investigated.  In all 
experiments the maximum facilitation was observed at an interstimulus interval 
of 50ms, which is in agreement with previously published work (Nathan et al., 
1990). 
In control mice, the paired-pulse ratio at 50ms is 2.0 ± 0.06 for males (n = 6/3) 
and 1.79 ± 0.13 for females (n = 5/3) mice (Fig. 3.3A). There is no significant 
difference (p > 0.05, repeated measures ANOVA) in the paired-pulse ratio in 
male or female control mice at interstimulus intervals ranging from 20 – 500ms. 
In 3xTg mice, the paired-pulse ratio at 50ms is 1.45 ± 0.08 for male (n = 5/3) and 
1.57 ± 0.06 for female (n = 8/5) mice (Fig. 3.3B). There is no significant 
difference (p > 0.05, repeated measures ANOVA) in the paired-pulse ratio in 
male or female 3xTg mice at interstimulus intervals ranging from 20 – 500ms. 
Given that gender did not influence the paired-pulse ratio for either genotype the 
data for male and female mice were combined. Collectively, the paired-pulse 
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ratio at 50ms is 1.90 ± 0.07 for control (n = 11/6) and 1.52 ± 0.05 for 3xTg (n = 
13/8) mice (Fig. 3.4). There is a significant decrease in the paired-pulse ratio in 
3xTg when compared to control mice (p < 0.05, repeated measures ANOVA, 
followed by unpaired t-test at individual intervals) at interstimulus intervals of 50, 
100, 200, 300, 400 and 500 ms.  
 
 
3.2.2.3: Long-term potentiation  
 
 
LTP was measured in the CA1 region for 2 month 3xTg and control mice. These 
experiments were performed in both male and female mice and both normalised 
and non-normalised data were generated. 
In all experiments a baseline fEPSP was recorded at 30 second intervals until the 
slope of the fEPSP was stabilised and constant over a 10 min period before 
delivery of the theta burst stimulus. In the following section the slope of the 
fEPSP is normalised to baseline (i.e. 100%) for each recording.  
In 2 month old control male mice (n = 7/5), the peak enhancement of the slope of 
the fEPSP is 225 ± 11%, with a mean from 50-60 minutes following the theta 
burst stimulus of 155 ± 11%. In 2 month old control female mice (n = 6/3), the 
peak enhancement is 185 ± 28%, with a mean from 50-60 minutes of 131 ± 7% 
(Fig. 3.5A). 
In 2 month old 3xTg male mice (n = 7/3), the peak enhancement of the slope of 
the fEPSP is 263 ± 47%, with a mean from 50-60 minutes following the theta 
burst stimulus of 187 ± 23%. In 2 month 3xTg female mice (n = 9/5), the peak 
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enhancement is 191 ± 17%, with a mean from 50-60 minutes of 146 ± 4 % (Fig. 
3.5B).  
There is no significant difference (p > 0.05, repeated measures ANOVA) 
between the magnitude of LTP in any of the four groups. There is a trend for 
enhanced LTP in the male 3xTg mice which reflects variability between the data 
obtained (at all times points determined), shown by the relatively large error bars 
associated with this group. 
Combining the results obtained for each gender, a comparison was then made 
between the 3xTg and control mice. In 2 month control mice (n = 15/8), the peak 
enhancement of the slope of the fEPSP is 223 ± 12%, with a mean from 50-60 
minutes following the theta burst stimulus of 152 ± 9%. In 2 month old 3xTg 
mice (n = 17/8), the peak enhancement is 221 ± 23%, with a mean from 50-60 
minutes of 163 ± 11% (Fig. 3.6).  
There is no significant difference (p > 0.05, repeated measures ANOVA) 
between the magnitude of LTP in 2 month old 3xTg and control mice. This is the 
case for all phases of LTP, from the initial peak to the plateau phase.  
 
 
3.2.2.4: Non-normalised long-term potentiation 
 
 
When the slope of the fEPSP is not normalised to control and the actual values 
(mV/ms) are utilised, in 2 month control mice the mean baseline fEPSP is 0.21 ± 
0.03 mV/ms, the peak enhancement following theta burst is 0.51 ± 0.10 mV/ms, 
and the mean from 50-60 minutes is 0.32 ± 0.05 mV/ms. In 2 month 3xTg mice, 
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the mean baseline fEPSP is 0.36 ± 0.05 mV/ms, the peak enhancement is 0.87 ± 
0.16 mV/ms, and the mean from 50-60 minutes is 0.57 ± 0.09 mV/ms (Fig. 3.7).   
There is a significant increase in the baseline fEPSP slope and the magnitude of 
LTP (p < 0.05, repeated measures ANOVA) in 2 month 3xTg mice when 
compared to control mice. This is present in all phases of LTP, from the initial 
peak to the plateau phase.  
 
3.2.2.5: Summary 
 
 
There are several differences in hippocampal CA1 synaptic function apparent in 
the 3xTg mice at 2 months old. No gender-dependent effects were observed on 
the magnitude of LTP in either 3xTg or control mice therefore both male and 
female data were pooled together. The 3xTg mice show a decrease in PPF, with 
no differences in input-output function, but a trend for an increased fEPSP at 
higher intensities. This is replicated in the non-normalised LTP graph with a 
baseline fEPSP slope value that is significantly greater than control. However, 
the normalised LTP graph shows that the magnitude of LTP is similar between 
the two groups. These data suggests that, although 2 months is an age prior to the 
intraneuronal accumulation of Aβ observed by Oddo et al., there are measurable 
electrophysiological changes in the 3xTg mice. 
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Figure 3.1: Normalised input-output curves obtained from 2 month old 
male and female 3xTg and control mice. The fEPSP slope was measured at 
a range of stimulus intensities and then normalised in male (n = 5/3) and 
female (n = 6/3) control mice (A) and male (n = 5/3) and female (n = 8/5) 
3xTg mice (B). p > 0.05, unpaired t-test. 
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Figure 3.2: Normalised and non-normalised input-output curves obtained from 
2 month old 3xTg and control mice. The fEPSP slope was measured at a range of 
stimulus intensities and then normalised in control (n = 12/7) and 3xTg mice (n = 
13/8) (A). The non-normalised fEPSP slope measurement in control (n = 11/7) and 
3xTg mice (n = 14/8) is shown in (B). p > 0.05, unpaired t-test. 
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Figure 3.3: Paired-pulse facilitation determined in 2 month old male and female 
3xTg and control mice. The paired-pulse ratio was calculated at a range of inter-
stimulus intervals in (A) male (n = 6/3) and female (n = 5/3) control mice and (B) in 
male (n = 5/3) and female (n = 8/5) 3xTg mice. p > 0.05, repeated measures 
ANOVA. 
A 
B 
0 100 200 300 400 500
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
Pa
ire
d-
pu
ls
e 
ra
tio
Interstimulus interval (ms)
 2 month control male (n = 6)
 2 month control female (n = 5)
p > 0.05, repeated measures ANOVA
0 100 200 300 400 500
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
Pa
ire
d-
pu
ls
e 
ra
tio
Interstimulus interval (ms)
 2 month 3xTg male (n = 5)
 2 month 3xTg female (n = 8)
p > 0.05, repeated measures ANOVA
  
122 
Figure 3.4: Paired-pulse facilitation determined in 2 month old 3xTg and control 
mice.  The paired-pulse ratio was calculated at a range of interstimulus intervals in 
control mice (n = 11/6) and 3xTg mice (n = 13/8).   = p < 0.05, repeated measures 
ANOVA followed by unpaired t-test at individual intervals. 
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Figure 3.5: The influence of gender on long-term potentiation recorded from 2 
month old 3xTg and control mice. The potentiation of the fEPSP slope obtained 
following four-pulse theta burst was measured in (A)  control male (n = 7/5) and 
female mice (n = 6/3) and (B) 3xTg male (n = 7/3) and female mice (n = 9/5). All data 
are normalised to the average slope of the fEPSP for each genotype prior to delivery 
of the theta burst stimulus. p > 0.05, repeated measures ANOVA. 
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Figure 3.6: Long-term potentiation in 2 month old 3xTg and control 
mice. The enhancement of the fEPSP slope following a 4 pulse theta burst 
protocol was measured in control mice (n = 15/8) and 3xTg mice (n = 17/8). 
All data are normalised to the average slope of the fEPSP for each genotype 
prior to delivery of the theta burst stimulus. p > 0.05, repeated measures 
ANOVA. 
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Figure 3.7: A comparison of long-term potentiation in 2 month old 3xTg and 
control mice (non-normalised).  The enhancement of the fEPSP slope following 4 
pulse theta burst was measured in control (n = 15/8) and 3xTg mice (n = 17/8) and 
is presented here as the actual values obtained in mV/ms.  p < 0.05, repeated 
measures ANOVA. 
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3.2.3: Electrophysiological characterisation of 6 month old 3xTg 
mice 
 
 
Following experiments with 2 month old 3xTg mice, another subset of mice were 
allowed to age to 6 months and studies were carried out to observe any 
differences between the transgenic and control mice. 
 
 
3.2.3.1: Input-output function  
 
 
Input-output curves were generated and compared for 6 month old 3xTg mice 
and 6 month old control mice of both genders. A normalised input-output curve, 
where the maximum field slope is set to 100%, was generated, coupled with a 
non-normalised input-output curve using the actual values (mV/ms) obtained. 
In 6 month control mice, there is no significant difference (p > 0.05, unpaired t-
test) between the normalised input-output curve of male (n = 5/3) and female (n 
= 9/4) mice (Fig. 3.8A). Similarly, in 6 month 3xTg mice, there is no significant 
difference (p > 0.05, unpaired t-test) between the normalised input-output curve 
of male (n = 5/3) and female (n = 12/4) mice (Fig. 3.8B). 
Given these findings the male and female data were pooled together. When the 
two groups are compared, there is no significant difference (p > 0.05, unpaired t-
test) between the normalised input-output curve of the 3xTg (n = 15/7) and 
control (n = 15/7) mice (Fig. 3.9A).  
For the non-normalised input-output curve, the control mice exhibit an fEPSP 
slope at 1 mA of 0.60 ± 0.05 mV/ms, while the 3xTg mice exhibit an fEPSP 
slope at 1 mA of 0.41 ± 0.05 mV/ms. There is no significant difference (p > 0.05, 
  
127 
unpaired t-test) between the two groups, although there is a trend for a reduced 
fEPSP slope at higher stimulus intensities in the 3xTg mice (p = 0.058 at 1mA, 
unpaired t-test) (Fig. 3.9B).   
 
 
3.2.3.2: Paired-pulse facilitation  
 
 
Paired-pulse facilitation was compared between 6 month old 3xTg mice and 
control mice, and the effect of gender on both genotypes was determined. In all 
experiments the maximum facilitation was observed at an interstimulus interval 
of 50ms. 
In control mice, the paired-pulse ratio at 50ms is 1.47 ± 0.05 for male (n = 5/3) 
and 1.52 ± 0.03 for female (n = 8/4) mice (Fig. 3.10A). There is no significant 
difference (p > 0.05, repeated measures ANOVA) in the paired-pulse ratio in 
male or female control mice at interstimulus intervals from 20 – 500ms.  
In the 3xTg mice, the paired-pulse ratio at 50ms is 1.52 ± 0.08 for male (n = 6/3) 
and 1.60 ± 0.12 for female (n = 7/4) mice (Fig. 3.10B). There is no significant 
difference (p > 0.05, repeated measures ANOVA) in the paired-pulse ratio in 
male or female 3xTg mice at interstimulus intervals from 20 – 500ms.  
Given that gender did not influence the paired-pulse ratio for either genotype, the 
data for male and female mice were combined. Collectively, the paired-pulse 
ratio at 50ms is 1.49 ± 0.03 for control (n = 13/7) and 1.56 ± 0.07 for 3xTg (n = 
13/7) mice. There is no significant difference in the paired-pulse ratio between 
the 3xTg and control mice (p > 0.05, repeated measures ANOVA) at any 
interstimulus interval measured from 20-500 ms (Fig. 3.11).  
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3.2.3.3: Long-term potentiation 
 
 
LTP was measured in the CA1 region for 6 month 3xTg and control mice. These 
experiments were divided by gender and both normalised and non-normalised 
data was generated. 
In all experiments a baseline fEPSP was recorded at 30 second intervals until the 
slope of the fEPSP was stabilised and constant over a 10 min period before 
delivery of the theta burst stimulus. In the following section the slope of the 
fEPSP is normalised to baseline (i.e. 100%) for each recording.  
In 6 month control male mice (n = 6/5), the peak enhancement of the slope of the 
fEPSP is 222 ± 14%, with a mean from 50-60 minutes following the theta burst 
stimulus of 165 ± 6%. In 6 month control female mice (n = 8/3), the peak 
enhancement is 229 ± 29%, with a mean from 50-60 minutes of 178 ± 10% (Fig. 
3.12A). 
In 6 month 3xTg male mice (n = 8/4), the peak enhancement of the slope of the 
fEPSP is 258 ± 36%, with a mean from 50-60 minutes following the theta burst 
of 181 ± 25%. In 6 month 3xTg female mice (n = 12/4), the peak enhancement is 
250 ± 34%, with a mean from 50-60 minutes of 151 ± 16% (Fig. 3.12B). 
There is no significant difference (p > 0.05, repeated measures ANOVA) 
between the magnitude of LTP in any of the four groups.  
Combining the results obtained for each gender, a comparison was then made 
between the 3xTg and control mice. In 6 month control mice (n = 14/8), the peak 
enhancement of the slope of the fEPSP is 225% ± 14%, with a mean from 50-60 
minutes following the theta burst stimulus of 170 ± 6%. In 6 month 3xTg mice (n 
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= 20/8), the peak enhancement is 254 ± 25%, with a mean from 50-60 minutes of 
164 ± 14%. 
There is no significant difference (p > 0.05, repeated measures ANOVA) 
between the magnitude of LTP in 6 month 3xTg and 6 month control mice (Fig. 
3.13). This is the case for all phases of LTP, from the initial peak to the plateau 
phase.  
 
 
3.2.3.4: Non-normalised long-term potentiation 
 
 
When the slope of the fEPSP is not normalised to control and the actual values 
(mV/ms) are utilised, in 6 month control mice the mean baseline fEPSP is 0.23 ± 
0.04 mV/ms, the peak enhancement following the theta burst stimulus is 0.52 ± 
0.06 mV/ms, and the mean from 50-60 minutes is 0.41 ± 0.07 mV/ms. In 6 
month 3xTg mice the mean baseline fEPSP is 0.20 ± 0.02 mV/ms, the peak 
enhancement is 0.52 ± 0.07 mV/ms, and the mean from 50-60 minutes is 0.38 ± 
0.05 mV/ms. (Fig. 3.14).  
There is no significant difference (p > 0.05, repeated measures ANOVA) 
between LTP in the 6 month 3xTg and control mice using the non-normalised 
LTP values.  
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3.2.3.5: Summary 
 
 
At 6 months of age there are no differences in hippocampal CA1 synaptic 
function apparent in the 3xTg mice. In addition, no gender-dependent effects 
were observed so both male and female data were pooled together. The 3xTg 
mice show no alterations in PPF, in input-output function or in normalised or 
non-normalised LTP values. These data show that in our colony of 3xTg mice 
there are no electrophysiological changes which could be linked to the reported 
development of pathological features at this age. 
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Figure 3.8: Normalised input-output curves obtained from 6 month old male 
and female 3xTg and control mice. The fEPSP slope was measured at a range of 
stimulus intensities and then normalised in (A) male (n = 5/3) and female (n = 9/4) 
control mice and (B) male (n = 5/3) and female (n = 12/4) 3xTg mice. p > 0.05, 
unpaired t-test. 
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Figure 3.9: Normalised and non-normalised input-output curves obtained 
from 6 month old 3xTg and control mice. The fEPSP slope was measured at 
a range of stimulus intensities and then normalised in control (n = 15/7) and 
3xTg mice (n = 15/7) (A). The non-normalised fEPSP slope measurement in 
control (n = 8/4) and 3xTg mice (n = 16/ 8) is shown in (B).  p > 0.05, 
unpaired t-test. 
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Figure 3.10: Paired-pulse facilitation determined in 6 month old male and 
female 3xTg and control mice. The paired-pulse ratio was calculated at a range of 
interstimulus intervals in (A) male (n = 5/3) and female (n = 8/4) control mice and 
(B) in male (n = 6/3) and female (n = 7/4) 3xTg mice. p > 0.05, repeated measures 
ANOVA. 
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Figure 3.11: Paired-pulse facilitation determined in 6 month old 3xTg and 
control mice. The paired-pulse ratio was calculated at a range of interstimulus 
intervals in control mice (n = 13/7) and 3xTg mice (n = 13/7). p > 0.05, repeated 
measures ANOVA. 
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Figure 3.12: The influence of gender on long-term potentiation recorded from 
6 month old 3xTg and control mice. The potentiation of the fEPSP slope obtained 
following four-pulse theta burst was measured in (A) control male (n = 6/5) and 
female mice (n = 8/3) and (B) 3xTg male (n = 8/4) and female mice (n = 12/4). All 
data are normalised to the average slope of the fEPSP for each genotype prior to 
delivery of the theta burst stimulus. p > 0.05, repeated measures ANOVA. 
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Figure 3.13: Long-term potentiation in 6 month old 3xTg mice and control. 
The potentiation of the fEPSP slope following four pulse theta burst was measured 
in control mice (n = 14/8) and 3xTg mice (n = 20/8). All data are normalised to the 
average slope of the fEPSP for each genotype prior to delivery of the theta burst 
stimulus. p > 0.05, repeated measures ANOVA. 
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Figure 3.14: A comparison of long-term potentiation in 6 month old 3xTg and 
control mice (non-normalised).  The potentiation of the fEPSP slope following 
four pulse theta burst was measured in control (n = 10/8) and 3xTg mice (n = 16/8) 
and is presented here as the actual values obtained. p > 0.05, repeated measures 
ANOVA.  
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3.2.4: Electrophysiological characterisation of 12 month old 3xTg 
mice  
 
 
3.2.4.1: Input-output function  
 
 
As there was no difference in input-output function or LTP at 6 months of age in 
3xTg mice, it was decided to use older mice for the study to see if the 
electrophysiological deficits previously reported (Oddo et al., 2003) could be 
obtained. At 12 months 3xTg mice are reported to show not only intraneuronal 
amyloid accumulation, but the deposition of amyloid plaques in cortex and 
hippocampus (Oddo et al., 2003). Electrophysiological measurements were 
therefore carried out at 12 months when the pathology was expected to be well 
established. 
Input-output curves were generated and compared for 12 month old 3xTg mice 
and control mice of both genders. A normalised input-output curve, where the 
maximum field slope is set to 100%, was generated, along with a non-normalised 
input-output curve using the actual values obtained. 
In 12 month old control mice, there is no significant difference (p > 0.05, 
unpaired t-test) between the normalised input-output curve of male (n = 6/3) and 
female (n = 8/4) mice (Fig. 3.15A). Similarly for the 12 month old 3xTg mice 
there is no significant difference (p > 0.05, unpaired t-test) between the 
normalised input-output curve of male (n = 6/3) and female (n = 5/4) mice (Fig. 
3.15B). 
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The male and female data were pooled together, which resulted in a significant 
reduction (p < 0.05, unpaired t-test) in the normalised fEPSP slope in the 12 
month 3xTg mice (n = 11/7) compared with control mice (n = 14/7) (Fig. 3.16A). 
For the non-normalised input-output curve, the control 12 month old mice exhibit 
an fEPSP slope at 1 mA of 0.40 ± 0.04 mV/ms while the 3xTg mice exhibit a 
fEPSP slope at 1 mA of 0.17 ± 0.02 mV/ms (Fig. 3.16B). There is again a 
significant reduction (p < 0.05, unpaired t-test) in the fEPSP slope in the 12 
month 3xTg mice compared with control.  
 
 
3.2.4.2: Paired-pulse facilitation  
 
 
Paired-pulse facilitation was compared between 12 month old 3xTg mice and 12 
month old control mice, and the effect of gender was also investigated. In all 
experiments, the maximum facilitation was observed at an inter-stimulus interval 
of 50ms. 
In control mice, the paired-pulse ratio at 50ms is 1.70 ± 0.07 for male (n = 8/3) 
and 1.62 ± 0.09 for female (n = 6/3) mice. There is no significant difference (p > 
0.05, repeated measures ANOVA) in the paired-pulse ratio in male or female 
control mice at interstimulus intervals from 20 – 500ms (Fig. 3.17A). 
In the 3xTg mice, the paired-pulse ratio at 50ms is 1.71 ± 0.10 for male (n = 7/3) 
and 1.65 ± 0.11 for female (n = 6/3) mice. There is no significant difference (p > 
0.05, repeated measures ANOVA) in the paired-pulse ratio in male, or female 
3xTg mice at interstimulus intervals from 20 – 500ms (Fig. 3.17B). 
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Given that gender did not influence the paired-pulse ratio for either genotype, the 
data for male and female mice were combined. Collectively, the paired-pulse 
ratio at 50ms is 1.67 ± 0.05 for control (n = 14/6) and 1.68 ± 0.07 for 3xTg (n = 
13/6) mice. There is no significant difference in the paired-pulse ratio in 3xTg 
when compared to control mice (p > 0.05, repeated measures ANOVA) at any 
inter-stimulus interval measured from 20-500 ms (Fig. 3.18).  
 
 
3.2.4.3: Long-term potentiation 
 
 
LTP was measured in the CA1 region for 12 month old 3xTg and control mice. 
These experiments were divided by gender and both normalised and non-
normalised data was generated. 
In all experiments a baseline fEPSP was recorded at 30 second intervals until the 
slope of the fEPSP was stabilised and constant over a 10 min period before 
delivery of the 4 pulse theta burst stimulus. In the following section the slope of 
the fEPSP is normalised to baseline (i.e. 100%) for each recording.  
In 12 month control male mice (n = 11/3), the peak enhancement of the slope of 
the fEPSP is 252 ± 24%, with a mean from 50-60 minutes following the theta 
burst stimulus of 184 ± 12%. In 12 month control female mice (n = 6/4), the peak 
enhancement is 197 ± 19%, with a mean from 50-60 minutes of 163 ± 10% (Fig. 
3.19A). 
In 12 month 3xTg male mice (n = 6/3), the peak enhancement of the slope of the 
fEPSP is 314 ± 27%, with a mean from 50-60 minutes following the theta burst 
stimulus of 240 ± 7%. In 12 month 3xTg female mice (n = 5/3), the peak 
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enhancement is 287 ± 35%, with an average from 50-60 minutes of 155 ± 13% 
(Fig. 3.19B). 
There is a significant difference (p < 0.05, repeated measures ANOVA) between 
the magnitude of LTP in male and female 3xTg mice, with enhancement greater 
in males in the plateau phase following theta burst stimulation. There is no 
significant difference (p > 0.05, repeated measures ANOVA) between LTP in 
male and female control mice. 
Combining the results for both genders, a comparison was then made between 
the 3xTg and control mice. In 12 month control mice (n = 17/7), the peak 
enhancement of the fEPSP slope is 233 ± 18%, with a mean from 50-60 minutes 
of 177 ± 8%. In 12 month 3xTg mice (n = 11/6), the peak enhancement is 302 ± 
21%, with a mean from 50-60 minutes of 210 ± 13% (Fig 3.20).  
There is a significant difference (p < 0.05, repeated measures ANOVA) in the 
magnitude of LTP in the initial phase from 0-20 minutes following theta burst 
stimulation, with LTP greater in 3xTg mice than in control mice. This is caused 
by the increased potentiation observed in male 3xTg mice.  
 
3.2.4.4: Non-normalised long-term potentiation 
 
 
When the slope of the fEPSP is not normalised to control and the actual values 
(mV/ms) are utilised, in 12 month control mice, the mean baseline fEPSP is 0.31 
± 0.04 mV/ms, the peak enhancement following four pulse theta burst is 0.76 ± 
0.10 mV/ms, and the mean from 50-60 minutes is 0.55 ± 0.07 mV/ms. In 12 
month 3xTg mice the mean baseline fEPSP is 0.11 ± 0.01 mV/ms, the peak 
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enhancement is 0.34 ± 0.04 mV/ms, and the mean from 50-60 minutes is 0.24 ± 
0.04 mV/ms.  
There is a clear reduction in the magnitude of LTP in the 12 month old 3xTg 
mice compared with control which is statistically significant (p < 0.05, repeated 
measures ANOVA) (Fig. 3.21). 
 
 
3.2.4.5: Summary 
 
 
There are several differences in hippocampal CA1 synaptic function observed in 
12 month 3xTg mice. Although there are no changes in PPF, there is a significant 
reduction in the fEPSP slope as measured in both the normalised and the non-
normalised input-output curve. This is mirrored in the non-normalised LTP data 
where the values for 3xTg are significantly lower than control. However, the 
normalised LTP graph shows that the magnitude of LTP is slightly increased 
relative to baseline measurements. This data shows that an age-dependent 
reduction in basal synaptic transmission and alterations in LTP are apparent by 
12 months in the 3xTg mice. 
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Figure 3.15: Normalised input-output curves obtained from 12 month old 
male and female 3xTg and control mice. The fEPSP slope was measured at a 
range of stimulus intensities and then normalised in (A) male (n = 5/3) and female 
(n = 8/4) control mice and (B) male (n = 6/3) and female (n = 5/4) 3xTg mice. p > 
0.05, unpaired t-test. 
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Figure 3.16: Normalised and non-normalised input-output curves obtained 
from 12 month old 3xTg and control mice. The fEPSP slope was measured at a 
range of stimulus intensities and then normalised for both the 3xTg mice (n = 
11/6) and the control mice (n = 14/7) (A). The non-normalised fEPSP slope 
measurement in control (n = 14/7) and 3xTg mice (n = 11/6) is shown in (B).  
p < 0.05, unpaired t-test. 
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Figure 3.17: Paired-pulse facilitation determined in 12 month old male and 
female 3xTg and control mice. The paired-pulse ratio was calculated at a range of 
interstimulus intervals in (A) male (n = 8/3) and female (n = 6/3) control mice and 
(B) male (n = 7/3) and female (n = 6/3) 3xTg mice. p > 0.05, repeated measures 
ANOVA. 
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Figure 3.18: Paired-pulse facilitation determined in 12 month old 3xTg and 
control mice. The paired-pulse ratio was calculated at a range of interstimulus 
intervals in 3xTg mice (n = 13/6) and in control mice (n = 14/6). p > 0.05, repeated 
measures ANOVA. 
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Figure 3.19: The influence of gender on long-term potentiation recorded from 
12 month old 3xTg mice and control mice. The potentiation of the fEPSP slope 
obtained following four-pulse theta burst was measured in (A) control male (n = 
11/3) and female mice (n = 6/4) and (B) 3xTg male (n = 6/3) and female mice (n = 
5/3). All data are normalised to the average slope of the fEPSP for each genotype 
prior to delivery of the theta burst stimulus.  = p < 0.05, repeated measures 
ANOVA. 
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Figure 3.20: Long-term potentiation in 12 month old 3xTg mice and control. 
The potentiation of the fEPSP slope following four pulse theta burst was measured 
in control mice (n = 17/7) and 3xTg mice (n = 11/6). All data are normalised to the 
average slope of the fEPSP for each genotype prior to delivery of the theta burst 
stimulus. 
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Figure 3.21: A comparison of long-term potentiation in 12 month old 3xTg 
and control mice (non-normalised).  The potentiation of the fEPSP slope 
following four pulse theta burst was measured in control (n = 17/7) and 3xTg mice 
(n = 11/6) and is presented here as the actual values obtained.  p < 0.05, repeated 
measures ANOVA. 
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3.2.5: Electrophysiological characterisation of 17 month old 3xTg 
mice 
 
 
3.2.5.1: Input-output function  
 
 
17 month old 3xTg mice were used as the final group for electrophysiological 
measurements. Mice of this age have not previously been studied, but should 
fully express all the pathological features of the AD model, including 
extracellular amyloid plaques and intraneuronal tangle formation. 
Input-output curves were generated and compared for 17 month old 3xTg mice 
and 17 month old control mice; due to the limited number of mice available it 
was not possible to divide these investigations by gender. A normalised input-
output curve, where the maximum field slope is set to 100%, was generated, 
together with a non-normalised input-output curve using the actual values 
obtained. 
There is a significant reduction (p < 0.05, unpaired t-test) in the normalised 
input-output curve values for 17 month old mice 3xTg mice (n = 6/3) when 
compared to control mice (n = 11/6). This difference is particularly apparent at 
low stimulus intensities (Fig. 3.22). 
For the non-normalised input-output curve, the control mice exhibit an fEPSP 
slope at 1 mA of 0.45 ± 0.06 mV/ms, while the 3xTg mice exhibit an fEPSP 
slope at 1 mA of 0.15 ± 0.04 mV/ms. There is a significant reduction (p < 0.05, 
unpaired t-test) in the fEPSP slope in the 17 month old 3xTg mice when 
compared with control (Fig. 3.23). 
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3.2.5.2: Paired-pulse facilitation  
 
 
Paired-pulse facilitation was compared between 17 month old 3xTg mice and 17 
month old control mice. In all experiments, the maximum facilitation was 
observed at an interstimulus interval of 50ms. 
In control mice (n = 13/6), the paired-pulse ratio at 50ms is 1.58 ± 0.04, while in 
3xTg mice (n = 11/6) it is 1.64 ± 0.11. There is no significant difference (p > 
0.05, repeated measures ANOVA) in the paired-pulse ratio in 3xTg when 
compared to control mice at any interstimulus interval measured from 20-500ms 
(Fig. 3.23). 
 
 
3.2.5.3: Long-term potentiation 
 
 
LTP was measured in the CA1 region for 17 month 3xTg and control mice. The 
results were separated by gender and both normalised and non-normalised data 
was generated. 
In all experiments a baseline fEPSP was recorded at 30 second intervals until the 
slope of the fEPSP was stabilised and constant over a 10 min period before 
delivery of the theta burst stimulus. In the following section the slope of the 
fEPSP is normalised to baseline (i.e. 100%) for each recording.  
In 17 month control male mice (n = 8/3), the peak enhancement of the slope of 
the fEPSP is 256 ± 14%, with a mean from 50-60 minutes following the theta 
burst stimulus of 183 ± 9%. In 17 month old control female mice (n = 9/3), the 
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peak enhancement is 205 ± 11%, with a mean from 50-60 minutes of 169 ± 11% 
(Fig. 3.24A). 
In 17 month 3xTg male mice (n = 7/3), the peak enhancement of the slope of the 
fEPSP is 300 ± 79%, with a mean from 50-60 minutes following the theta burst 
stimulus of 211 ± 23%. In 17 month 3xTg female mice (n = 3/3), the peak 
potentiation is 277 ± 84%, with a mean from 50-60 minutes of 230 ± 35% (Fig. 
3.24B). The large error bars are due to the limited number of female mice used in 
this experiment. 
There is no significant difference (p > 0.05, repeated measures ANOVA) 
between the magnitude of potentiation in male and female control, or male and 
female 3xTg, in any phase of LTP. 
Combining the results obtained for each gender, a comparison was then made 
between the 3xTg and control mice. For 17 month old control mice (n = 17/6), 
the peak enhancement of the slope of the fEPSP is 227 ± 12%, with a mean from 
50-60 minutes following the theta burst stimulus of 176 ± 7%. In 17 month 3xTg 
mice (n = 10/6), the peak enhancement is 294 ± 58%, with a mean from 50-60 
minutes of 217 ± 18%.  
There is a significant difference (p < 0.05, repeated measures ANOVA) between 
the magnitude of LTP in 17 month 3xTg and control mice in the plateau phase 
from 40 minutes onwards following theta burst stimulation (Fig. 3.25). 
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3.2.5.4: Non-normalised long-term potentiation 
 
 
When the slope of the fEPSP is not normalised to control and the actual values 
(mV/ms) are utilised, in 17 month control mice the mean baseline fEPSP is 0.24 
± 0.03 mV/ms, the peak enhancement following theta burst is 0.57 ± 0.06 mV/ms, 
and the mean from 50-60 minutes is 0.39 ± 0.03 mV/ms. In 17 month 3xTg mice 
the mean baseline fEPSP is 0.11 ± 0.02 mV/ms, the peak enhancement is 0.29 ± 
0.07 mV/ms, and the mean from 50-60 minutes is 0.23 ± 0.05mV/ms.  
There is a significant decrease (p < 0.05, repeated measures ANOVA) in the 
potentiation of the fEPSP slope in 17 month 3xTg mice when compared to 
control mice (Fig. 3.26). 
 
 
3.2.5.5: Summary 
 
 
At 17 months, the oldest age group studied, there are a number of changes in 
hippocampal CA1 synaptic function in the 3xTg mice. There is no alteration in 
PPF, but a significant reduction in the slope of the fEPSP as measured by both 
the normalised and non-normalised input-output curves. Despite this, however, 
there is an increase in the magnitude of LTP when normalised to the baseline 
values, which becomes significant in the plateau phase. These 
electrophysiological changes may be related to the progressive nature of the 
pathology reported in these mice. 
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Figure 3.22: Normalised and non-normalised input-output curves obtained 
from 17 month old 3xTg and control mice. The fEPSP slope was measured at a 
range of stimulus intensities and then normalised in control (n = 11/6) and 3xTg 
mice (n = 6/3) (A). The non-normalised fEPSP slope measurement in control (n = 
14/7) and 3xTg mice (n = 11/6) is shown in (B).  p < 0.05, unpaired t-test. 
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Figure 3.23: Paired-pulse facilitation determined for 17 month old 3xTg and 
control mice. The paired-pulse ratio was calculated at a range of interstimulus 
intervals in 3xTg mice (n = 11/6) and in control mice (n = 13/6). p > 0.05, repeated 
measures ANOVA. 
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Figure 3.24: The influence of gender on long-term potentiation obtained in 17 
month old 3xTg mice and control mice. The potentiation of the fEPSP slope 
obtained following four-pulse theta burst was measured in (A) control male (n = 
8/3) and female mice (n = 9/3) and (B) 3xTg male (n = 7/3) and female mice (n = 
3/3). All data are normalised to the average slope of the fEPSP for each genotype 
prior to delivery of the theta burst stimulus. p > 0.05, repeated measures ANOVA. 
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Figure 3.25: Long-term potentiation in 17 month old 3xTg and control mice. 
The potentiation of the fEPSP slope following four pulse theta burst was measured 
in control mice (n = 17/6) and 3xTg mice (n = 10/6). All data are normalised to 
the average slope of the fEPSP for each genotype prior to delivery of the theta 
burst stimulus.  = p < 0.05, repeated measures ANOVA. 
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Figure 3.26: A comparison of long-term potentiation in 17 month old 3xTg 
and control mice (non-normalised).  The potentiation of the fEPSP slope 
following four pulse theta burst was measured in control mice (n = 17/6) and 3xTg 
mice (n = 10/6) and is presented here as the actual values obtained. p < 0.05, 
repeated measures ANOVA. 
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3.2.6: Comparison of results obtained in 3xTg and control mice 
by age 
 
 
The following graphs present a summary of some of the results obtained over the 
full age range studied (2 – 17 months old) for 3xTg and control mice. This allows 
comparison to be carried out not only within but between different age groups. 
 
 
3.2.6.1: Input-output function  
 
 
Input-output curves were generated at the ages of 2, 6, 12 and 17 months in 3xTg 
and control mice. The non-normalised input-output curve, which uses the actual 
fEPSP slope values, was compared between all ages of 3xTg mice and all ages of 
control mice studied. 
In the control mice, the 2 month group has an fEPSP slope at 1 mA of 0.46 ± 
0.11 mV/ms (n = 12/7), the 6 month group (n = 15/7) of 0.60 ± 0.05 mV/ms, the 
12 month group (n = 14/7) of 0.40 ± 0.04 mV/ms and the 17 month group (n = 
11/6) of 0.45 ± 0.06 mV/ms (Fig. 3.27A).  
There is a statistically significant effect of age on the fEPSP slope (p < 0.05, 
repeated measures ANOVA) but this is not a progressive age-dependent deficit 
as observed in 3xTg mice.  
In the 3xTg mice, the 2 month group (n = 13/8) has an fEPSP slope at 1 mA of 
0.71 ± 0.14 mV/ms, the 6 month group (n = 15/7) of 0.41 ± 0.05 mV/ms, the 12 
month group (n = 11/7) of 0.17 ± 0.02 mV/ms, and the 17 month group (n = 6/3) 
of 0.15 ± 0.04 mV/ms (Fig. 3.27B). 
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There is a progressive reduction in the fEPSP slope from the ages of 2 months to 
12 months, which then stabilises between 12 and 17 months. There is a 
statistically significant effect of age between the 2 month group and the other 
groups (p < 0.05, repeated measures ANOVA, Newman-Keuls post hoc). 
 
 
3.2.6.2: Maximum fEPSP slope and amplitude 
 
 
The maximum fEPSP slope in 3xTg and control was calculated in a number of 
slices (n = 6-14 slices per age group) using a stimulus intensity of 1.5mA, at the 
plateau region at the top of the input-output curve. There is a reduction in the 
fEPSP slope with age in 3xTg mice which is not apparent in control mice. By the 
age of 12 months in the 3xTg mice the fEPSP slope is significantly lower than 
that observed in the control and remains so at 17 months (p < 0.05, unpaired t-
test) (Fig. 3.28). 
 
 
3.2.6.3: Paired-pulse facilitation  
 
 
Paired-pulse facilitation was measured and the paired-pulse ratio was recorded 
from 2, 6, 12 and 17 month 3xTg and control mice and compared.  
In the control mice, at 2 months (n = 11/6) the paired-pulse ratio at 50ms is 1.90 
± 0.07, at 6 months (n = 13/7) it is 1.49 ± 0.03, at 12 months (n = 14/6) it is 1.67 
± 0.05, and at 17 months (n = 13/6) it is 1.58 ± 0.04 (Fig. 3.29A). 
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There is a significant difference in the paired-pulse ratio in 2 month old mice 
compared with 12 and 17 month mice (p < 0.05, repeated measures ANOVA, 
Newman-Keuls post-hoc).  
In the 3xTg mice, at 2 months (n = 13/8) the paired-pulse ratio at 50ms is 1.52 ± 
0.05, at 6 months (n = 13/7) the paired-pulse ratio at 50ms is 1.56 ± 0.07, at 12 
months (n = 13/6) the paired-pulse ratio at 50ms is 1.68 ± 0.07, and at 17 months 
(n = 11/6) the paired-pulse ratio at 50ms is 1.64 ± 0.11 (Fig. 3.29B). 
There is no significant difference in the paired-pulse ratio overall with age in the 
3xTg mice (p > 0.05, repeated measures ANOVA). 
 
 
3.2.6.4: Long-term potentiation 
 
 
In control mice when LTP was normalised the following values were obtained. 
In 2 month control mice (n = 15/8), the mean enhancement of the fEPSP during 
the plateau phase from 50-60 minutes following theta burst is 152 ± 9%, in 6 
month control mice (n = 14/8) it is 170 ± 6%, in 12 month control mice (n = 17/7) 
it is 177 ± 8% and in 17 month control mice (n = 17/6) it is 176 ± 7% (Fig. 
3.30A). 
LTP is significantly lower at 2 months than at the older age ranges (p < 0.05, 
repeated measures ANOVA, Newman-Keuls post hoc). 
In 3xTg mice when LTP was normalised the following values were obtained. In 
2 month 3xTg mice (n = 17/8), the mean enhancement of the fEPSP during the 
plateau phase from 50-60 minutes following theta burst is 163 ± 11%, in 6 month 
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3xTg mice (n = 20/8) it is 164 ± 14%, in 12 month 3xTg mice (n = 11/6) it is 210 
± 13% and in 17 month 3xTg mice (n = 10/6) it is 217 ± 18% (Fig. 3.31A). 
There is an increase in the magnitude of LTP with age which is statistically 
significant in the 17 month group when compared with the 2 and 6 month groups 
(p < 0.05, repeated measures ANOVA, Newman-Keuls post hoc). 
 
 
3.2.6.5: Non-normalised long-term potentiation 
 
 
When the slope of the fEPSP is not normalised to control and the actual values 
(mV/ms) are utilised, in 2 month control mice, the mean enhancement of the 
fEPSP from 50-60 minutes following theta burst is 0.32 ± 0.05 mV/ms, in 6 
month control mice, the mean enhancement is 0.41 ± 0.07 mV/ms, in 12 month 
control mice, the mean enhancement is 0.55 ± 0.07 mV/ms and in 17 month 
control mice (n = 17/6), the mean enhancement from 50-60 minutes is 0.39  ± 
0.03 mV/ms (Fig. 3.30B). 
In the control mice, there is a significant effect of age on the magnitude of LTP 
with it appearing lowest at 2 months and highest at 12 months. 
When the slope of the fEPSP is not normalised to control and the actual values 
(mV/ms) are utilised, in 2 month 3xTg mice the mean enhancement of the fEPSP 
from 50-60 minutes is 0.57 ± 0.09 mV/ms, in 6 month 3xTg mice the mean 
enhancement is 0.38 ± 0.05 mV/ms, in 12 month 3xTg mice the mean 
enhancement is 0.24 ± 0.04 mV/ms, and in 17 month 3xTg mice (n = 10/6), the 
mean enhancement from 50-60 minutes is 0.23 ± 0.05 mV/ms (Fig. 3.31B). 
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In the 3xTg mice, there is a decrease in the magnitude of non-normalised LTP 
with age which appears to stabilise between 12 and 17 months of age. There is a 
statistically significant difference between 17 months and the other groups, and 
between 2 and 12 months (p < 0.05, repeated measures ANOVA, Newman-
Keuls post hoc). 
 
 
3.2.6.6: Summary 
 
 
There are several alterations in synaptic transmission which can be observed in 
the 3xTg mice at different ages. PPF is the only measurement that remains stable 
with age from 2-17 months. There is a progressive reduction in the fEPSP slope 
along with a decreased magnitude of non-normalised LTP between 2-12 months. 
Despite the decrease in the fEPSP slope, there is actually an increased magnitude 
of LTP with age when the data are normalised. All measurements remain stable 
between 12 and 17 months. These data show that in the 3xTg mice there are 
progressive and age-dependent differences in a number of the parameters that 
measure synaptic function. 
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Figure 3.27: Non-normalised input-output curve for slope obtained at all ages 
in 3xTg and control mice. The fEPSP slope data generated at the ages of 2, 6, 12 
and 17 months is displayed together for (A) control and (B) 3xTg mice. p < 0.05, 
repeated measures ANOVA. 
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Figure 3.28: Average maximum fEPSP slope in 3xTg and control at different 
ages.  The maximum fEPSP slope obtained in a number of slices (n ≥ 6 slices per 
group) is shown for 3xTg and control mice of 2, 6, 12 and 17 months (A).  
 = p < 0.05, unpaired t-test. Sample fEPSP traces for 2 and 17 months are shown 
below the graph (B).  
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Figure 3.29: Paired-pulse facilitation determined at all ages in 3xTg and 
control mice. The paired-pulse facilitation data generated at the ages of 2, 6, 12 
and 17 months is displayed together for (A) control and (B) 3xTg mice. For A, p 
< 0.05, repeated measures ANOVA between 2 and 12, and 2 and 17 month 
groups. p > 0.05 for all other comparisons.  For B, p > 0.05, repeated measures 
ANOVA. 
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Figure 3.30: A comparison of normalised and non-normalised LTP in control 
mice from 2-17 months.  The enhancement of the fEPSP slope obtained following 
four-pulse theta burst was measured in 2, 6, 12 and 17 month control mice and 
normalised to the average slope of the fEPSP prior to delivery of the theta burst 
stimulus (A). The potentiation of the fEPSP slope is also presented here as the 
actual values obtained (B). For A, p < 0.05, repeated measures ANOVA between 2 
month and other groups. p > 0.05 for all other comparisons.  For B, p < 0.05, 
repeated measures ANOVA. 
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Figure 3.31: A comparison of normalised and non-normalised LTP in 3xTg 
mice from 2-17 months.  The enhancement of the fEPSP slope obtained following 
four-pulse theta burst was measured in 2, 6, 12 and 17 month 3xTg mice and 
normalised to the average slope of the fEPSP prior to delivery of the theta burst 
stimulus (A). The potentiation of the fEPSP slope is also presented here as the 
actual values obtained (B). For A, p < 0.05, repeated measures ANOVA between 2 
and 17 month, and 6 and 17 month groups. p > 0.05 for all other comparisons.  For 
B, p < 0.05, repeated measures ANOVA between 2 and 12 months, 2 and 17 
months, 6 and 17 months and 12 and 17 months. p > 0.05 for all other 
comparisons.   
A 
B 
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3.2.7: Electrophysiological characterisation of 2 month old 
TASTPM mice 
 
 
The TASTPM mouse, which carries both mutant APP and PS1 transgenes, shows 
Aβ deposition from the age of 3 months, and cognitive deficits from the age of 6 
months (Howlett et al., 2004). For this reason, it was decided to use mice of 2 
and 6 months of age for electrophysiological studies. 2 month old mice should be 
free from pathology and should therefore possess normal synaptic function, 
while 6 month old mice may show electrophysiological deficits, as at this age the 
Aβ deposition is well established. The control mice for the 3xTg transgenic line 
were used as a comparison, and due to availability a mixture of male and female 
TASTPM mice were used for this study. 
 
 
3.2.7.1: Input-output function  
 
 
Input-output curves were generated and compared for 2 month old TASTPM and 
2 month old control mice. A normalised input-output curve, where the maximum 
field slope is set to 100%, was generated, along with a non-normalised input-
output curve using the real values. 
There is no significant difference (p > 0.05, unpaired t-test) in the normalised 
input-output curve in 2 month control (n = 12/7) and TASTPM mice (n = 9/6) 
(Fig. 3.32A). 
For the non-normalised input-output curve, the control mice exhibit an fEPSP 
slope at 1 mA of 0.46 ± 0.11 mV/ms while the TASTPM mice exhibit an fEPSP 
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slope at 1 mA of 0.45 ± 0.08 mV/ms. There is no significant difference (p > 0.05, 
unpaired t-test) between the TASTPM and control mice (Fig. 3.32B). 
 
 
3.2.7.2: Paired-pulse facilitation  
 
 
Paired-pulse facilitation was compared between 2 month old TASTPM and 
control mice. In all experiments, the maximum facilitation was observed at an 
interstimulus interval of 50ms. 
In control mice (n = 11/6), the paired-pulse ratio at 50ms is 1.90 ± 0.07 while in 
TASTPM mice (n = 11/7) the paired-pulse ratio at 50ms is 1.64 ± 0.09. 
There is a significant decrease in the paired-pulse ratio of 2 month TASTPM 
when compared to control mice (p < 0.05, repeated measures ANOVA followed 
by unpaired t-test) at an interstimulus interval of 50ms, but not at other 
interstimulus intervals (Fig. 3.33).  
 
 
3.2.7.3: Long-term potentiation 
 
 
LTP was measured in the CA1 region for 2 month TASTPM and control mice. 
In all experiments a baseline fEPSP was recorded at 30 second intervals until the 
slope of the fEPSP was stabilised and constant over a 10 min period before 
delivery of the theta burst stimulus. In the following section the slope of the 
fEPSP is normalised to baseline (i.e. 100%) for each recording.  
In 2 month control mice (n = 15/8), the peak enhancement of the slope of the 
fEPSP is 223 ± 12%, with a mean from 50-60 minutes following the 4 pulse theta 
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burst stimulus of 152 ± 9%. In 2 month TASTPM mice (n = 10/6), the peak 
enhancement is 198 ± 17%, with a mean from 50-60 minutes of 148 ± 9%.  
There is no significant difference (p > 0.05, repeated measures ANOVA) 
between the magnitude of LTP in 2 month TASTPM and control mice (Fig. 3.34). 
 
3.2.7.4: Summary 
 
There are no differences in electrophysiology measurements at 2 months in 
input-output function or LTP, with the sole change a minor reduction in PPF at 
this age. This suggests that there are few functional changes in the TASTPM 
mice at 2 months, an age reported to be prior to the development of any overt 
pathological features.  
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Figure 3.32: Normalised and non-normalised input-output curves obtained 
from 2 month old TASTPM and control mice. The fEPSP slope was measured at 
a range of stimulus intensities and then normalised in control (n = 12/7) and 
TASTPM mice (n = 9/6) (A). The non-normalised fEPSP slope measurement in 
control mice (n = 12/7) and TASTPM mice (n = 9/6) is shown in (B). p > 0.05, 
unpaired t-test. 
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B 
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Figure 3.33: Paired-pulse facilitation determined in 2 month old TASTPM 
and control mice. The paired-pulse ratio was calculated at a range of interstimulus 
intervals in control mice (n = 11/6) and TASTPM mice (n = 11/7).  = p < 0.05, 
repeated measures ANOVA followed by unpaired t-test. p > 0.05 for all other 
interstimulus intervals. 
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Figure 3.34: Long-term potentiation in 2 month TASTPM and control mice. 
The potentiation of the fEPSP slope following four pulse theta burst was 
measured in control mice (n = 15/8) and TASTPM mice (n = 10/6). All data are 
normalised to the average slope of the fEPSP for each genotype prior to delivery 
of the theta burst stimulus. p > 0.05, repeated measures ANOVA. 
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3.2.8: Electrophysiological characterisation of 6 month old TASTPM mice 
 
 
In the 6 month old TASTPM mice it was much more difficult to obtain an fEPSP 
of reasonable size to allow further experiments to take place. A large number of 
slices had to be discarded as an fEPSP could not be obtained or was too small to 
use. Of the 30 slices tested, only 8 were useable (a total of 27%) and LTP was 
only induced in 3 of these slices. It is normal for an fEPSP to be obtained in 
around 80-90% of healthy slices with LTP being induced in the majority of these. 
LTP was measured in the CA1 region for 6 month TASTPM and control mice. In 
all experiments a baseline fEPSP was recorded at 30 second intervals until the 
slope of the fEPSP was stabilised and constant over a 10 min period before 
delivery of the theta burst stimulus. In the following section the slope of the 
fEPSP is normalised to baseline (i.e. 100%) for each recording.  
In 6 month TASTPM mice (n = 3/2) the peak enhancement of the slope of the 
fEPSP is 361 ± 39%, with a mean from 50-60 minutes following the theta burst 
stimulus of 231 ± 40% (Fig. 3.35).  
There is a significant increase (p < 0.05, repeated measures ANOVA) in the 
magnitude of LTP obtained in the TASTPM slices. However it should be noted 
that, as stated above, these slices in which LTP were induced were a very small 
proportion of those tested and so may not be representative of the functional 
changes overall in the TASTPM mice. There are also large error bars due to the 
low number of slices used in the experiment. 
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Figure 3.35: Long-term potentiation in 6 month TASTPM and control mice. 
The potentiation of the fEPSP slope following four pulse theta burst was measured 
in control mice (n = 14/8) and TASTPM mice (n = 3/2). All data are normalised to 
the average slope of the fEPSP for each genotype prior to delivery of the theta burst 
stimulus. p < 0.05, repeated measures ANOVA. 
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3.2.9: Treatment of 6 month TASTPM slices with kynurenic acid 
 
 
3.2.9.1: Introduction 
 
 
As a result of the difficulties in obtaining an fEPSP in 6 month TASTPM mice, 
measures were attempted to improve neuronal viability in the hippocampal slices.  
Neuronal injury is an inevitable consequence of the slicing process and is due to a 
transient period of hypoxia combined with the mechanical severance of dendritic 
processes. This results in an initial phase of cytotoxic oedema where the opening 
of membrane cation channels causes Na+ influx and a concomitant increase in 
intracellular Cl- and water, leading to neuronal swelling and possible rupture 
(Siklos et al., 1997). The following, more slowly-evolving phase, delayed Ca2+-
induced neuronal degeneration, results in downstream mitochondrial dysfunction, 
caspase and calcineurin activation and eventual neuronal death (Dong et al., 
2009). Excitotoxic mechanisms in brain slices may be different to those observed 
in vivo due to the changes in brain metabolic processes and lack of cerebral blood 
flow in the isolated preparation. 
The initial trigger for these degenerative processes appears to be the simultaneous 
fusion and exocytosis of multiple synaptic vesicles resulting in a marked increase 
in extracellular glutamate concentrations (Fiala et al., 2003) which causes the 
simultaneous activation of glutamate receptors, in particular the NMDA receptor. 
There are several methods that can be used to reduce the effects of glutamate 
toxicity during slicing, including modification of the ionic composition of the 
aCSF or the addition of the compound kynurenic acid. The ability of kynurenic 
acid to guard against excitotoxicity is due to its actions as a NMDA receptor 
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antagonist at the glycine site; although it appears to have little effect on protecting 
against the initial neuronal swelling it is effective at preventing Ca2+ - induced 
neuronal degeneration (Richerson and Messer, 1995). 
Fitzjohn et al., (2001) reported the ability of kynurenic acid to reverse 
electrophysiological deficits obtained in the APPSwe mouse when added during 
the slicing process. They suggested that an increased susceptibility to 
excitotoxicity might underlie some of the observed deficits in these mice, and that 
the neurons might be more sensitive to insults including hypoxia. The 3xTg and 
TASTPM mice have also been generated to carry the APPSwe mutation. For this 
reason, experiments were carried out with kynurenic acid added to the aCSF 
during tissue slicing from the 3xTg and TASTPM mice to observe if this 
improved slice viability. 
 
 
3.2.9.2: Methods  
 
 
To improve the chances of obtaining successful fEPSPs in the 6 month old 
TASTPM mouse, 1mM of kynurenic acid was added to the aCSF during slicing 
and for one hour subsequent to this. Slices were then transferred to an incubation 
pot containing normal aCSF to ensure that the kynurenic acid was washed off 
prior to transfer to the recording bath. This process was repeated in control mice. 
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3.2.9.3: fEPSP measurements 
 
 
The fEPSP amplitude at an input stimulation of 1.5mA, at the top of the input 
output curve, was recorded for a number of slices. The amplitude rather than the 
slope was chosen as it is easier to record the amplitude in smaller fEPSPs where 
the shape of the field may be altered. In control mice, the maximum amplitude of 
the fEPSP is 1.2 ± 0.15 mV under normal conditions. However, in 6 month 
TASTPM mice the fEPSP amplitude is very small, with an average of 0.4 ± 0.10 
mV/ms. When treated with 1mM kynurenic acid, the amplitude increases 
significantly (p < 0.05, unpaired t-test) to 1.72 ± 0.27 mV (Fig. 3.36A). 
The percentage of slices which showed useable fEPSPs in the 6 month TASTPM 
slices was only 27%. However, when kynurenic acid was added during slicing 
the percentage of slices in which fEPSPs could be obtained increased to 100%, 
showing that the compound increases slice viability (Fig. 3.36B).  
 
 
3.2.9.4: Long-term potentiation 
 
 
LTP was measured in the CA1 region in slices treated with 1mM kynurenic acid. 
In all experiments a baseline fEPSP was recorded at 30 second intervals until the 
slope of the fEPSP was stabilised and constant over a 10 min period before 
delivery of the theta burst stimulus. In the following section the slope of the 
fEPSP is normalised to baseline (i.e. 100%) for each recording.  
The magnitude of LTP obtained in slices treated with 1mM kynurenic acid was 
also recorded. In untreated TASTPM slices (n = 3/2) the peak enhancement of 
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the slope of the fEPSP is is 361 ± 39%, with a mean following 4 pulse theta burst 
stimulus from 50-60 minutes of 231 ± 40%. In slices treated with kynurenic acid, 
(n = 10/4), the peak enhancement is 263 ± 14%, with a mean from 50-60 minutes 
of 166 ± 7%. This is similar to the results obtained in control mice (n = 14/8), 
where the peak enhancement is 225% ± 14%, with a mean from 50-60 minutes of 
170 ± 6% (Fig. 3.37A). 
Incubation with 1mM kynurenic acid significantly reduces the magnitude of LTP 
in 6 month TASTPM slices (p < 0.05, repeated measures ANOVA). There is no 
difference between LTP obtained in kynurenic acid treated TASTPM slices 
compared with control (p > 0.05, repeated measures ANOVA) (Fig. 3.37B). 
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Figure 3.36: Maximum fEPSP amplitude and percentage of successful fEPSPs 
obtained from slices in 6 month old TASTPM mice treated with 1mM 
kynurenic acid. The fEPSP amplitude at 1.5mA input (which produces the 
maximum fEPSP) was recorded in slices incubated in normal aCSF (n = 10) and 
aCSF containing 1mM kynurenic acid (n = 13) (A). The percentage of slices in 
which an fEPSP could be successfully obtained is shown in (B). p < 0.05, unpaired 
t-test. 
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B 
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Figure 3.37: Long term potentiation in 6 month TASTPM mice, with and 
without treatment with 1mM kynurenic acid, and control mice. The 
potentiation of the fEPSP slope obtained following four-pulse theta burst was 
measured in 6 month control mice (n = 14/8), TASTPM slices incubated in normal 
aCSF (n = 3/2) and aCSF containing 1mM kynurenic acid (n = 10/4). All data are 
normalised to the average slope of the fEPSP for each genotype prior to delivery of 
the theta burst stimulus. p < 0.05, TASTPM and control. p > 0.05, TASTPM + 
1mM KA and control.   
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3.2.10: Treatment of 12 month 3xTg slices with kynurenic acid 
 
 
Following the results obtained in the TASTPM mice, studies were conducted on 
12 month 3xTg mice to see if the fEPSP amplitude was increased following 
treatment with 1mM kynurenic acid. A more detailed analysis including input-
output function and PPF could be carried out as fEPSPs are readily obtained in 
both 12 month control and 3xTg slices. 
 
 
3.2.10.1: fEPSP measurements 
 
 
The fEPSP amplitude at an input stimulation of 1.5mA, at the top of the input 
output curve, was recorded for a number of slices. In control slices, the 
maximum fEPSP amplitude is 1.28 ± 0.1 mV. In 3xTg slices incubated in normal 
aCSF, the fEPSP amplitude is 0.61 ± 0.2 mV. Under normal conditions, there is a 
significant difference between 3xTg and control (p < 0.05, unpaired t-test).  
Following incubation with 1mM kynurenic acid, there is a slight, but not 
significant increase in the maximum fEPSP amplitude (p > 0.05, unpaired t-test) 
in the control mice, to 1.5 ± 0.2 mV/ms. However, there is a significant increase 
(p < 0.05, unpaired t-test) in the maximum fEPSP amplitude in 3xTg mice, to 
1.54 ± 0.2 mV/ms (Fig. 3.38). This shows that incubation with kynurenic acid 
recovers the fEPSP amplitude in 3xTg mice to a level similar to control, where 
there is no significant difference between the two groups (p > 0.05, unpaired t-
test). 
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3.2.10.2: Input-output function 
Input-output function was also measured in 12 month 3xTg and control mice 
treated with 1mM kynurenic acid. A normalised input-output curve, where the 
maximum field slope is set to 100%, was generated, along with a non-normalised 
input-output curve using the actual values obtained. 
In the 12 month control mice, there is no significant difference in the input-
output curve between treated and untreated slices (p > 0.05, unpaired t-test) (Fig. 
3.39A). However in 3xTg mice there is a significant increase in the normalised 
input-output curve following incubation with kynurenic acid (p < 0.05, unpaired 
t-test) (Fig 3.39B). 
For the non-normalised input-output curve, the untreated control mice have an 
fEPSP slope at 1 mA of 0.40 ± 0.04 mV/ms, and in slices incubated with 1mM 
kynurenic acid, the control mice have an fEPSP slope at 1 mA of 0.67 ± 0.14 
mV/ms (Fig. 3.40A) 
For the non-normalised input-output curve, the untreated 3xTg mice have an 
fEPSP slope at 1 mA of 0.17 ± 0.02 mV/ms, and in slices incubated with 1mM 
kynurenic acid, the 3xTg mice have an fEPSP slope at 1 mA of 0.82 ± 0.13 
mV/ms (Fig. 3.40B). 
There is a significant increase (p < 0.05, unpaired t-test) in the fEPSP slope at 
0.2 and 0.3mA only in control mice, while there is a significant increase (p < 
0.05, unpaired t-test) at all stimulus intensities from 0.2mA – 1mA in 3xTg mice 
after kynurenic acid treatment.  
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3.2.10.3: Paired-pulse facilitation 
 
 
Paired-pulse facilitation was measured in slices from 3xTg and control mice 
incubated in kynurenic acid. In all experiments, the maximum facilitation was 
observed at an interstimulus interval of 50ms.  
In control mice (n = 14/6) the paired-pulse ratio at 50ms is 1.67 ± 0.05. In slices 
treated with 1mM kynurenic acid (n = 14/5), the paired-pulse ratio at 50ms is 
1.45 ± 0.04 (Fig. 3.41A).  
In 3xTg mice (n = 13/6), the paired-pulse ratio at 50ms is 1.68 ± 0.07. In slices 
treated with 1mM kynurenic acid (n = 11/5), the paired-pulse ratio at 50ms is 
1.34 ± 0.03 (Fig. 3.41B).  
There is a significant decrease in PPF in control mice only at interstimulus 
intervals up to 100ms (p < 0.05, repeated measures ANOVA followed by 
unpaired t-test). There is a significant decrease in PPF at all intervals when 3xTg 
mice are treated with 1mM kynurenic acid (p < 0.05, repeated measures 
ANOVA).  
 
 
3.2.10.4: Long-term potentiation  
 
 
LTP was measured in the CA1 region in slices treated with 1mM kynurenic acid. 
In all experiments a baseline fEPSP was recorded at 30 second intervals until the 
slope of the fEPSP was stabilised and constant over a 10 min period before 
delivery of the theta burst stimulus. In the following section the slope of the 
fEPSP is normalised to baseline (i.e. 100%) for each recording.  
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In untreated slices, in 12 month control mice (n = 17/7), the peak enhancement of 
the slope of the fEPSP is 233 ± 18%, with a mean from 50-60 minutes following 
the theta burst stimulus of 177 ± 8%. In slices incubated with 1mM kynurenic 
acid, in 12 month control mice (n = 11/4), the peak enhancement is 176 ± 14%, 
with a mean from 50-60 minutes of 155 ± 8% (Fig. 3.42A).  
In untreated slices, in 12 month 3xTg mice (n = 11/6), the peak enhancement of 
the fEPSP slope is 302 ± 21%, with a mean from 50-60 minutes of 210 ± 13%. In 
slices incubated with 1mM kynurenic acid, in 12 month 3xTg mice (n = 8/4), the 
peak enhancement is 183 ± 18%, with a mean from 50-60 minutes of 140 ± 5% 
(Fig 3.42B).  
There is no difference in the magnitude of LTP in control mice with (n = 10/4) 
and without (n = 17/7) kynurenic acid. There is a significant decrease in the 
magnitude of LTP in 3xTg mice (n = 11/6) with the addition of 1mM kynurenic 
acid during slicing (n = 8/4).  
 
 
3.2.10.5: Summary 
 
 
Incubation of slices with 1mM kynurenic acid improves slice viability in both 
3xTg and TASTPM mice. This is shown by the increase in fEPSP amplitude and 
markedly higher percentage of successful fEPSPs in slices treated with kynurenic 
acid. In 3xTg mice when other electrophysiological parameters are studied there 
is found to be a decrease in PPF at all stimulus intensities, and a significant 
decrease in the magnitude of LTP with kynurenic acid treatment which is not 
observed in control mice. 
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Figure 3.38: A comparison of fEPSP amplitude in 12 month 3xTg and control 
mice with and without treatment with 1mM kynurenic acid. The fEPSP 
amplitude at 1.5mA input (which produces the maximum fEPSP) was recorded in 
control slices (n = 10/5) and 3xTg slices (n = 11/6) incubated in normal aCSF, and 
compared with control slices (n = 12/4) and 3xTg (n = 12/4) incubated in aCSF 
containing 1mM kynurenic acid.  = p < 0.05, unpaired t-test. 
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Figure 3.39: Normalised input-output curves obtained from 12 month old 
male and female 3xTg and control mice treated with 1mM kynurenic acid. 
The fEPSP slope was measured at a range of stimulus intensities and then 
normalised in slices from control (n = 14/7) and control (n = 10/4) incubated in 
1mM kynurenic acid (A). p > 0.05, unpaired t-test. This was repeated in slices from 
3xTg mice (n = 11/6) and 3xTg mice (n = 11/5) incubated in 1mM kynurenic acid 
(B). p < 0.05, unpaired t-test. 
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Figure 3.40: Non-normalised input-output curves obtained from 12 month old 
male and female 3xTg and control mice treated with 1mM kynurenic acid. 
The fEPSP slope was measured at a range of stimulus intensities in slices from 
control (n = 14/7) and control incubated in 1mM kynurenic acid (n = 10/4) (A).  p 
< 0.05, unpaired t-test, at stimulus intensities of 0.2 and 0.3 mA only. The fEPSP 
slope was measured at a range of stimulus intensities in slices from 3xTg mice (n = 
11/6) and 3xTg mice incubated in 1mM kynurenic acid (n = 11/5) (B). p < 0.05, 
unpaired t-test. 
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Figure 3.41: Paired-pulse facilitation determined in 12 month 3xTg and control 
treated with 1mM kynurenic acid. The paired-pulse ratio was calculated at a range 
of interstimulus intervals in control mice in untreated slices (n = 14/7) and slices 
incubated in 1mM kynurenic acid (n = 11/4) (A). p < 0.05, repeated measures 
ANOVA followed by unpaired t-test, at interstimulus intervals up to 100ms only. 
The paired-pulse ratio was calculated at a range of interstimulus intervals in 3xTg 
mice in untreated slices (n = 13/6) and slices incubated in 1mM kynurenic acid (n = 
11/4) (B). p < 0.05, repeated measures ANOVA 
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Figure 3.42: Long term potentiation in 12 month 3xTg and control with and 
without 1mM kynurenic acid. The potentiation of the fEPSP slope obtained 
following four-pulse theta burst was measured in slices from control mice (n = 
17/7) and control slices incubated in 1mM kynurenic acid (n = 10/4) (A). p > 0.05, 
repeated measures ANOVA. The potentiation of the fEPSP slope was measured in 
3xTg mice (n = 11/6) and 3xTg mice incubated in 1mM kynurenic acid (n = 8/4). 
All data are normalised to the average slope of the fEPSP for each genotype prior 
to delivery of the theta burst stimulus (B).  p < 0.05, repeated measures ANOVA. 
B 
A 
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3.3: Discussion  
 
Alterations in synaptic transmission and plasticity have been observed in mouse 
models of AD including the 3xTg and TASTPM models, however results from 
different research groups have proved inconsistent. Electrophysiological 
recordings were made from 3xTg and TASTPM mice to observe if there were 
any differences in synaptic function in these models and if these findings were 
consistent with previously reported results.  
 
 
3.3.1: Technical aspects 
 
 
There are a number of technical variables which can affect slice viability and 
LTP measurements, such as the mechanisms of slice preparation, temperature 
and recording used (summarised in Table 3.1). For this reason, it is difficult to 
compare studies of hippocampal electrophysiology between individual research 
groups if these variables are not standardised. Critically, the stimulation protocol 
used may result in the activation of distinct signalling pathways; for example the 
ability of acutely applied Aβ oligomers to impair LTP depends upon the 
paradigm used (HFS vs. TBS) (Smith et al., 2009).  
Other technical issues associated with electrophysiological recordings are the 
biochemical changes which inevitably occur during the preparation of the 
hippocampal slice. This may involve alterations in phosphorylation of cellular 
proteins, such as the AMPA receptor, CaMKII and Src family kinases (Ho et al., 
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2004) and in gene regulation and transcription (Taubenfeld et al., 2002). Specific 
to transgenic models of AD, it has been suggested that extracellular soluble Aβ 
may in fact diffuse out of slices, resulting in a reduction of the concentration of 
Aβ within the tissue (Waters 2010).  
The acute slice preparation is a useful experimental tool to study hippocampal 
synaptic function, but these examples highlight the limitations present with the 
technique. There may be biochemical and functional differences in the transgenic 
mice which might only become apparent using studies in the intact animal e.g. in 
vivo electrophysiology. 
 
 
Table 3.1: Technical variables in hippocampal slice recordings 
Variable Effect Reference 
Hippocampal 
subdivision 
(CA1, DG) 
Regional anatomical and 
functional differences  
Swanson-Park et al. 
1999 
Ionic composition of 
aCSF (Mg2+,Ca2+, 
glucose) 
Altered neuronal viability and 
synaptic transmission, 
likelihood of epileptiform 
activity 
Richerson et al. 1995 
Slice preparation (ice 
cold aCSF, glutamate 
receptor antagonists) 
Degree of excitotoxicity and 
neuronal viability 
Fitzjohn et al. 2001 
Slice recovery 
temperature (cold, 
room temp., 37°C) 
Metabolic alterations, 
susceptibility to epileptiform 
activity 
Watson et al. 1997 
Stimulation protocol  
(HFS, TBS) 
Activation of alternative 
signalling pathways 
Hernandez et al. 
2005 
Interface or 
submerged recording 
Activation of alternative 
signalling pathways 
Capron et al. 2006 
Bath temperature 
(30°C - 37°C) 
Reduction of fEPSP amplitude 
at higher temperatures 
Masino et al. 2000 
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3.3.2: Characterisation of the 3xTg mouse 
 
 
In the 3xTg mouse model, multiple parameters were recorded including input-
output function, PPF and LTP. The results obtained are discussed below in the 
following sections. 
 
3.3.2.1: Paired-pulse facilitation in the 3xTg model 
 
 
PPF was measured from 2 to 17 months in 3xTg and control mice. In control 
mice, PPF remained stable with a ratio of 1.5 – 1.7 at 50ms from 6 to 17 months, 
but there was a significant increase in PPF at 2 months compared with the other 
ages studied (a ratio of 1.9 at 50ms), a difference that was most marked in male 
mice. In 3xTg mice, the magnitude of PPF remained stable with age (1.5 – 1.7), 
with a similar ratio to that of control mice. Consequently, this results in a 
significant difference between the magnitude of PPF in 3xTg and control mice at 
2 months only. However, it is not clear whether this is due to an enhancement of 
PPF in the younger control mice or a reduction in PPF in the 3xTg mice.  The 
magnitude of PPF recorded in the mouse hippocampus shows variation between 
research groups; values are generally within the range of 1.3 – 2.0, so PPF in 
control mice is of the expected range in our colony. Age-dependent differences 
have not previously been observed in control mice (Ris et al., 2005, Fitzjohn et 
al., 2010) but a comprehensive analysis of the effects of PPF with ageing has not 
been carried out so developmental changes, strain or gender-dependent 
differences can not be ruled out.  
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PPF is dependent on the intracellular Ca2+ concentration within the presynaptic 
terminal, with the residual rise in Ca2+ following the first stimulus allowing 
enhanced vesicular neurotransmitter release on the second stimulus (Nathan et al., 
1990). The difference in the paired-pulse ratio between 2 month old 3xTg and 
control mice suggests an alteration in presynaptic function between the two 
groups. Of the three transgenes present in the 3xTg mouse, PS1 is widely known 
to be involved in neuronal Ca2+ regulation, with the PS1M146V mutation markedly 
increasing Ca2+ release and signalling in cortical neurons (Stutzmann et al., 2004). 
Oddo et al (2003) reported that the PS1M146V mutation increased PPF at 6 months 
in transgenic mice, and this was also observed in double transgenic mice with the 
additional tauP301L transgene. The presence of the single APPSwe mutation alone 
has no effect on the magnitude of PPF (Fitzjohn et al., 2001). Surprisingly, the 
combination of the three transgenes together in the 3xTg mouse results in a 
masking of the effects of the PS1M146V mutation as PPF has been reported to be 
normal at 1 and 6 months (Oddo et al., 2003). This result has been replicated in 
our colony of 3xTg mice at older ages showing that the progression of pathology 
in these mice does not result in an age-dependent effect on presynaptic function. 
 
3.3.2.2: Basal synaptic transmission in the 3xTg model 
 
 
The normalised input-output curve reveals the electrical stimulation required to 
elicit an fEPSP of increasing magnitude. There is a significant rightward shift in 
12 and 17 month 3xTg mice. This shows that a higher input current is required to 
obtain an fEPSP of similar magnitude to control and shows that deficits in basal 
synaptic transmission are present in these mice at older ages.  
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The non-normalised output curve provides the actual numerical fEPSP slope 
values obtained at each stimulus intensity. Control mice show no age-dependent 
changes in input-output function, but in contrast, 3xTg mice demonstrate a 
progressive reduction in the fEPSP slope from the ages of 2 to 12 months. In our 
colony of 3xTg mice at 6 months, there is no difference in input-output function 
or baseline fEPSP recordings compared to control, while at 12 and 17 months 
both the input-output curve and the baseline fEPSP recordings are markedly 
reduced. These findings may reflect the recruitment of a smaller population of 
neurons at each input intensity, which could be due to neuronal damage through 
excitotoxicity (discussed in more detail in Section 3.3.1.7.)  However, at 2 
months there is a significant enhancement in the baseline fEPSP. These results 
show that basal synaptic transmission is enhanced in young 3xTg mice. The 
mechanism of this perturbation is not known and may vary depending on the 
stimulus intensity, as experimental stimulus strength can differentially affect 
presynaptic and postsynaptic function (Chakroborty et al., 2009). However, it 
may involve an increase in neuronal excitability as 3xTg mice show a 
hyperactivity of glutamatergic synapses in the hippocampus observed as an 
increased rate of spontaneous firing in patch clamp studies (Arsenault et al., 
2011). This increased excitatory drive may result in a degree of network 
dysfunction; this has been suggested as a factor contributing to cognitive 
dysfunction in other transgenic models of AD and is discussed further below in 
Section 3.3.2.6.  
The fEPSP slope value obtained in the 3xTg mice at 2 months of 0.4mV/ms at 
1mA is similar to that obtained by Chakroborty et al. (2009), showing that the 
magnitude is within the normal range, but the values are markedly less than the 
  
197 
1mV/ms at 1mA obtained by Oddo et al. (2003), which may reflect differences 
in experimental protocol for extracellular recording. Oddo et al. (2003) reported 
a normal input-output function in the 3xTg mouse at 1 month of age, but a 
reduction in the fEPSP slope at 6 months; this occurred in control but was more 
marked in 3xTg mice. At this age, the fEPSP slope in 3xTg mice was ~ half that 
of control, a ratio which is not observed in our colony of mice until 12 months of 
age. This suggests that the development of pathological features has occurred 
more rapidly in the colony of mice studied by Oddo et al. This group also 
observed identical changes in the single-transgenic PS1M146V and double-
transgenic PS1M146V, tauP301L models, implicating the PS1 transgene in alterations 
of basal synaptic transmission. However, these results were not replicated by 
another group who noted no difference in synaptic function in PS1
 M146V mice 
(Wang et al., 2004). In 3xTg mice, Chakroborty et al. (2009) reported no 
differences in input-output function at 6-8 weeks of age, but noted the presence 
of alterations in evoked postsynaptic Ca2+ release (see Section 3.3.2.5). It is 
possible that there are age-independent changes in basal synaptic transmission 
due to the presence of the transgenes during development, as observed in our 
colony of mice at 2 months where despite the lack of observed biochemical 
changes (see Chapter 4) there are electrophysiological differences at this age. 
These alterations in basal synaptic transmission are followed by age-dependent 
deficits linked to the development of pathological features in 3xTg mice. 
 
3.3.2.3: Long-term potentiation in the 3xTg model 
 
 
LTP was measured in our colony of 3xTg mice at ages from 2 to 17 months to 
observe if there were any alterations in this form of synaptic plasticity. To 
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summarise, in our colony at 2 and 6 months there are no differences in the 
enhancement of the fEPSP slope observed relative to the baseline following the 
theta burst stimulus compared to control mice. However, at 12 and 17 months 
there is a significant increase in the enhancement following theta burst which 
occurs during the initial peak phase at 12 months and the plateau phase 
(characteristic of LTP) at 17 months. However, it should be remembered that the 
overall magnitude of LTP still remains reduced when compared to control due to 
the smaller baseline fEPSP amplitude (see Section 3.3.2.2). However, these 
results show that despite the reduction in basal synaptic transmission, LTP can 
still be induced in the 3xTg mice and appears to show an age-dependent 
enhancement. There are several possible reasons for this finding which will be 
discussed in more detail below.  
A distinction should be made between enhancement of the peak phase following 
the theta burst protocol, observed in 12 month 3xTg, and enhancement of the 
later plateau phase observed in 17 month 3xTg. The peak phase incorporates a 
short-term process of synaptic facilitation known as post-tetanic potentiation 
(PTP). While LTP is considered to involve both pre- and post-synaptic 
mechanisms (see Chapter 1.5.3), PTP is regarded as a purely presynaptic 
phenomenon. Similar to PPF, it is dependent on intracellular Ca2+ and involves 
enhanced neurotransmitter release, a consequence of an increase in the Ca2+ 
sensitivity of vesicular fusion (Korogod et al., 2007). In these experiments there 
is an overlapping contribution of PTP and LTP and it is likely that in the 3xTg 
mice there are alterations in both processes. 
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As the increase in LTP occurs at older ages in the 3xTg mice it is conceivable 
that this change in synaptic plasticity is linked to the development of pathology 
and Aβ deposition. The enhanced susceptibility to excitotoxicity observed in 
these mice at older ages will result in many neurons showing dysfunction or even 
death. As a result, LTP may be induced only in a subset of neurons which remain 
healthy; it is possible that compensatory mechanisms are present which may 
influence plasticity in these remaining neurons. Even though a smaller fEPSP is 
generated the enhancement in the 3xTg mice following theta burst is greater than 
in control, but this may not be representative of the full neuronal population. The 
reported perturbations in Ca2+ homeostasis could also affect the magnitude of 
LTP, which is critically dependent on the intracellular Ca2+ concentration for its 
induction. Finally, the presence of the PS1 and APP transgenes can alter the 
magnitude of LTP obtained (see Section 3.3.2.4 below). 
Several groups have studied synaptic plasticity in the 3xTg mouse model. Oddo 
et al. (2003) reported a decrease in the magnitude of LTP at 6 months in the 
3xTg mouse when compared to control, but there are several differences in this 
study which should be taken into consideration. This group observed a marked 
increase in LTP in control mice between the ages of 1 month and 6 months, from 
around 140% to 190%, which served to enhance the reported deficit in the 3xTg 
mice. Although an age-dependent increase was observed in our colony of mice 
from 2 to 6 months this was not as marked; the magnitude of potentiation was 
157% at 2 months and 170% at 6 months. An important observation is the use by 
Oddo et al. of four bursts of high-frequency stimulation (HFS) repeated at 20 
second intervals for the induction of LTP. This is characterised as a very strong 
stimulation protocol in comparison to TBS, and it is known that the choice of 
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induction protocol recruits different biochemical pathways (Hernandez et al., 
2005). Another technical difference that can influence the interpretation of 
results is the use of an interface chamber by Oddo et al.  rather than a submersion 
recording chamber as used in my experiments. In other studies of 3xTg mice, 
Chakroborty et al. (2009) showed no changes in the magnitude of LTP induced 
in young 3xTg mice at 6-8 weeks. This finding would be expected if the 
perturbation of LTP is linked to the age-dependent development of pathological 
features. Another group to have studied synaptic plasticity in the 3xTg mouse 
reported that at 10 months the magnitude of LTP induced by TBS was similar to 
that obtained in control mice, which is in contrast to the original findings (Zhang 
et al., 2010b). From these studies it is evident that the measurement of LTP in the 
3xTg mouse has given inconsistent results and must be interpreted with care due 
to variations in technical protocol between individual groups.  
 
3.3.2.4: Effects of the individual transgenes on synaptic plasticity 
 
 
A number of studies have been carried out to investigate the effects of APP, PS1 
and tau transgene expression on synaptic plasticity. In the original paper which 
characterised the 3xTg model, Oddo et al. reported that LTP could be induced 
normally in both the single transgenic PS1M146V and the double transgenic 
PS1M146V, tauP301L mice at 2 and 6 months of age. Immediately following 
induction there was actually a significant increase in the magnitude of 
potentiation in the PS1
 M146V mice at 6 months of age when compared to control. 
Similar effects of the PS1M146V mutation were observed in another study, but 
interestingly this change was accompanied by a decrease in the magnitude of the 
sustained phase of LTP, L-LTP, and both E-LTP and L-LTP reduced with 
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advancing age in older mice (Auffret et al., 2010). These findings suggest that 
there may be a dissociation between the effects of PS1
 M146V on E-LTP and L-
LTP. As my studies of the 3xTg mice only examined E-LTP, it would be of 
interest to investigate whether there were differences in L-LTP in these mice. 
Studies using other PS1 transgenic mice suggest that familial AD mutations may 
have an overall effect of enhancing the magnitude of LTP. Both PS1∆E9 (exon 9 
deleted) and PS1A246E mice exhibit increased potentiation compared to control 
following LTP induction, an effect which has been attributed to an enhancement 
in postsynaptic intracellular Ca2+ following NMDA receptor activation (Parent et 
al., 1999, Zaman et al., 2000). A similar mechanism could be present in the 3xTg 
mice, which might result in the observed increase in LTP. If alterations in Ca2+ 
signalling become more pronounced with age this could result in the increased 
potentiation observed in older mice relative to the baseline fEPSP. 
In contrast, there is evidence that familial APP mutations may reduce the 
magnitude of LTP, although there have been conflicting results between research 
groups, with some reporting no effect of APP mutation on synaptic plasticity 
(Fitzjohn et al., 2001). This inconsistency may be due to differences in 
experimental protocol (see Section 3.3.1) which can have a marked effect on the 
results obtained. In the commonly used Tg2576 model, which expresses the 
single APPSwe transgene, several groups have reported reduced hippocampal LTP. 
For example, in the CA1 region, LTP is normal until 8 months, but there is a 
decrease in the magnitude of LTP at 15 months with no reduction in basal fEPSP 
amplitude  (Chapman et al., 1999b). Similarly, reduced LTP has been reported in 
another region of the hippocampus, the DG, from the age of 4 months (Jacobsen 
et al., 2006). This suggests that the APPSwe transgene causes an age-dependent 
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reduction of synaptic plasticity in the hippocampus. However, the mechanism 
underlying this is not fully understood.  
Several studies have used the application of Aβ oligomer preparations to study 
the effects of acute exposure to Aβ on synaptic plasticity in hippocampal slices. 
This may mimic some of the effects of excessive Aβ generation associated with 
APP transgene expression. The treatment of isolated hippocampal slices with Aβ 
oligomers reduces the magnitude of LTP which can be obtained (Walsh et al., 
2002, Shankar et al., 2008) although this may also be dependent on the 
stimulation protocol used (Smith et al., 2009). This perturbation is thought to 
occur through an NMDA receptor-mediated pathway, with Aβ causing AMPA 
receptor endocytosis and leading to loss of dendritic spines (Hsieh et al., 2006). 
Another possibility is that Aβ oligomers increase susceptibility to excitotoxicity, 
and this is discussed in Section 3.3.2.7. 
The 3xTg mouse also carries the tauP301L transgene, but relatively little work has 
been carried out on the effects of tau mutations on synaptic plasticity. One study 
found that LTP was enhanced in 2 month tauP301L mice prior to the development 
of tau hyperphosphorylation (Boekhoorn et al., 2006). Another investigation 
reported a requirement for the tau protein in acute Aβ-induced impairment of 
LTP, although the mechanism underlying this interaction is not known (Shipton 
et al., 2011). This finding reveals that the presence of the tauP301L transgene may 
also affect synaptic plasticity. However, the similar results obtained in this thesis 
for the 3xTg and for the TASTPM mice that do not carry the tau transgene, 
suggest that tau may have little effect on synaptic function in these models. 
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In conclusion, there may be differential effects of the APP and PS1 transgenes on 
LTP. This complexity highlights the difficulties of using models such as the 
3xTg that contain multiple transgenes, which may have conflicting effects on 
synaptic function. Further work is required using standardised procedures 
between laboratories to help explain the discrepancies in the 3xTg model and 
other mouse models of AD. It is likely that alterations in synaptic plasticity occur 
through a number of different age-dependent and age-independent processes and 
further work would be required to separate the mechanisms involved. It would be 
interesting to use immunohistochemical approaches and neuronal imaging to 
study glutamate receptor localisation and other molecular alterations which occur 
in LTP and link this more closely to the development of pathological changes.  
 
 
Alterations in synaptic function in the 3xTg model: multiple hypotheses 
 
 
There are several factors which have been mentioned above that could result in 
alterations in synaptic function, and it is likely a combination of these which 
cause the electrophysiological changes in the 3xTg mice. These include 
alterations in Ca2+ regulation and homeostasis, neuronal network dysfunction and 
the progressive development of pathological features causing an increased 
susceptibility to excitotoxicity. The overall effects of these on synaptic function 
will be discussed in more detail below.  
 
3.3.2.5: Calcium regulation in the 3xTg model 
 
 
The regulation of neuronal Ca2+ regulation is critical for all forms of plasticity 
from PPF to LTP, and the dynamics of Ca2+ release influences the magnitude and 
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direction of synaptic plasticity (Cormier et al., 2001). Disruptions in Ca2+ 
homeostasis have been suggested as a cause of alterations in synaptic function in 
the 3xTg model. From an early age, neurons from 3xTg mice show enhanced 
Ca2+ -induced Ca2+ release (CICR), a process whereby the influx of Ca2+ into the 
neuron, primarily through the NMDA receptor, results in activation of the 
ryanodine receptor (RyR) and the consequent release of further Ca2+ from the 
endoplasmic reticulum (ER) stores (Sandler and Barbara, 1999). Cortical neurons 
from 3xTg mice at ages from 6 weeks to 18 months display enhanced CICR in 
response to RyR activation (Stutzmann et al., 2006), as do hippocampal CA1 
neurons at 6-8 weeks, which is accompanied by an increase in expression of the 
RyR in the ER membrane (Chakroborty et al., 2009). Interestingly, these 
alterations in Ca2+ release appear to be solely due to the presence of the PS1M146V 
mutation, as similar changes are observed in single transgenic PS1M146V mice, but 
not in the double transgenic APPSwe, tauP301L mice (Stutzmann et al., 2006). 
Presenilins may function as leak channels to control steady state Ca2+ levels in 
the ER, with impairment due to mutation resulting in a higher concentration of 
Ca2+ in the ER and increased RyR expression (Zhang et al., 2010a). In addition, 
Ca2+ responses in neuronal dendrites and spines are enhanced in response to 
NMDA receptor activation in the 3xTg mice and the TASTPM mice, both of 
which carry the PS1
 M146V mutation (Goussakov et al., 2010). 
These results suggest that there may be age-independent, lifelong disruptions in 
Ca2+ functioning in the 3xTg mice which affect aspects of synaptic plasticity. It 
has been reported that PPF and input-output function are similar to control in the 
3xTg mice under normal conditions, but are altered by the presence of the RyR 
antagonist dantrolene in 3xTg mice only (Chakroborty et al., 2009). These results 
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suggest that there may be compensatory mechanisms present in these mice to 
maintain neuronal homeostasis. However, it is possible that under conditions of 
neuronal stress both pre- and post-synaptic alterations in synaptic function could 
manifest themselves; these changes could contribute to the differences in input-
output function and LTP observed in the 3xTg mice. Further work would be 
required to investigate whether alterations in Ca2+ function are a feature of our 
colony of 3xTg mice. Such studies could deploy techniques such as whole-cell 
voltage clamp or Ca2+ imaging with fluorescent dyes to observe Ca2+  transients 
in individual neurons.  
 
3.3.2.6: The network dysfunction hypothesis  
 
 
There is growing interest in the way that individual molecular and neuronal 
alterations may affect functioning at the network level. It has been suggested that 
an imbalance between excitatory and inhibitory transmission in the hippocampus 
results in alterations in synaptic function in mouse models of AD. A general 
increase in neuronal excitability, which manifests as an increased amplitude of 
evoked excitatory postsynaptic currents (EPSCs) and a decreased amplitude of 
evoked inhibitory postsynaptic currents (IPSCs), occurs in the CA1 region of the 
CRND8 mouse, which expresses both the APPSwe and APPInd (V717F) mutations 
(Jolas et al., 2002). This mouse shows a decrease in the maximum fEPSP 
amplitude and an increase in the magnitude of LTP, similar to my findings in the 
3xTg mouse. In the J20 mouse, which expresses the same mutations on a 
different background strain, GABAergic fibre sprouting in the dentate gyrus (DG) 
is observed and suggested to be a compensatory remodelling of the hippocampal 
circuits to protect against abberant excitatory network activity (Palop et al., 
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2007). These models suggest that widespread changes in inhibitory and 
excitatory activity may result in alterations of neuronal circuitry. 
In the 3xTg mouse model, studies in the entorhinal cortex (EC) have shown a 
higher frequency of spontaneous EPSCs in 6-8 week old mice, suggesting an 
increased activity of glutamatergic synapses. This perturbation does not appear to 
alter total synapse number as levels of the presynaptic protein synaptophysin 
remain unchanged (Arsenault et al., 2011). The EC, DG and CA1 regions are 
linked through a primarily unidirectional neuronal pathway, and Aβ pathology in 
the EC has been shown to affect functioning of CA1 neurons (Harris et al., 2010). 
In my study of 3xTg mice, alterations in the fEPSP amplitude in the CA1 region 
occured from the age of 12 months, but no increased frequency of epileptiform 
bursting was observed. This suggests that there are no major abnormalities in 
GABAergic functioning, although confirmation of this would require a more 
detailed study. It would be interesting to observe the frequency of spontaneous 
EPSCs and amplitude of evoked EPSCs/ IPSCs in the 3xTg mice with the use of 
whole-cell voltage clamp techniques. Interestingly, it has been suggested that the 
relative contribution of glutamatergic and GABAergic neurons may depend on 
the LTP induction protocol used; differences may occur between HFS and TBS 
(Jolas et al., 2002) and this should be taken into account when comparing 
experimental results from different laboratories. Overall, it is possible that 
alterations in the balance between excitatory and inhibitory transmission within 
the hippocampal network could be a mechanism involved in changes in synaptic 
plasticity in 3xTg mice. 
 
  
207 
3.3.2.7: Excitotoxicity and its mechanisms 
 
 
In both the 3xTg and the TASTPM mouse models (discussed in Section 3.3.3), 
there is a marked reduction in the magnitude of the fEPSP in the CA1 region 
with increasing age. However, incubation with 1mM kynurenic acid during 
slicing enhanced neuronal viability as shown by an increase in the fEPSP 
amplitude combined with a higher percentage of slices in which an fEPSP could 
be obtained. This suggests that a susceptibility to excitotoxicity may underlie 
some of the observed results in these mice, in particular the age-dependent 
reduction of fEPSP amplitude. This feature appears to be due to the presence of 
the APP or PS1 transgenes, as it is common to both strains of transgenic mice. 
Neuronal death and dysfunction due to glutamate excitotoxicity is a mechanism 
considered to be important in AD. This form of neurotoxicity involves the influx 
of Ca2+ through the NMDA receptor and subsequent release of Ca2+ from internal 
stores, resulting in the activation of downstream signalling pathways (Dong et al., 
2009). Consequently, the NMDA receptor channel blocker memantine is now 
used therapeutically as a treatment for AD. The increased susceptibility to 
excitotoxicity in transgenic mice could be associated with a number of different 
biochemical and functional changes, which could be studied using several 
different techniques. 
It is most likely that this feature is due to dysfunction of the glutamatergic 
neurotransmitter system, although alterations in other neurotransmitters such as 
GABA could alter the inhibitory-excitatory balace within the hippocampus. The 
role of the NMDA receptor in this process could be confirmed by the use of 
selective antagonists, for example the use-dependent channel blocker MK-801. 
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Alterations could occur at any stage during glutamatergic synaptic transmission, 
for example in transmitter release, glutamate uptake and transport, or the 
intracellular Ca+ response to NMDA receptor activation.  
The release of glutamate in response to neuronal damage could be measured 
using electrochemical techniques, as it is possible that increased presynaptic 
vesicular release in response to hypoxic or mechanical insult could contribute to 
enhanced excitotoxic damage. Alternatively, glutamate uptake could be 
indirectly measured using techniques such as the measurement of synaptically 
activated glutamate transporter currents; astrocytes within the CA1 region are 
thought to take up the majority of glutamate released through a high level of 
expression of glutamate transporters (Diamond 2005). These cells rapidly 
decarboxylate and inactivate glutamate to form glutamine, which diffuses across 
the extracellular space and can enter presynaptic terminals.   It is possible that in 
transgenic mice there is an alteration in glutamate uptake by astrocytic cells and 
this could be measured using antagonists for the most abundant transporter 
proteins, excitatory amino-acid transporters 1 and 3 (EAAT1, EAAT3), such as 
the commonly used TBOA (Danbolt 2001) . Evidence suggests that in conditions 
of cellular stress such as ischemia, alterations in ionic balance such as an increase 
in extracellular K+  caused by disrupted metabolic function may result in the 
reversal of transporter uptake. This occurs because the movement of glutamate 
across the transporter is dependent on the electrochemical gradient of  cations 
such as K+  and Na+ and could contribute to an increase in the synaptic glutamate 
concentration, which promotes excitotoxicity (Roettger and Lipton, 1996) . 
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There is evidence that both APP and PS1 can influence neuronal sensitivity to 
cellular stressors and may have their effects through alterations of neuronal Ca2+ 
homeostasis. Aβ oligomers interact with the NMDA receptor in a binding 
complex and increase intraneuronal Ca2+, an effect blocked by the clinically used 
antagonist memantine (De Felice et al., 2007). In human cortical neurons, 
application of β-amyloid peptides enhances neurotoxicity mediated by the 
NMDA receptor and increases the Ca2+ response to excitotoxic insult (Mattson et 
al., 1992). It is therefore possible that neuronal tissue containing elevated levels 
of Aβ peptide, as in the 3xTg and TASTPM mice, may be ‘primed’ to show an 
enhanced response to an external excitotoxic event.  In addition, single 
transgenic PS1M146V knock-in mice show enhanced kainic acid-induced 
neurodegeneration in vivo, with dissociated neurons showing a greater 
intracellular Ca2+ response to exogenous glutamate exposure, an enhancement of 
glutamate-induced oxidative stress, and mitochondrial dysfunction (Guo et al., 
1999). It is possible that in 3xTg and TASTPM mice the combination of the 
APPSwe and PS1 M146V mutations may result in an enhanced Ca2+ response to 
glutamate release during excitotoxic insults such as brain slicing, which increases 
the level of neuronal degeneration observed in these mice. 
The increased susceptibility to excitotoxicity is age-dependent as there is a 
progressive reduction in the magnitude of the fEPSP with increasing age. It is 
known that Ca2+ regulation in hippocampal neurons alters with age as a result of 
a reduction in NMDA receptor expression combined with an increase in Ca2+ 
channel expression (Kumar et al., 2009). It is possible that this feature of the 
ageing brain is exacerbated in the 3xTg and TASTPM mice due to the presence 
of pathological features such as Aβ deposition. Fitzjohn et al. (2001) have 
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reported that in aged APPSwe mice kynurenic acid is only partially successful in 
restoring the fEPSP to normal magnitude, suggesting that a point is reached 
when pathological features in these mice are sufficiently advanced to affect basal 
synaptic transmission through a different mechanism. 
Pre-treatment of 3xTg hippocampal slices with kynurenic acid increased the 
fEPSP slope, measured by the input-output curve, showing that the same current 
evokes a larger synaptic response and therefore that the viability of the slice has 
improved. This occurs in 3xTg mice at all stimulus intensities and in control 
mice at lower stimulation intensities, showing that kynurenic acid has an effect, 
although more modest, in normal brain slices. These observations suggest that 
some neuronal damage through excitotoxicity is an inevitable part of the slice 
preparation process. In addition in 3xTg mice there is a decrease in PPF and a 
reduced magnitude of LTP with kynurenic acid treatment. These findings suggest 
that the prevention of excitotoxicity may result in alterations in pre- and 
postsynaptic function which may alter electrophysiological measurements. 
Previously published work has shown similar conclusions in two other mouse 
models of AD. Age-related deficits are apparent in basal synaptic transmission in 
12 month old single-transgenic APPSwe transgenic mice and in 14 month old 
APPSwe x PS1A246E mice (Fitzjohn et al., 2001, Fitzjohn et al., 2010). However, 
these deficits can be abolished by incubation of the hippocampal slices in aCSF 
containing 1mM of kynurenic acid during preparation, suggesting that these mice 
also have an increased susceptibility to excitotoxic neuronal damage. The authors 
suggest this may be a result of the background strain, but the presence of similar 
findings in our colony of TASTPM mice argue against this as the C57BL/6 
  
211 
background is relatively resistant to excitotoxicity (Schauwecker and Steward, 
1997). 
Several methods are used by research groups to improve slice viability and 
reduce glutamate release. Most commonly used are slicing in ice-cold aCSF, the 
use of a glutamate receptor antagonist such as kynurenic acid, or slicing in aCSF 
with a different ionic composition from the recording solution. The use of each 
of these processes may have a different effect on slice recordings. In 
hippocampal extracellular recordings the use of the fEPSP as a measure of slice 
‘health’ may result in recordings being made from viable but damaged neurons, 
or from a subset of CA1 neurons which are for some reason less susceptible to 
injury. This makes comparison between groups challenging when different slice 
preparation methods are used. For example, Oddo et al. (2003) used ice-cold 
aCSF in their 3xTg hippocampal preparation which acts to limit glutamate 
release but has been also shown to cause metabolic alterations within the slice 
(Watson et al., 1997). In my studies, none of these measures were routinely used 
due to the ease at which an fEPSP could be obtained in non-transgenic mice. 
However, based on the findings in this thesis I would take measures to reduce 
excitotoxicity during slice preparation in any future experiments carried out. 
In conclusion, these results have shown that an altered susceptibility to 
excitotoxicity following neuronal stressors may be a feature of mouse models of 
AD possessing the APPSwe or PS1 transgenes. It is likely that this involves 
alterations in glutamatergic transmission, such as neurotransmitter release, 
receptor or transporter function, but the mechanisms underlying this would 
require further study. It is not known whether this phenomenon is observed in 
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other APP transgenic mice and it is likely that this will be affected by the 
background strain of the mouse and the variables inherent in each model. It also 
highlights that differences in experimental procedures between research groups 
which influence excitotoxic mechanisms could explain some of the disparate 
findings in measurements of synaptic function in mouse models of AD. 
 
3.3.2.8: Summary of electrophysiological findings in 3xTg mice 
 
 
In summary, the 3xTg mice show several electrophysiological changes including 
an age-dependent decrease in the fEPSP amplitude and an increase in the 
magnitude of LTP when normalised from 12 months onwards. This suggests that 
the development of pathological changes is linked to alterations in synaptic 
function in these mice. In particular, these mice may show a particular 
susceptibility to excitotoxicity under conditions of enhanced cellular stress. 
There may also be a contribution of other age-dependent and -independent 
mechanisms, which have been previously explored by other groups, such as 
alterations in Ca2+ functioning, although further experiments would be required 
to ascertain if this was a significant factor in our colony of 3xTg mice. 
 The deficits originally reported by other groups initially occurring at 6 months 
of age were not observed in our 3xTg mice. Firstly, differences in experimental 
protocol may also affect measurements of synaptic function and this should be 
taken into consideration when comparing results. However, the lack of observed 
changes at this age, when Aβ deposition should be established, shows that the 
development of pathological features occurs later in this colony than previously 
reported, and this is supported by the biochemical data presented in Chapter 4. 
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The presence of such differences between individual colonies of 3xTg mice 
should be taken into account for future studies of this model. 
 
3.3.3: TASTPM mouse 
 
 
Studies of synaptic function and plasticity were carried out in TASTPM mice at 
2 months and 6 months of age. The aim was to compare results obtained in the 
3xTg mice with the TASTPM mice to attempt to elucidate the effects of the 
individual transgenes, in particular the tau transgene, and to see if similar 
changes in synaptic function were observed in the two models.  
 
 
3.3.3.1: Synaptic function in 2 month TASTPM mice 
 
 
PPF, input-output function and LTP were measured in 2 month old TASTPM 
mice. In these mice, cerebral Aβ accumulation occurs from the age of 3 months 
(Howlett et al., 2004). As Aβ pathology initiates in the cortex and then 
progresses to the hippocampus, it is unlikely that there is any Aβ accumulation in 
the hippocampus by 2 months and as a result the presence of electrophysiological 
changes was not expected. 
In the TASTPM mice at 2 months old an fEPSP is readily obtainable and this is 
of similar magnitude to the control mice, resulting in a normal input-output curve. 
This finding shows that at 2 months there are no differences in basal synaptic 
transmission. There is a reduction in the magnitude of PPF, which is only 
significant at an interstimulus interval of 50ms. The value obtained at this 
interval is similar to that obtained in the 3xTg mice, and due to the lack of other 
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alterations in TASTPM mice it is likely that the effect is due to an increase in the 
magnitude of PPF in control mice, the mechanism of which is unknown. 
Importantly, the control mice used are of mixed C57BL/6 x 129/Sv background, 
similar to the 3xTg mice, while the TASTPM mice are on a pure C57BL/6 
background. Strain-dependent differences have been observed in measures of 
synaptic function (Nguyen 2006) and so this could account for the minor 
difference observed in PPF between the control and TASTPM. Preliminary 
experiments (data not shown) using C57/BL6 mice have shown a similar level of 
PPF to that observed in TASTPM mice, suggesting the difference may be due to 
background strain. 
There is no difference in the magnitude of LTP obtained in 2 month TASTPM 
mice and control mice, showing that LTP can be induced and maintained 
normally in TASTPM mice of this age. Overall, these results show that prior to 
the development of Aβ deposition there are no functional changes observed due 
to the presence of the transgenes. 
 
3.3.3.2: Synaptic function in 6 month TASTPM mice 
 
 
By 6 months, the TASTPM mice show plaque deposition in the cortex and 
marked APP expression in the hippocampus, in particular in the CA1 and CA3 
regions (Howlett et al., 2004). At this age, marked abnormalities in synaptic 
function were observed in hippocampal slices. It proved difficult in the majority 
of slices to obtain an fEPSP of sufficient magnitude for meaningful experiments 
to be performed. This suggests the presence of significant neuronal dysfunction 
or toxicity in hippocampal neurons in the TASTPM mice at the age of 6 months. 
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A similar reduction in basal synaptic transmission has been observed previously 
in TASTPM mice at 8 months (Spencer et al., 2004). 
As the TASTPM mouse carries the APPSwe and PS1M146V transgenes similar to 
the 3xTg mouse, it is likely that similar mechanisms account for the alterations in 
synaptic function observed. In particular, treatment with 1mM kynurenic acid 
markedly increased the magnitude of the fEPSP to the levels obtained in control 
mice. This observation suggests that an increased susceptibility to excitotoxicity 
is also a feature of the TASTPM mouse model (see Section 3.3.2.7). This shows 
that the susceptibility is due to the presence of the APPSwe or the PS1M146V 
mutations, with the major contribution likely to be the APPSwe mutation as this 
feature also occurs in single APP transgenic mice (Fitzjohn et al., 2001). 
Considering the data obtained from the TASTPM and the 3xTg mice together, it 
is likely that the presence of the tauP301L transgene has little effect on the changes 
to the fEPSP and LTP. It also shows that, as the TASTPM mouse is generated on 
a different background strain than the 3xTg mouse, the susceptibility appears to 
be independent of the strain used to generate the model.  
Synaptic plasticity was studied in slices from 6 month old TASTPM mice either 
in normal aCSF or aCSF additionally containing kynurenic acid. In normal aCSF, 
LTP was only induced in a small subset of the experiments due to the marked 
reduction of fEPSP amplitude in the slices. Therefore, it is probable that the 
increased magnitude of LTP observed in the TASTPM mice is due to the low 
sample size used, reflecting a neuronal population which for some reason was 
less susceptible to the effects of excitotoxicity. When LTP was induced in slices 
incubated with kynurenic acid, the magnitude was similar to that obtained in 
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control slices. This finding shows that despite the presence of the APP transgene, 
LTP can be expressed at normal levels in TASTPM mice. As this model was 
only studied up to the age of 6 months, it is not known whether age-dependent 
alteration in synaptic plasticity would become evident, particularly due to the 
presence of plaque deposition at older ages.   
In conclusion, the TASTPM mice exhibit electrophysiological changes which are 
similar to those observed in the 3xTg mice, suggesting that a susceptibility to 
excitotoxicity may be a feature of multiple mouse models of AD. However, 
direct comparisons between the two models are made difficult due to the marked 
differences in the time course of the development of pathology in the 3xTg and 
TASTPM mice.  In the TASTPM mice this occurs much earlier in the lifespan, 
possibly due to the more rapid onset of Aβ deposition in this mouse model. Due 
to this feature, this model may be a useful tool for electrophysiology studies. 
3.3.3: Summary 
 
 
Changes in synaptic function are a feature of a number of mouse models of AD 
including the 3xTg and TASTPM mice. In particular, an age-dependent reduction 
in the amplitude of the fEPSP is observed in both models. This is accompanied 
by a relative increase in the magnitude of LTP in aged 3xTg mice. However, the 
mechanism of these changes are not fully understood and are complicated by the 
difficulties in the use of the hippocampal slice model, where alterations in 
experimental protocol can cause marked differences in the results obtained. In 
addition, the slow development of pathological features in our colony of 3xTg 
mice, as shown by the biochemical measurements in Chapter 4, made studies 
difficult and complicates comparisons with the work of other groups. These 
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findings show that it is important to characterise the development of biochemical 
changes in individual colonies of the 3xTg mice in order to link this with other 
findings, such as studies of synaptic function. Further work, which could include 
more detailed electrophysiological studies (eg single cell voltage-clamping), 
immunohistochemistry, imaging, and in vivo studies, is required to elucidate the 
mechanisms which underlie changes in synaptic functioning in mouse models of 
AD. In particular, studies of our colonies of 3xTg and TASTPM mice have 
shown that an increased susceptibility to excitotoxicity may be a characteristic of 
multiple mouse models. This observation could be used to further study the 
mechanisms which underlie the excitotoxic neuronal death which is present in 
AD and its relationship to cellular stressors.  However, the use of multiple 
models, combined with a standardised experimental approach, is required to give 
a full picture of synaptic function in AD. 
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Chapter 4 
 
Biochemistry 
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4.1: Introduction  
 
 
One of the aims of this thesis is to observe at which stage of phenotype 
development in the 3xTg and TASTPM models the molecular changes occur 
relative to the electrophysiological deficits. It is hypothesised that events such as 
kinase activation and hyperphosphorylation of cellular proteins may occur in 
parallel to functional alterations in synaptic activity and plasticity; any 
biochemical changes which are present at this time point may therefore be a 
contributory factor to synaptic dysfunction. The links between these different 
aspects are summarised in Fig. 4.1. 
In this chapter, the levels and phosphorylation of a number of proteins are 
measured by Western blotting in both the 3xTg and TASTPM models at several 
ages and in different regions of the brain. A homogenised lysate of frozen brain 
tissue (cortical samples for all experiments except those described in section 
4.2.3 and 4.2.7) was used; sample preparation is discussed in section 2.2.2. 
To establish that transgene expression was present, overexpression of APP was 
confirmed using the antibody 6E10, raised against the first 16 residues of the 
amyloid β protein. 6E10 only recognises human protein, which contains three 
amino acid differences within the 6E10 recognition region, compared to the 
mouse orthologue (DeStrooper et al., 1995). Although 6E10 is directed against 
Aβ it also recognises this sequence within full length APP, and so can be used to 
measure the expression of human APP which has a high molecular weight on a 
Western blot. 
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The 3xTg mouse also has a mutated tau transgene, so the use of the total tau 
antibody Tau5, was used to verify this. Measurement of total tau protein 
expression also allowed analysis of the stoichiometry of phosphorylation of 
specific residues on the protein to be carried out. The antibody AT8, which 
recognises phosphorylated serine 202 and threonine 205, and antibodies for 
serine 396 and 404 were chosen as these are sites which are known to be 
hyperphosphorylated in Alzheimer’s disease and associated with the kinase 
GSK3 (Mandelkow et al., 1992).  
CRMP2 is a protein which regulates microtubule assembly and has been 
previously studied in our lab. Importantly,  hyperphosphorylation of CRMP2 has 
been shown to be an early marker of AD progression in both human and 
transgenic mouse tissue (Cole et al., 2007b). An antibody to total CRMP2 was 
used, along with two different phospho-specific antibodies, for CRMP2 at the 
509/514 and 522 sites. These sites are key residues for phosphorylation of the 
protein, with the 509/514 sites phosphorylated by the enzyme GSK3. Prior to 
GSK3 phosphorylation of the 509/514 sites, the 522 site must be phosphorylated 
by the priming kinase Cdk5.  
Cdk5 is regulated by an activator protein known as p35, and cleavage of p35 by 
calpain results in the generation of a fragment known as p25. p25 binding results 
in altered cellular localisation and activation of Cdk5. Increased p25 levels or 
altered Cdk5 activity have been reported in some studies of AD brain and may 
contribute to disease progression (Patrick et al., 1999). A p35 antibody, which 
also detects p25, was used to examine any possible changes in these proteins. 
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Finally, an antibody to the synaptic vesicle protein synaptophysin was also used 
as synaptic loss is reported to be present in mouse models of AD. As synaptic 
dysfunction was observed in the 3xTg and TASTPM models (see Chapter 3) I 
wanted to observe if there were global changes in the expression of synaptic 
proteins. 
In summary, in this chapter I have used Western blotting to examine a range of 
proteins which are associated with AD in the 3xTg and TASTPM mouse models.  
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Figure 4.1: Synaptic and biochemical alterations in mouse models of AD. In mouse models expressing the APP transgene the excessive 
generation of Aβ results in direct effects on synaptic function and alterations in synaptic plasticity. Additionally, hyperphosphorylation of 
cellular proteins such as CRMP2 and tau occur through the activity of cellular protein kinases; kinases such as GSK3 may themselves have a 
influence on synaptic function and plasticity. These processes occur at an early stage of pathological development but the exact time course 
of progression is not known. It is hypothesised that if molecular changes such as protein phosphorylation occur prior to or concurrently with 
observed alterations in synaptic transmission that they may have a role in the development of synaptic dysfunction.  
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4.2: Results 
4.2.1: Age dependent effects on cortical expression of AD-related 
proteins in 3xTg mice 
 
 
Western blotting was carried out on cortical lysates from mice of different ages 
to chart any differences in pathological features which might be linked to the 
electrophysiological findings. 3xTg mice of 2 months of age, before the 
appearance of any deficits, were compared to 12 month old mice, an age when 
the changes in synaptic function were first noted. At 2 months of age there is no 
evidence reported of Aβ or tau deposition or any cognitive deficits in this model 
(Billings et al., 2005). In addition, only very minor differences are observed in 
specific aspects of electrophysiology at this age, including changes in PPF and 
non-normalised LTP, suggesting the mice may show some molecular 
abnormalities despite undetectable pathology at 2 months. At 12 months old the 
electrophysiological deficits are more pronounced with a reduction in fEPSP 
amplitude and alterations in LTP; these coincide with detection of amyloid 
plaques and hyperphosphorylated tau (Oddo et al., 2003). It was therefore 
hypothesised that biochemical changes responsible for the major 
electrophysiological deficits would become apparent between the ages of 2 and 
12 months. In these experiments, male and female mice were analysed separately 
to see if there were gender-specific differences in the expression or modification 
of AD related proteins during ageing. 
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4.2.1.1: APP 
 
 
The presence of the APPSwe transgene in the 3xTg mice was confirmed by 
genotyping (carried out by Linda Gallacher). As expected, there is a significant 
difference (p < 0.05, two-way ANOVA) in the levels of  human APP between 
the 3xTg and control mice at both 2 and 12 month of age in both male (Fig. 
4.2A) and female (Fig. 4.3A) mice with expression of this protein absent in 
control mice. There is a trend for increased hAPP expression as the mice age, in 
both male and female 3xTg mice (Fig. 4.2A - males, 4.3A - females). This 
confirms that the transgene is present and functional (Fig. 4.2A - males, 4.3A - 
females).  
 
4.2.1.2: CRMP2 (total and phosphorylated) 
 
 
There is no difference in the expression of total CRMP2 between 3xTg and 
control (p > 0.05, two-way ANOVA) at 2 or 12 months (Fig. 4.2B - males, Fig. 
4.3B - females), and in contrast to previous findings in this model (Cole et al., 
2007b) the CRMP2 protein from 3xTg cortex did not exhibit increased 
phosphorylation at either the 509/514 (Fig. 4.2C - GSK3 sites) or 522 (Fig. 4.2D 
- Cdk5 sites) residues in males at both ages examined (p > 0.05, two-way 
ANOVA). Identical findings were obtained from cortex of the female 3xTg mice 
(Fig. 4.3C and D). 
 
4.2.1.3: Tau (total and phosphorylated) 
 
 
The presence of the tauP301L transgene in the 3xTg mice was confirmed by 
genotyping (carried out by Linda Gallacher). There is a significant increase (p < 
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0.05, two-way ANOVA) in the levels of total tau in the male 3xTg mice 
compared to the control, although in contrast to APP there is no significant 
difference in expression of the transgenic tau between 2 month and 12 month 
3xTg (p > 0.05, two-way ANOVA). However this may be related to the small 
sample set as the average expression was greater in 12 month old 3xTg than 2 
month old 3xTg, yet endogenous tau expression in the control male mice showed 
a trend for a decrease with age (Fig. 4.4A). There is also a strong trend for 
increased total tau in the female 3xTg compared to control at both ages, although 
this does not reach significance (p = 0.067) (Fig. 4.5A). In contrast to the male 
mice there is no difference in tau expression (p > 0.05, two-way ANOVA) 
between 2 or 12 month old animals in either genotype (Fig. 4.5A). 
There is no increase in phosphorylation of tau (p > 0.05, two-way ANOVA) at 
the AD related AT8 or 404 epitopes in the male 3xTg compared to controls at 
either age (Fig. 4.4B and C). In fact, there seems to be a decreased level of tau 
396 phosphorylation in the 12 month male 3xTg compared to the control 
although this does not reach significance (Fig. 4.4D). Perhaps surprisingly 
phosphorylation at the AT8 epitope in female 12 month old 3xTg mice is 
reduced (p < 0.05, two-way ANOVA) compared to controls (Fig. 4.5B), and this 
seems to be related to an increase in AT8 phosphorylation in the older control 
mice that is not recapitulated in the older 3xTg female mice (Fig. 4.5B). As in the 
male mice, there are no differences observed in 404 phosphorylation (p > 0.05, 
two-way ANOVA) across all 4 groups (Fig. 4.5C); there is a slightly reduced 
level of tau 396 phosphorylation in the female 3xTg compared to control in both 
2 and 12 month old mice (Fig. 4.5D), which just fails to reach significance in the 
12 month mice (p = 0.054). This suggests that although the levels of total tau are 
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increased this is not matched by an increase in phosphorylation at the sites 
investigated.  
 
 
4.2.1.4: Other proteins 
 
 
There are no clear differences (p > 0.05, two-way ANOVA) in the levels of 
synaptophysin or the Cdk5 co-factors p35 or p25 in male (Fig. 4.6) or female 
(Fig. 4.7) 3xTg compared to control mice at the ages measured, and the 
expression of these proteins does not alter with age or gender in either genotype.  
 
4.2.1.5: Summary 
 
 
Although the expression of the APP and tau transgenes is confirmed these results 
suggest that some of the processes associated with the development of pathology, 
such as the hyperphosphorylation of tau originally observed by Oddo et al. and  
the hyperphosphorylation of CRMP2 which was observed previously in our lab 
from tissue from a different colony (Cole et al., 2007b) are developing more 
slowly in our colony of 3xTg mice. There appears to be higher tau expression in 
female 3xTg mice at 12 months than in control animals or in male 3xTg mice. 
However the level of phosphorylation of some key residues on tau in the female 
3xTg actually appears to decrease compared with control animals. No changes in 
expression or modification of APP, tau, CRMP2, synaptophysin, or p35 in 3xTg 
cortex were observed that could explain the reported electrophysiological or 
behavioural abnormalities in these animals. 
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Figure 4.2: APP, total and phosphorylated CRMP2 in 2 and 12 month 
male 3xTg and control mice. 10µg of cortical lysate (n = 3 in each group) was 
used in SDS-PAGE, transferred to a nitrocellulose membrane and probed with 
the following antibodies: 6E10 (A), Total CRMP2 (B), CRMP2 phospho 
509/514 (C), CRMP2 phospho 522 (D). Representative blots are displayed 
along with the graphs showing densitometry calculations. APP and total 
CRMP2 are normalised to actin while phosphorylated CRMP2 is normalised to 
total CRMP2 protein.  = p < 0.05, two-way ANOVA. 
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Figure 4.3: APP, total and phosphorylated CRMP2 in 2 and 12 month  
female 3xTg and control mice. 10µg of cortical lysate (n = 3 in each group) 
was used in SDS-PAGE, transferred to a nitrocellulose membrane and probed 
with the following antibodies: 6E10 (A), Total CRMP2 (B), CRMP2 phospho 
509/514 (C), CRMP2 phospho 522 (D). Representative blots are displayed 
along with the graphs showing densitometry calculations. APP and total 
CRMP2 are normalised to actin while phosphorylated CRMP2 is normalised 
to total CRMP2 protein.  = p < 0.05, two-way ANOVA. 
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Figure 4.4: Total and phosphorylated tau in 2 and 12 month male 3xTg 
and control mice. 10µg of cortical lysate (n = 3 in each group) was used in 
SDS-PAGE, transferred to a nitrocellulose membrane and probed with the 
following antibodies: Tau5 (A), Tau AT8 (B), Tau phospho 396 (C), Tau 
phospho 404 (D). Representative blots are displayed along with the graphs 
showing densitometry calculations. Total tau is normalised to actin while 
phosphorylated tau is normalised to total tau.  = p < 0.05, two-way 
ANOVA. 
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Figure 4.5: Total and phosphorylated tau in 2 and 12 month female 3xTg 
and control mice. 10µg of cortical lysate (n = 3 in each group) was used in 
SDS-PAGE, transferred to a nitrocellulose membrane and probed with the 
following antibodies: Tau5 (A), Tau AT8 (B), Tau phospho 396 (C), Tau 
phospho 404 (D). Representative blots are displayed along with the graphs 
showing densitometry calculations. Total tau is normalised to actin while 
phosphorylated tau is normalised to total tau.   = p < 0.05, two-way 
ANOVA. 
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Figure 4.6: Synaptophysin, p35 and p25 in 2 and 12 month male 3xTg and 
control mice. 10µg of cortical lysate (n = 3 in each group) was used in SDS-
PAGE, transferred to a nitrocellulose membrane and probed with the 
following antibodies: Synaptophysin (A), p35 (B) which also shows p25 (C), 
and actin. Representative blots are displayed along with the graphs showing 
densitometry calculations. Synaptophysin, p35 and p25 are normalised to 
actin. 
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Figure 4.7: Synaptophysin, p35 and p25 in 2 and 12 month female 3xTg 
and control mice.  10µg of cortical lysate (n = 3 in each group) was used in 
SDS-PAGE, transferred to a nitrocellulose membrane and probed with the 
following antibodies: Synaptophysin (A), p35 (B) which also shows p25 (C), 
and actin. Representative blots are displayed along with the graphs showing 
densitometry calculations. Synaptophysin, p35 and p25 are normalised to actin. 
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4.2.2: Analysis of cortical expression of AD-related proteins in 
aged 3xTg mice 
 
 
Western blotting was carried out on mice of 17 months of age, when the 
pathology was expected to be well developed with amyloid plaques and 
neurofibrillary tangles apparent. It was hoped to find biochemical differences 
that might correlate with the electrophysiological alterations that occur at this age, 
which include a marked reduction in fEPSP amplitude and changes in LTP 
expression. Due to the late occurrence of electrophysiological deficits in our 
colony of 3xTg mice, it seemed important to characterise the development of 
biochemical changes as the mice aged to see if this too differed from that 
previously reported. In contrast to the original report of this model studies by 
Mastrangelo et al. (2008) and Hirata-Fukae et al. (2008) suggested that plaque 
pathology may not be apparent until 14 or 15 months of age, and it is known that 
tangle pathology occurs late in the lifespan at around 12-18 months. 
The experiments at 17 months were carried out in male mice only due to 
availability and the potential for gender-dependent differences.  
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4.2.2.1: APP 
 
 
As expected there is a significant difference in APP expression in 17 month old 
3xTg mice compared to control (p < 0.05, unpaired t-test), with no expression 
detected in control mice (Fig. 4.8A) which confirms that the transgene is present 
in these mice.  
 
 
4.2.2.2: CRMP2 (total and phosphorylated) 
 
 
There is no difference (p > 0.05, unpaired t-test) in the levels of total CRMP2 
between 17 month old 3xTg and control mice (Fig. 4.8B). However, there is a 
significant increase in phosphorylation (p < 0.05, unpaired t-test) at the 509/514 
residues (Fig. 4.8C – GSK3 sites). This was previously observed in our lab in 6 
month old 3xTg mice Cole et al (2007), so this biochemical change is occurring 
at a much later stage of development in the 3xTg colony than that observed 
previously. There is no difference (p > 0.05, unpaired t-test) in phosphorylation 
at the 522 residues between the 3xTg and controls (Fig. 4.8D – Cdk5 sites), in 
contrast to previous work in the model. 
 
 
4.2.2.3: Tau (total and phosphorylated) 
 
 
There is a significant increase (p < 0.05, unpaired t-test) in the expression of tau 
in 3xTg mice at 17 months compared to control (Fig. 4.9A). There is no increase 
(p > 0.05, unpaired t-test) in phosphorylation at the AT8 (Fig. 4.9B) or 396 (Fig. 
4.9C) epitopes, although this may be due to the small sample set as there is a 
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trend for increased phosphorylation, particularly at the 396 and 404 epitopes 
(similar to data from 12 month old mice, see section 4.2.1.3). This very nearly 
reaches significance at the 404 epitope (p = 0.054, independent t-test) (Fig. 
4.9D).  
 
4.2.2.4: Other proteins 
 
 
There is no difference (p > 0.05, unpaired t-test) in the levels of synaptophysin or 
p35/p25 Cdk5 co-factors in 3xTg mice compared to control mice at 17 months 
(Fig. 4.10). 
 
4.2.2.5: Summary 
 
 
Although APP and tau are overexpressed, the only other molecular changes 
detected are an increase in phosphorylated CRMP2 at the 509/514 epitope, and a 
slight increase in tau phosphorylation. This suggests that the marked 
hyperphosphorylation of cellular proteins expected is not occurring at this age in 
our colony of 3xTg mice. As tau hyperphosphorylation occurs prior to tangle 
formation this suggests this feature has not developed in these mice, although 
confirmation of this would require further studies such as immunohistochemical 
analysis. 
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Figure 4.8: APP, total and phosphorylated CRMP2 in 17 month 3xTg and 
control mice. 10µg of cortical lysate (n = 4 in each group) was used in SDS-
PAGE, transferred to a nitrocellulose membrane and probed with the 
following antibodies: 6E10 (A), Total CRMP2 (B), CRMP2 phospho 509/514 
(C), CRMP2 phospho 522 (D). Representative blots are displayed along with 
the graphs showing densitometry calculations. APP and total CRMP2 are 
normalised to actin while phosphorylated CRMP2 is normalised to total 
CRMP2 protein.  = p < 0.05, unpaired t-test. 
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Figure 4.9: Total and phosphorylated tau in 17 month 3xTg and control 
mice. 10µg of cortical lysate (n = 4 in each group) was used in SDS-PAGE, 
transferred to a nitrocellulose membrane and probed with the following 
antibodies: Tau5 (A), Tau AT8 (B), Tau phospho 396 (C), Tau phospho 404 
(D). Representative blots are displayed along with the graphs showing 
densitometry calculations. Total tau is normalised to actin while 
phosphorylated tau is normalised to total tau.  = p < 0.05, unpaired t-test. 
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Figure 4.10: Synaptophysin, p35 and p25 in 17 month 3xTg and control 
mice.  10µg of cortical lysate (n = 4 in each group) was used in SDS-PAGE, 
transferred to a nitrocellulose membrane and probed with the following 
antibodies: Synaptophysin (A), p35 (B) which also shows p25 (C), and actin. 
Representative blots are displayed along with the graphs showing densitometry 
calculations. Synaptophysin, p35 and p25 are normalised to actin. 
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4.2.3: AD related protein expression and phosphorylation in 
different brain regions in 17 month mice 
 
 
It is known that different areas of the brain are more susceptible to the 
development of pathology in AD than others. The entorhinal cortex and 
hippocampus seem particularly vulnerable to tau pathology, as it is there that 
neurofibrillary tangle formation initiates. Later affected are areas of the cortex 
such as the frontal and temporal regions. However, some areas of the brain such 
as the somatosensory cortex and the cerebellum are relatively spared from the 
pathological features. Little is known about the mechanisms that control the 
susceptibility of particular subsets of neurons. 
A similar progression from one brain region to another occurs in the 3xTg mouse 
model. Tau pathology is first apparent in the hippocampus, in particular the 
neurons of the CA1 region, and spreads to involve the cortex (Oddo et al., 2003, 
Oddo et al., 2007). The Aβ pathology initiates in the cortex, in particular the 
frontal regions, before spreading several months later to the hippocampus in a 
progression that appears to be a reversal of the pattern of tau deposition. 
For this reason it was decided to study three brain regions in the 3xTg mouse: the 
hippocampus, the region used for electrophysiological experiments, the cortex, 
which was used for the majority of biochemical analysis, and the cerebellum, 
which should be relatively free of pathological features. This was carried out in 
17 month old male mice using the same cortical samples as in the previous 
experiments (section 4.2.2). The samples consisted of cortex from one 
hemisphere which was mainly the frontal/temporal regions, the hippocampal 
formation from the same hemisphere, and the whole cerebellum. If a difference 
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between brain regions was observed then the experiment was repeated in control 
mice to determine if this was a region-specific effect observed in the normal 
mouse brain. 
 
4.2.3.1: APP 
 
 
There is a significant difference in APP expression between the cortex and the 
cerebellum, and the hippocampus and cerebellum, with APP levels being lowest 
in the cerebellum (p < 0.05, one-way ANOVA) (Fig. 4.11A), suggesting that the 
transcription of the APPSwe transgene is likely reduced in this region or the 
stability of APP is reduced in the cerebellum. There is no difference (p > 0.05, 
one-way ANOVA) between APP expression in the hippocampus and cortex (Fig. 
4.11A).  
 
4.2.3.2: CRMP2 (total and phosphorylated) 
 
 
There is no difference (p > 0.05, one-way ANOVA)  in the level of total CRMP2 
between the cortex, hippocampus and cerebellum (Fig. 4.11B). There is a 
significant difference (p < 0.05, one-way ANOVA) in the level of 
phosphorylated CRMP2 at the 509/514 residues between the hippocampus and 
the cerebellum but no difference (p > 0.05, one-way ANOVA) between 
hippocampus and cortex. The cortical phosphorylation of CRMP2 falls between 
that of cerebellum and hippocampus but the sample number was too small to 
provide statistical difference between measures in the cortex and other tissues 
(Fig. 4.11C – GSK3 sites). There is also no difference (p > 0.05, one-way 
ANOVA)  in the level of phosphorylated CRMP2 at the 522 residue (Fig. 4.11D 
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– Cdk5 sites). However phosphorylation of CRMP2 at both residues shows the 
same pattern of distribution in the brain regions measured, with levels lowest in 
the hippocampus  and highest in cerebellum (Fig. 4.11B - D). 
 
4.2.3.3: Tau (total and phosphorylated) in 3xTg mice 
 
 
There is no difference (p > 0.05, one-way ANOVA) in the levels of total tau 
between the hippocampus, cortex and cerebellum (Fig. 4.12A). However, there is 
significantly higher phosphorylation of tau at the AT8 epitope (Fig. 4.12B) and at 
the 396 epitope (Fig. 4.12C) in the cerebellum compared to the other brain 
regions (hippocampus and cortex) (p < 0.05, one-way ANOVA). In contrast there 
is significantly reduced phosphorylation of tau at 404 in the cerebellum 
compared to hippocampus (p < 0.05, one-way ANOVA) but no difference 
between hippocampus and cortex, or cerebellum and cortex (Fig. 4.12D). 
As the region-specific phosphorylation of tau appeared markedly different in the 
cerebellum, control mouse samples were probed with the Tau5, AT8, 396 and 
404 antibodies to determine if this was a hallmark of the disease process or 
normal regulation of tau in mice. 
 
4.2.3.4: Tau (total and phosphorylated) in control mice 
 
 
There is no difference (p > 0.05, one-way ANOVA)  in levels of total tau 
between 17 month old control hippocampus, cortex and cerebellum (Fig. 4.13A). 
However, there is a significant increase (p < 0.05, one-way ANOVA) in the 
levels of tau phosphorylation at the AT8 epitope (Fig. 4.13B) and the 396 epitope 
(Fig. 4.13C) between the cerebellum and the other brain regions. There is also a 
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significant reduction (p < 0.05, one-way ANOVA) in tau 404 phosphorylation in 
the cerebellum compared to cortex (Fig. 4.13D) but no difference (p > 0.05, one-
way ANOVA) between hippocampus and cortex, or hippocampus and 
cerebellum. This is very similar to the observations in the 3xTg mice and 
suggests that there are region-specific differences in the phosphorylation of tau in 
normal mice, a pattern which is not altered in this AD model. 
 
4.2.3.5: Other proteins 
 
 
There is a trend for higher levels of synaptophysin in the cortex which nearly 
reaches significance (p = 0.054, compared with cerebellum, p = 0.059, compared 
with hippocampus, one-way ANOVA) (Fig. 4.14A).  
There is a significant difference (p < 0.05, one-way ANOVA) between the levels 
of p35 in the hippocampus and the other brain regions (cortex and cerebellum), 
with p35 lower in the hippocampus (Fig. 4.14B). There is also a significant 
difference (p < 0.05, one-way ANOVA) between the levels of p25 in the cortex 
compared with the other brain regions (Fig. 4.14C), with levels higher in the 
cortex and at a similar level in hippocampus and cerebellum.  
 
4.2.3.6: Summary 
 
 
These results show that the most marked differences in protein levels occur in the 
cerebellum, with many of the proteins in the cortex and hippocampus expressed 
and regulated at similar levels. Therefore the biochemical analysis carried out in 
the cortex should be a reasonable surrogate for the biochemical status of the 
hippocampal slices from these mice used in the electrophysiology studies. 
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Figure 4.11: APP, total and phosphorylated CRMP2 in 17 month 3xTg 
hippocampus, cortex and cerebellum. 10µg of hippocampal, cortical and 
cerebellar lysate from 17 month old 3xTg male mice (n = 4 of each region) 
was used in SDS-PAGE, transferred to a nitrocellulose membrane and probed 
with the following antibodies: 6E10 (A), Total CRMP2 (B), CRMP2 phospho 
509/514 (C), CRMP2 phospho 522 (D). Representative blots are displayed 
along with the graphs showing densitometry calculations. APP and total 
CRMP2 are normalised to actin while phosphorylated CRMP2 is normalised 
to total CRMP2 protein.  = p < 0.05, one way ANOVA. 
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Figure 4.12: Total and phosphorylated tau in 17 month 3xTg 
hippocampus, cortex and cerebellum.  10µg of hippocampal, cortical and 
cerebellar lysate from 17 month old 3xTg male mice (n = 4 of each region) 
was used in SDS-PAGE, transferred to a nitrocellulose membrane and probed 
with the following antibodies: Tau5 (A), Tau AT8 (B), Tau phospho 396 (C), 
Tau phospho 404 (D). Representative blots are displayed along with the graphs 
showing densitometry calculations. Total tau is normalised to actin while 
phosphorylated tau is normalised to total tau.  = p < 0.05, one way ANOVA. 
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Figure 4.13: Total and phosphorylated tau in 17 month control 
hippocampus, cortex and cerebellum.  10µg of hippocampal, cortical and 
cerebellar lysate from 17 month old control male mice (n = 4 of each region) 
was used in SDS-PAGE, transferred to a nitrocellulose membrane and probed 
with the following antibodies: Tau5 (A), Tau AT8 (B), Tau phospho 396 (C), 
Tau phospho 404 (D). Representative blots are displayed along with the 
graphs showing densitometry calculations. Total tau is normalised to actin 
while phosphorylated tau is normalised to total tau.  = p < 0.05, one way 
ANOVA. 
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Figure 4.14: Synaptophysin, p35 and p25 in 17 month 3xTg hippocampus, 
cortex and cerebellum.  10µg of hippocampal, cortical and cerebellar lysate 
from 17 month old 3xTg male mice (n = 4 of each region) was used in SDS-
PAGE, transferred to a nitrocellulose membrane and probed with the 
following antibodies: Synaptophysin (A), p35 (B) which also shows p25 (C), 
and actin. Representative blots are displayed along with the graphs showing 
densitometry calculations. Synaptophysin, p35 and p25 are normalised to 
actin.  = p < 0.05, one way ANOVA. 
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4.2.4: Correlations between APP, tau and electrophysiology in 
3xTg mice 
 
 
Cortical tissue was stored from some mice which had also been used for 
hippocampal extracellular recording, so data from Western blotting and 
electrophysiology was available from the same animals. I attempted to detect 
correlations between the levels of proteins such as APP and tau and 
measurements such as the maximum fEPSP amplitude and LTP values in the 
same mice. Experimental data were available from 6 of the 3xTg mice at 12 
months and 4 at 17 months. Densitometry values were used for 6E10 (used to 
measure total APP) and Tau5 (used to measure total tau) blots as a measure of 
the levels of these proteins, and the average maximum fEPSP amplitude and 
average magnitude of LTP in the plateau phase were used as electrophysiological 
measurements. Each mouse was ranked by transgene expression level (a 
surrogate measure of pathology development) and by electrophysiological 
measures from the highest to lowest values, and I looked for an inverse 
correlation between the levels of APP and/or tau and the fEPSP/LTP 
measurements. 
The data collected (Fig. 4.15) shows there is no simple correlation between the 
levels of APP and tau and the electrophysiological measurements, suggesting 
that larger numbers of experimental animals and a more complex statistical 
investigation will be required for such an analysis. As expected a mouse 
expressing higher levels of APP usually also expresses a higher level of tau (due 
to co-integration of the transgene) and the mice with the highest APP/tau 
expression (mouse B at 6 months and mouse J at 12 months) had the smallest (or 
second smallest) fEPSP amplitude and magnitude of LTP of the group.  
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Mouse APP Rank Tau Rank fEPSP Rank LTP Rank 
A 
 1.00 2 1 5 0.94 3 205.1 2 
B 
1.01 1 3.33 =2 0.28 5 142.1 6 
C 
0.54 5 3.33 =2 0.67 4 188.9 3 
D 
0.67 4 2.71 4 
Not 
measured 
       N/A 181.9 4 
E 
0.27 6 0.73 6 1.15 1 226.5 1 
F 
0.85 3 6.81 1 1.13 2 161.5 5 
 
G 
1.00 4 1 3 1.19 1 242.3 3 
H 
1.07 3 0.65 4 0.36 3 294.7 1 
I 
3.01 2 1.38 2 0.36 2 249.3 2 
J 
3.37 1 3.29 1 0.34 4 167.4 4 
 
 
Figure 4.15: Biochemical and electrophysiological measurements in 
individual 3xTg mice.  Mice A – F are 6 months of age while mice G – J are 
12 months of age. Densitometry values from APP and tau blots are shown in 
the table along with measurements of the average maximum fEPSP amplitude 
and average magnitude of LTP after 60 minutes. Each mouse is given a ranking 
based on the highest values for the group. Cells shaded in grey represent the 
subgroup with highest protein expression and lowest electrophysiological 
measurements. 
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Conversely mouse E had lowest APP/tau expression and the largest fEPSP and 
LTP of the 6 month old animals. However, other than these extreme measures 
little is gained from the analysis. 
 
4.2.5: Biochemical profiles in 2 month old TASTPM mice 
 
 
4.2.5.1: Overview 
 
 
Hippocampal slices were prepared from the TASTPM mouse at 2 months and 6 
months of age for electrophysiological analysis, with 2 month old mice showing 
normal synaptic plasticity and 6 month old mice showing marked deficits, with a 
reduction in fEPSP amplitude (Chapter 3.2.6, 3.2.7). Previous reports indicated 
that TASTPM mice show Aβ deposition in the cortex and hippocampus; cortical 
Aβ deposition initiates at 3-4 months and is well established by 6 months, and 
this is also the age when cognitive deficits present (Howlett et al., 2004). The 
pathology develops more rapidly in these mice than in single transgenic APP 
mice due to the additional expression of mutant human PS1. Therefore I 
examined protein expression in 2 and 6 month old brain lysates to directly 
compare with the electrophysiological studies and as likely representations of 
pre- and post-plaque deposition.  
Male and female mice were analysed separately as it is known that the pathology 
initiates earlier in female TASTPM mice (Howlett et al., 2004).  
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4.2.5.2: APP 
 
 
As expected there is a significant increase in the level of APP (measured using 
the 6E10 antibody) in TASTPM compared with control mice (p < 0.05, two-way 
ANOVA), with 6E10 staining of APP effectively absent in control mice (Fig. 
4.16A). There is no effect of gender (p > 0.05, two-way ANOVA)  on APP 
expression in TASTPM mice. 
 
 
4.2.5.3: CRMP2 (total and phosphorylated) 
 
 
Total CRMP2 levels (Fig. 4.16B) and phosphorylated CRMP2, at either the 
509/514 (Fig. 4.16C – GSK3 sites) or 522 sites (Fig. 4.16D – Cdk5 sites) are not 
significantly different (p > 0.05, two-way ANOVA) between the 2 month old 
TASTPM mice and age-matched controls. There is also no effect of gender (p > 
0.05, two-way ANOVA) on total CRMP2 or CRMP2 phosphorylated at the 
509/514 residues.  
 
 
4.2.5.4: Tau (total and phosphorylated) 
 
 
There is no difference (p > 0.05, two-way ANOVA) in total tau levels in the 
TASTPM mice compared with control mice which is expected as these mice do 
not possess a tau transgene (Fig. 4.17A). There is a decrease (p < 0.05, two-way 
ANOVA)  in the phosphorylation of tau at the AT8 epitope (Fig. 4.17B), but no 
changes (p > 0.05, two-way ANOVA)  at the 396 (Fig. 4.17C) or 404 (Fig. 
4.17D) phosphorylation sites in TASTPM compared to control. There is no effect 
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of gender (p > 0.05, two-way ANOVA) on total tau or phosphorylation at the 396 
or 404 epitopes with either genotype. However, there is a significant difference 
(p < 0.05, two-way ANOVA) between the levels of 404 phosphorylation in male 
and female TASTPM mice with a higher level of phosphorylation in female 
mice. 
 
4.2.5.5: Other proteins 
 
 
There is no difference (p > 0.05, two-way ANOVA)  in synaptophysin levels in 
the TASTPM mice compared to control (Fig. 4.18A). In addition, there is no 
effect of genotype or gender (p > 0.05, two-way ANOVA)  on the levels of p35 
(Fig. 4.18B) or p25 (Fig. 4.18C). 
 
4.2.5.6: Summary 
 
 
The only biochemical changes detected in 2 month TASTPM mice are the 
expected high levels of APP expression and a reduction in the phosphorylation of 
the tau 404 epitope compared to control mice. However as there are no detectable 
deficits in electrophysiology at this age it must be assumed that these 
biochemical alterations do not themselves directly affect LTP in 2 month old 
hippocampal slices.  
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Figure 4.16: APP, total and phosphorylated CRMP2 in 2 month TASTPM 
male and female mice. 10µg of cortical lysate from 2 month old TASTPM 
and control male (n = 3 in each group) and female (n = 3 in each group) mice 
was used in SDS-PAGE, transferred to a nitrocellulose membrane and probed 
with the following antibodies: 6E10 (A), Total CRMP2 (B), CRMP2 phospho 
509/514 (C), CRMP2 phospho 522 (D). Representative blots are displayed 
along with the graphs showing densitometry calculations. APP and total 
CRMP2 are normalised to tubulin while phosphorylated CRMP2 is normalised 
to total CRMP2 protein.  = p < 0.05, two way ANOVA. 
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Figure 4.17: Total and phosphorylated tau in 2 month TASTPM male and 
female mice. 10µg of cortical lysate from 2 month old TASTPM and control 
male (n = 3 in each group) and female (n = 3 in each group) mice was used in 
SDS-PAGE, transferred to a nitrocellulose membrane and probed with the 
following antibodies: Tau5 (A), Tau AT8 (B), Tau phospho 396 (C), Tau 
phospho 404 (D). Representative blots are displayed along with the graphs 
showing densitometry calculations. Total tau is normalised to tubulin while 
phosphorylated tau is normalised to total tau.  = p < 0.05, two way ANOVA. 
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Figure 4.18: Synaptophysin, p35 and p25 in 2 month TASTPM male and 
female mice. 10µg of cortical lysate from 2 month old TASTPM and control 
male (n = 3 in each group) and female (n = 3 in each group) mice was used in 
SDS-PAGE, transferred to a nitrocellulose membrane and probed with the 
following antibodies: Synaptophysin (A), p35 (B) which also shows p25 (C), 
and actin. Representative blots are displayed along with the graphs showing 
densitometry calculations. Synaptophysin, p35 and p25 are normalised to 
tubulin.  
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4.2.6: Biochemical profiles in 6 month old TASTPM mice 
 
 
At 6 months of age the TASTPM mice show marked electrophysiological 
deficits including a reduction in fEPSP amplitude (Chapter 3.2.7), while plaque 
pathology is reported to be well established (Howlett et al., 2004). Western 
blotting was carried out on brain lysates from mice of this age to investigate 
whether any biochemical changes might be responsible for the 
electrophysiological deficits. 
 
4.2.6.1: APP 
 
 
As expected the 6E10 antibody shows the presence of the human APP transgene 
in all of the TASTPM mice, while this human protein is not present in control 
mice (p < 0.05, two-way ANOVA). There is no difference (p > 0.05, two-way 
ANOVA) in the levels of APP at this age between male and female TASTPM 
mice (Fig. 4.19A).  
 
4.2.6.2: CRMP2 (total and phosphorylated) 
 
 
There is no difference (p > 0.05, two-way ANOVA)  in levels of total CRMP2 in 
six month old TASTPM mice (Fig. 4.19A). However, there is a significantly 
higher level (p < 0.05, two-way ANOVA) of phosphorylated CRMP2 at the 
509/514 residues (Fig. 4.19C - GSK3 sites) compared to age-matched controls. 
This hyperphosphorylation of CRMP2 is in agreement with work previously 
carried out in the lab (Cole et al., 2007b). The data suggests that the presence of 
both the APP and PS1 transgenes promotes increased phosphorylation of 
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CRMP2 at this residue. However, there is no difference (p > 0.05, two-way 
ANOVA) in the levels of phosphorylation at the 522 residue (Fig. 4.19D – Cdk5 
sites). There is no effect of gender (p > 0.05, two-way ANOVA) on total CRMP2 
or phosphorylated CRMP2 (Fig. 4.19A - D) in either TASTPM or control mice. 
 
4.2.6.3: Tau (total and phosphorylated) 
 
 
There is no difference (p > 0.05, two-way ANOVA)  in levels of total tau (Fig. 
4.20A) in the 6 month old TASTPM mice compared with age matched controls, 
or in the levels of tau phosphorylation at the AT8 (Fig. 4.20B), 396 (Fig. 4.20C) 
or 404 (Fig. 4.20D) epitopes. There is also no effect of gender (p > 0.05, two-
way ANOVA)  on tau phosphorylation. 
 
4.2.6.4: Other proteins 
 
 
There is no difference (p > 0.05, two-way ANOVA)  in synaptophysin levels in 
the TASTPM mice compared to control (Fig. 4.21A). In addition, there is no 
effect of genotype or gender (p > 0.05, two-way ANOVA)  on the levels of p35 
(Fig. 4.21B) or p25 (Fig. 4.21C). 
 
4.2.6.5: Summary 
 
 
As expected, the 6 month TASTPM mice express a high level of APP although, 
unlike the findings at 2 months, there is no difference in APP levels between 
male and female mice. The hyperphosphorylation of CRMP2 at the 509/514 
residue observed at 6 months of age (but not at 2 months of age) suggest that 
pathological alterations subsequent to APP processing by PS1 are beginning to 
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develop between 2 and 6 months and could be linked to the reported cognitive 
decline and the deficits I observed in the electrophysiological measurements. 
However, whether the abnormal changes in CRMP2 are linked to any of these 
deficits requires further study. 
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Figure 4.19: APP, total and phosphorylated CRMP2 in 6 month TASTPM 
male and female mice. 10µg of cortical lysate from 6 month old TASTPM and 
control male (n = 3 in each group) and female (n = 3 in each group) mice was 
used in SDS-PAGE, transferred to a nitrocellulose membrane and probed with 
the following antibodies: 6E10 (A), Total CRMP2 (B), CRMP2 phospho 
509/514 (C), CRMP2 phospho 522 (D). Representative blots are displayed 
along with the graphs showing densitometry calculations. APP and total 
CRMP2 are normalised to tubulin while phosphorylated CRMP2 is normalised 
to total CRMP2 protein.  = p < 0.05, two way ANOVA. 
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Figure 4.20: Total and phosphorylated tau in 6 month TASTPM male 
and female mice. 10µg of cortical lysate from 6 month old TASTPM and 
control male (n = 3 in each group) and female (n = 3 in each group) mice was 
used in SDS-PAGE, transferred to a nitrocellulose membrane and probed with 
the following antibodies: Tau5 (A), Tau AT8 (B), Tau phospho 396 (C), Tau 
phospho 404 (D). Representative blots are displayed along with the graphs 
showing densitometry calculations. Total tau is normalised to tubulin while 
phosphorylated tau is normalised to total tau.  
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Figure 4.21: Synaptophysin, p35 and p25 in 6 month TASTPM male and 
female mice.  10µg of cortical lysate from 6 month old TASTPM and control 
male (n = 3 in each group) and female (n = 3 in each group) was used in SDS-
PAGE, transferred to a nitrocellulose membrane and probed with the following 
antibodies: Synaptophysin (A), p35 (B) which also shows p25 (C), and actin. 
Representative blots are displayed along with the graphs showing densitometry 
calculations. Synaptophysin, p35 and p25 are normalised to tubulin. 
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4.2.7: AD related protein expression and phosphorylation in 
different brain regions of TASTPM mice  
 
 
Much less is known about the spatial progression of Aβ pathology in the 
TASTPM mice, however it is hypothesised to follow the same pattern as other 
models, with initiation in the cortex which then spreads to the hippocampus, with 
the cerebellum relatively spared. Samples from 6 month old TASTPM 
hippocampus, cortex, and cerebellum were used to compare the levels of protein 
expression in these regions. Male mice only were used for this experiment. 
 
4.2.7.1: APP 
 
There is a significant difference (p < 0.05, one-way ANOVA) in APP expression 
between the cortex, hippocampus and cerebellum, with levels highest in the 
cortex and lowest in the cerebellum (Fig. 4.22A). Similar to the 3xTg mice, the 
APP transgene is expressed under the Thy-1 promoter which results in a lower 
level of expression in the cerebellum. 
 
4.2.7.2: CRMP2 (total and phosphorylated) 
 
 
There is a significant difference (p < 0.05, one-way ANOVA) in levels of total 
CRMP2 between cortex, hippocampus and cerebellum (Fig. 4.22B), with levels 
lowest in the hippocampus and highest in the cerebellum. There is a significant 
difference (p < 0.05, one-way ANOVA) in CRMP2 phosphorylation at the 
509/514 residues between the cortex and cerebellum, with levels lowest in the 
cerebellum. There is no difference (p > 0.05, one-way ANOVA) between 
hippocampus and cortex, or hippocampus and cerebellum (Figure 4.22C – GSK3 
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sites). Despite the higher expression of CRMP2 in the cerebellum the levels of 
CRMP2 phosphorylated at the 522 residue are significantly higher (p < 0.05, 
one-way ANOVA) in the cortex and hippocampus compared with the cerebellum 
(Fig. 4.22D – Cdk5 sites). 
 
 
4.2.7.3: Tau (total and phosphorylated) 
 
 
Total tau levels are significantly higher (p < 0.05, one-way ANOVA) in the 
cerebellum, with no difference (p > 0.05, one-way ANOVA) between 
hippocampus and cortex (Fig. 4.23A). The cerebellum also shows significantly 
lower (p < 0.05, one-way ANOVA) levels of tau phosphorylated at the 396 (Fig. 
4.23B) and 404 (Fig. 4.23C) epitopes compared to the other regions. However 
between the cortex and hippocampus there is little difference, apart from tau 404 
phosphorylation which shows a trend for a reduction in the cortex (p = 0.06). 
These results show that, overall, the pattern of tau phosphorylation in the 
cerebellum of the TASTPM mice (as seen with control and 3xTg mice at an older 
age) is different from other brain regions. 
 
4.2.7.4: Other proteins 
 
 
There is no difference (p > 0.05, one-way ANOVA) in synaptophysin levels 
between the cortex, hippocampus and cerebellum (Fig. 4.24A). Levels of p35 are 
significantly lower (p < 0.05, one-way ANOVA) in the hippocampus compared 
with the cortex and cerebellum, but there is no difference between the two latter 
regions (Fig. 4.24B) Levels of p25 are significantly higher (p < 0.05, one-way 
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ANOVA) in the cortex than in the hippocampus and cerebellum; there is no 
difference between these regions  (Fig. 4.24C).  
 
4.2.7.5: Summary 
 
 
Similar to the 3xTg and control mice there are marked differences in CRMP2 
and tau regulation in the cerebellum relative to the cortex and hippocampus in 
the TASTPM model. There does not appear to be any major spatial alterations 
specific to this model or to the transgenes expressed. Therefore, the biochemical 
assessment of the cortex should be a reasonable surrogate for what is happening 
in the hippocampus and allow comparisons with deficits in hippocampal 
electrophysiology. 
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Figure 4.22: APP, total and phosphorylated CRMP2 in 6 month TASTPM 
hippocampus, cortex and cerebellum. 10µg of hippocampal, cortical and 
cerebellar lysate from 6 month old TASTPM male mice (n = 4 of each region) was 
used in SDS-PAGE, transferred to a nitrocellulose membrane and probed with the 
following antibodies: 6E10 (A), Total CRMP2 (B), CRMP2 phospho 509/514 (C), 
CRMP2 phospho 522 (D). Representative blots are displayed along with the graphs 
showing densitometry calculations. APP and total CRMP2 are normalised to actin 
while phosphorylated CRMP2 is normalised to total CRMP2 protein.  = p < 0.05, 
one way ANOVA. 
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Figure 4.23: Total and phosphorylated tau in 6 month TASTPM 
hippocampus, cortex and cerebellum. 10µg of hippocampal, cortical and 
cerebellar lysate from 6 month old TASTPM male mice (n = 4 of each region) 
was used in SDS-PAGE, transferred to a nitrocellulose membrane and probed 
with the following antibodies: Tau5 (A), Tau AT8 (B), Tau phospho 396 (C), 
Tau phospho 404 (D). Representative blots are displayed along with the 
graphs showing densitometry calculations. Total tau is normalised to actin 
while phosphorylated tau is normalised to total tau.  = p < 0.05, two way 
ANOVA. 
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Figure 4.24: Synaptophysin, p35 and p25 in 6 month TASTPM 
hippocampus, cortex and cerebellum. 10µg of hippocampal, cortical and 
cerebellar lysate from 6 month old TASTPM male mice (n = 4 of each region) 
was used in SDS-PAGE, transferred to a nitrocellulose membrane and probed 
with the following antibodies: Synaptophysin (A), p35 (B) which also shows 
p25 (C), and actin. Representative blots are displayed along with the graphs 
showing densitometry calculations. Synaptophysin, p35 and p25 are 
normalised to actin.  = p < 0.05, two way ANOVA. 
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4.2.8: Kynurenic acid treatment 
 
The presence of kynurenic acid during hippocampal slice preparation was able to 
rescue the deficits in fEPSP amplitude in 12 month old 3xTg and 6 month old 
TASTPM mice (Chapter 3.2.8, 3.2.9). Therefore, I examined expression and 
regulation of the proteins found to be altered in these models in slices treated 
with or without kynurenic acid to further correlate slice biochemistry with 
electrophysiological measurements. 
Brain slices from the hippocampus and cortex of 12 month old control and 3xTg 
mice were prepared as for electrophysiology (Chapter 2.2.1) and then incubated 
for one hour at room temperature in aCSF or aCSF containing 1mM kynurenic 
acid. The slices were then snap frozen, stored at -80ºC and subsequently 
processed for Western blotting (Chapter 2.2.2). Blotting was performed to detect 
the following: total CRMP2, phosphorylated CRMP2 509/514, total GSK3β, 
Phospho GSK3α/β Ser 21/9, total tau, phosphorylated tau AT8 epitope, 
phosphorylated tau 404 epitope, total MAPK, phosphorylated MAPK 
Thr209/Tyr 204, total PKB, phosphorylated PKB at serine 473, and actin as a 
loading control. Slices from 3 mice were used in each group. 
No differences were observed in the levels or regulation of any of these proteins 
(Fig. 4.25). This argues against alterations in their expression or regulation 
underlying the kynurenic acid-sensitive electrophysiological deficits in these 
models. 
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Figure 4.25: Kynurenic acid treatment of slices from 12 month old 3xTg 
and control mice. 10µg of hippocampal/cortical slice lysate from 12 month 
old 3xTg and control mice, incubated in normal aCSF or 1mM kynurenic acid, 
was used in SDS-PAGE, transferred to a nitrocellulose membrane and probed 
with the following antibodies: total CRMP2, phosphorylated CRMP2 509/514, 
total GSK3β, Phospho GSK3α/β Ser 21/9, total tau, tau AT8, tau 404, total 
MAPK, phosphorylated MAPK Thr209/Tyr 204, total PKB, phosphorylated 
PKB Ser 473, and actin. Representative blots are shown above. 
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4.3: Discussion 
 
4.3.1: Technical aspects 
 
 
There are a number of technical limitations which must be considered when 
interpreting the data obtained in the Western blot experiments. Firstly, an 
average of three mice of each gender and genotype were used for each 
experiment and, due to the marked variability in protein expression between 
individual animals, it would be advisable to increase the sample size to improve 
the robustness of the data. Western blotting is a semi-quantitative technique, 
which measures relative protein expression, although I have attempted to limit 
the inherent variability of the technique by focusing on comparisons within gels 
and normalising to actin. In many cases I carried out multiple experiments using 
the same samples which provided similar results, suggesting that the Western 
blotting protocol used is a highly reproducible method of measuring protein 
levels. However, a greater sample size and use of additional loading controls, 
such as GAPDH or tubulin, and internal standards (where available) would 
improve the robustness of the results obtained.  
The use of Western blotting has provided an indirect measure of some of the 
biochemical changes which may be associated with the development of the 
pathological features in the transgenic mice. However, no direct conclusions 
about the progression of amyloid and tau pathology can be drawn from this data; 
this would require the use of other techniques such as immunohistochemical 
staining of brain slices to examine Aβ deposition and tangle formation. 
Unfortunately, these additional experiments were not possible during the time 
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course of my PhD studies but would be necessary to give a full analysis of the 
development of pathological features in the 3xTg and TASTPM mice.  
 
4.3.2: Analysis of cortical expression of AD-related proteins in 
3xTg mice 
 
 
The expression of a number of proteins was analysed at 2, 12 and 17 months in 
3xTg cortex to provide a biochemical assessment at the same developmental 
stage as the electrophysiological measurements. The 3xTg mouse is a widely 
used model of AD, and as such biochemical or electrophysiological changes 
linked to disease progression would hopefully mirror at least some aspect of the 
development of the human pathology. One key aim of my thesis was to identify 
any biochemical changes associated with the genetic modification of the 3xTg 
mice that could be used as early-stage biomarkers of cellular damage, or 
developed as possible drug targets for the treatment of AD. 
 
4.3.2.1: APP expression in 3xTg mice 
 
 
Expression of the APPSwe transgene was studied in order to confirm the excess 
APP generation during the lifespan of this model. I observed that there was a 
significantly higher level of APP present at all ages studied.   
In AD, the deposition of Aβ is a progressive process, which involves not only a 
gradual increase in plaque load but also a regional dependence with pathology 
initiating in the cortex then later spreading to the hippocampus (Braak and Braak, 
1991). Ideally a mouse model would replicate these characteristics of the 
condition. In this respect the 3xTg mouse has been reported to show an age-
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dependent increase in Aβ levels and plaque formation, with a brain region-
specific progression similar to human AD. 6E10 staining occurs exclusively in 
the CNS and most strongly in the cortex, hippocampus and thalamus showing 
that the expression of the APPSwe transgene is region specific (Oddo et al., 2003). 
The presence of region-specific Aβ accumulation suggest that the 3xTg mouse is 
a good model for studying this feature of AD, although marked differences in the 
time course of this process are now being reported, with plaque development in 
the cortex ranging from 6 months to over 18 months (Oddo et al., 2003, 
Mastrangelo and Bowers, 2008). The original report observed the early 
deposition of intraneuronal Aβ between 3 and 4 months in the cortex, and by 6 
months in the hippocampus (Oddo et al., 2003). In our colony of 3xTg mice, 
APP expression shows a trend for an increase with age between 2 and 12 months 
although this does not reach statistical significance. This suggests that APP 
accumulation may not be maximal at 2 months, or even at 12 months of age. In a 
previous study, cortical 6E10 staining was found to be present from 2 months at 
low levels and increased progressively to the age of 26 months; this age-
dependent increase occured gradually and was purely intraneuronal until the 
development of plaques at 18 months (Mastrangelo and Bowers, 2008). In our 
colony of 3xTg mice it is likely that plaque development occurs late in the 
lifespan, although further immunohistochemical studies would be required to 
confirm this. 
To further explore this area, and to confirm the presence of elevated Aβ levels in 
our colony of 3xTg mice, would require the use of more specific Aβ antibodies 
which is technically more difficult due to the small molecular weight of the 
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protein and its lower abundance. Immunohistochemical techniques could also be 
used to give a measure of amyloid plaque deposition in the 3xTg mice. Both 
methods have been successfully used by other research groups to give a more 
detailed analysis of the development of pathology in these mice (see Chapter 
1.4.5). 
Although not studied in detail, gender did not affect APP expression at 2 or 12 
months in our colony of 3xTg mice. It has been suggested by others that female 
3xTg mice exhibit more extensive amyloid pathology, which manifests as an 
increase in Aβ load and plaque numbers, and also develop plaques earlier in the 
lifespan (Hirata-Fukae et al., 2008, Carroll et al., 2010). These effects become 
markedly more pronounced with ageing, so it is possible that a difference might 
be observed in our colony at older ages such as in the 17 month group; these 
experiments were not carried out due to low numbers of mice available at this 
age. 
 
4.3.2.2: Tau expression in 3xTg mice 
 
 
The method of derivation of the model means that in the founder line the APP 
and tau transgenes are co-integrated at a single locus, hence both human genes 
(APP and tau) are expressed at a similar level (Oddo et al., 2003).  
I found a higher level of tau expression relative to controls in all ages of 3xTg 
mice. The 3xTg mouse carries both human tau and the endogenous mouse tau 
genes, and both are recognised by the tau5 antibody, so the two to threefold 
higher levels of tau in these mice suggest that the human protein has been 
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expressed. However, Oddo et al. (2003) reported up to an eightfold increase in 
total tau levels; this is much higher than observed in our colony and could 
contribute to the slower development of disease-related symptoms.   
I observed no age-dependent increase in total tau expression in our colony of 
3xTg mice. The development of tau pathology is known to occur subsequent to 
that of Aβ, and studies using antibodies specific for human tau have suggested 
this is relatively late in the lifespan of the model. Immunohistochemical studies 
have observed human-specific tau immunoreactivity to a limited extent in 
animals from 2 months onwards, but this only becomes pronounced from around 
6 months of age (Oddo et al., 2003, Mastrangelo and Bowers, 2008); The tauP301L 
mutation in the 3xTg mice is known to accelerate the process of filament 
formation which eventually leads to tangle generation (vonBergen et al., 2001), 
however the original report suggests that this does not occur until approximately 
12 months and tangles are initially observed in hippocampus only (Oddo et al., 
2007). It is therefore likely that in our colony of 3xTg mice the deposition of tau 
was not sufficient even in older mice to allow any age-dependent differences to 
be observed. 
One limitation of using only the Tau5 antibody is that it detects both human and 
mouse tau and so the individual levels of these cannot be calculated. To 
complicate matters further, human and mouse tau can co-aggregate in tangles 
(Sydow and Mandelkow, 2010). A combination of total tau and human or mouse 
specific antibodies, combined with immunohistochemical studies, would be 
required to study further the expression of tau in the 3xTg mice and its 
relationship to the tangle pathology observed in AD. There is also a distinction 
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between soluble tau and insoluble, tangle-associated tau, with the two pools 
separable by fractionation. Insoluble tau increases with ageing and may show a 
distinct pattern of phosphorylation compared to soluble tau (Hirata-Fukae et al., 
2009). In our colony of 3xTg it is likely that only soluble forms of tau were 
present even at 17 months of age. 
The levels of tau expression at 2 and 12 months in our male and female 3xTg 
mice were similar. In comparison to the Aβ pathology, little has been reported on 
gender-dependent differences in tau pathology. No gender difference was found 
in hippocampal total tau levels at ages up to 9 months (Clinton et al., 2007) or in 
the phosphorylation of tau at several epitopes in aged 3xTg mice (Hirata-Fukae 
et al., 2008). Overall this suggests that tau expression is not affected by gender in 
this mouse model. 
 
4.3.2.3: Tau phosphorylation in 3xTg mice 
 
 
Hyperphosphorylation of tau occurs prior to tangle formation in AD and has been 
reported previously to occur in the 3xTg mouse. For example, increased 
phosphorylation occurs at sites recognised by the AT100 and 12E8 antibodies 
(Thr 212/Ser 214 and Ser262) in 6 month old 3xTg mice, but not at the AT8 (Ser 
202, Thr 205) and AT180 (Thr 231) sites until around 12-15 months (Oddo et al., 
2007). In our colony of 3xTg mice there was no difference in levels of 
phosphorylation at any site investigated (including AT8) compared to control 
mice. The possible exception was in males at 17 months where there was a trend 
for an increase at the 396 and 404 epitopes.  
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In human AD, in contrast to Aβ pathology, tau pathology initiates in the 
hippocampus and spreads to the cortex (Braak and Braak, 1991), so the 
hyperphosphorylation of tau in the 3xTg mice may be expected to occur later in 
this region of the brain. There are, however, marked differences between 
experimental reports with regard to the time course of these phosphorylation 
events. In the original paper by Oddo et al. (2003), increased phosphorylation at 
the AT8 epitope was apparent at 12 months of age in the hippocampus and 
previous work in our lab, using tissue from a different colony of 6 month old 
3xTg mice, found increased phosphorylation at the AT8 epitope in the cortex 
(Cole et al., 2007b). However, one study reports that PHF-1 phosphorylation 
(which recognises phosphorylated residues including both 396 and 404 sites) is 
not apparent until 15 or 16 months in the 3xTg and may not be detectable in the 
cortex until 26 months of age (Mastrangelo and Bowers, 2008), while another 
reports a low level of cortical staining at this site from 9 months (Oh et al., 2010). 
Such discrepancies between groups serve to highlight the inconsistencies of the 
3xTg model and the differences between individual colonies of these mice. In 
our colony of 3xTg mice it is likely that the lack of a significant difference in 
AT8, 396 or 404 phosphorylation reflects a very slow progression of tau 
pathology compared to previous studies.  
It should not be forgotten that there are a large number of potentially 
phosphorylatable sites on human tau and over 35 sites are phosphorylated in 
tangles from AD brain (Hanger et al., 2007). Many of the AD-related 
phosphorylation sites have not been studied in the 3xTg model, mainly as it is 
technically challenging to quantify phosphorylation of so many tau residues from 
a single sample. However this will be essential to establish whether each 
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becomes hyperphosphorylated in the model and if they follow separate time 
courses which may permit correlation to symptoms of the disease.  
4.3.2.4: CRMP2 phosphorylation in 3xTg mice 
 
 
Previous work in our lab, using samples from a different colony of 3xTg mice, 
showed an increase in CRMP2 phosphorylation at both the 509/514 GSK3 sites 
and the Cdk5 site at serine 522 in the cortex at 2 months of age (Cole et al., 
2007b). However, in our 3xTg colony an increase in CRMP2 phosphorylation is 
only apparent at the 509/514 sites and occurs in older animals, again suggesting 
that the pathological features are developing more slowly in these mice. A 
marked decline in the inactive serine 9-phosphorylated form of GSK3β (an 
indication of increased GSK3β activity) has previously been reported between 12 
and 15 months of age in 3xTg mice (Oddo et al., 2007) and this could be 
associated with the increase in CRMP2 509/514 phosphorylation observed. It is 
unclear why there is no concomitant increase in CRMP2 522 phosphorylation, as 
this is the Cdk5 priming site for GSK3 phosphorylation of the 509/514 residues, 
and thus is a limiting step in the phosphorylation of 509/514. The data is 
consistent with my analysis of the regulatory subunits of Cdk5 (see sections 
4.2.1.4 / 4.2.2.4) which are not altered in my 3xTg mice compared to control. An 
alternative explanation is that the change in 509/514 phosphorylation is due to a 
change in phosphatase activity rather than an increase in GSK3 activity. 
Phosphorylation at the GSK3 and Cdk5 sites is regulated by separate protein 
phosphatases (Cole et al., 2008). 
The phosphorylation of CRMP2 is increased in human AD cortical tissue (Cole 
et al., 2007b) so the higher level of phosphorylation observed in the 3xTg mouse 
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may suggest a mechanistic link between APP or tau pathology and the regulation 
of CRMP2, and hence may be a useful characteristic of this model; indeed the 
late development of this feature in our colony of mice is consistent with CRMP2 
phosphorylation changes occurring subsequent to abnormal APP processing.  
 
4.3.2.5: p35/p25 in 3xTg mice 
 
 
The generation of p25 from p35 and subsequent activation of Cdk5 has been 
suggested to contribute to neurodegeneration in AD but this has been disputed 
(Patrick et al., 1999, Tandon et al., 2003).  I did not find any difference in the 
levels of the Cdk5 co-factor p35 or its cleavage product p25 at any age in the 
3xTg mice compared to controls. This is in agreement with previous work in our 
lab which found no differences in p35 or p25 levels, or Cdk5 expression or 
activity, in the cortex of 6 month old 3xTg mice compared to age matched 
controls (Cole et al., 2007b). In contrast, an age-dependent increase in Cdk5 
activity has been reported in another study by Oddo et al. (2007) which studied 
mice of 6, 12 and 17 months. An increase in p25 levels, the co-factor which 
causes prolonged activation of Cdk5, could account for the increased Cdk5 
activity in these mice. In contrast, there were no changes in p35 levels (Oddo et 
al., 2007). It was suggested that these changes could partially mediate the 
increase in tau phosphorylation observed with advancing age in their study, when 
accompanied by a higher level of GSK3β activity. The discrepancies between 
these reports suggest that further studies of p35/p25 and Cdk5 activity are 
required in the 3xTg mice. However, the lack of any differences in our colony of 
3xTg mice could be explained by the relatively slow development of pathology 
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resulting in a delay in alterations of Cdk5 or p35/p25 activity which may also 
partly explain the slow development of tau hyperphosphorylation in these mice. 
4.3.2.6: Synaptophysin in 3xTg mice 
 
 
In AD, the majority of studies have shown a decrease in synaptophysin levels in 
both cortex and hippocampus and this is due to an initial loss of synapses 
followed by neuronal death (Masliah et al., 1991). I found no difference in 
synaptophysin levels in 3xTg mice compared to control at any age. As 
synaptophysin is a synaptic vesicle protein, this suggests that even at 17 months 
of age the synapses within the cortex remain relatively well preserved. However, 
there is the possibility that synaptophysin is still present in neurons, and thus 
detectable by Western blotting, despite the retraction of dendritic spines and so 
this would have to be confirmed by immunohistochemical or imaging studies. 
However,  the results in our colony of 3xTg are in agreement with several groups 
who have reported no change in synaptophysin levels in 3xTg mice (Hirata-
Fukae et al., 2009, Julien et al., 2010, Arsenault et al., 2011), and levels of other 
presynaptic proteins such as dynamin and synaptotagmin are also unchanged 
(Yao et al., 2005b). It would be interesting to look at postsynaptic proteins such 
as PSD-95 as alterations in these have previously been reported (Arsenault et al., 
2011).  
The lack of alterations in synaptic proteins or neuronal loss in the 3xTg mice 
highlights the limitations of this model in that it only replicates some of the 
pathological features of AD.  
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It is likely that in 3xTg mice the synapses remain intact, but this does not rule out 
the possibility of structural changes within the synapse.  Hirata-Fukae et al. 
(2009) report no changes in synaptophysin at ages up to 23 months but a trend 
for reduced NMDA receptor 2A and AMPA GluR2 subunit expression with 
ageing. I attempted to characterise NMDA receptor levels in our 3xTg mice but 
this was unsuccessful due to a lack of antibody specificity. It would be 
interesting to study glutamate receptor expression in these mice which would 
require the use of imaging and immunohistochemical techniques and could 
further correlate biochemical and electrophysiological data.  
4.3.2.7: Summary 
 
 
The increased levels of APP and tau protein shows that the 3xTg mice are 
expressing the transgenes as expected. An age-dependent increase in the 
expression of APP mirrors that observed in AD, although no such gradual 
increase is observed with transgenic tau. Other features such as 
hyperphosphorylation of CRMP2 are observed, albeit relatively late in the life of 
our colony of 3xTg mice, and this late onset significantly limits the use of the 
model. Unfortunately, the lack of biochemical changes in the 3xTg mice means 
that it is difficult to carry out one of the early aims of the project which was to 
provide links between synaptic function and alterations in protein 
phosphorylation. 
An ideal model of AD would develop pathological features earlier than 12 to 18 
months aiding more rapid assessment of the contribution of pathology to 
behavioural or electrophysiological changes. Unfortunately, the delayed onset of 
the phenotype and lack of biochemical differences observed at earlier ages have 
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made studies in our colony of 3xTg mice difficult in the timeframe of PhD 
studies. However, variability within this model has been reported by other groups 
(Hirata-Fukae et al., 2008), and it is this variability from colony to colony and 
research group to research group which is the most frustrating aspect of the 
model. It becomes almost impossible to design studies using the model, as the 
timeframe for development of features is difficult to predict. In addition, crossing 
onto other lines with different aspects of AD would have to be very carefully 
controlled with littermates from the original cross. These technical problems will 
limit the usefulness of the 3xTg in the study of AD.  
 
 
4.3.3: AD related protein expression and phosphorylation in 
different brain regions of 3xTg 
 
 
Protein expression was measured in the hippocampus, cortex and cerebellum of 
17 month 3xTg mice. This was primarily to ensure that there were no obvious 
biochemical differences between the cortex (main biochemical studies) and 
hippocampus (electrophysiological studies). Cerebellar tissue was used as a 
control as levels of the transgenic human APP are much reduced in this region. 
As expected, APP levels in our colony of 3xTg mice were significantly higher in 
the cortex and hippocampus than in the cerebellum. It is likely that this is due to 
protein stability, as the transgene is driven by the Thy-1 promoter which is 
expressed at its highest levels in this region (Andra et al., 1996). This mirrors 
human AD, where the cerebellum is relatively resistant to developing the 
pathological features of the disease, possibly due to a lower level of APP protein 
expression (Causevic et al., 2010).  
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The levels of total tau in 3xTg mice remain stable across the cortex, 
hippocampus and cerebellum. This is likely due to the high abundance of 
endogenous mouse tau which is detected by the antibody. In humans total tau 
levels are similar in the cortex and hippocampus and again reduced in the 
cerebellum (Causevic et al., 2010), but the phosphorylation status of tau has not 
been studied. In 3xTg mice there is a marked increase in tau phosphorylation at 
the AT8 and 396 epitopes, with a reduction at the 404 epitope in the cerebellum 
compared to the other brain regions. However the level of tau phosphorylation is 
similar between cortex and hippocampus. This is also observed in control mice, 
suggesting that regulation of tau phosphorylation is region-specific in the mouse 
brain, and the regional variation is not related to the genetic modification. 
In the 3xTg mouse the levels of p25 and p35 also vary across different brain 
regions, with p35 levels highest in the cerebellum and p25 highest in the cortex. 
However, this may be related to the normal distribution of these proteins in 
mouse brain, as region-specific differences have previously been observed in 
rodents (Wu et al., 2000).  
In conclusion, I have observed region-specific differences in tau protein levels 
and phosphorylation in both 3xTg and control mice but it is not known if similar 
changes are apparent in human brain. As abnormal phosphorylation of tau is 
associated with tangle formation and thus AD development it is important to 
understand the normal physiological regulation of tau by phosphorylation. If 
there are brain region specific differences this implies differential activity of 
pathways that control tau phosphorylation in healthy brain, and has to be kept in 
mind when developing interventions targeting tau phosphorylation. 
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4.3.4: Correlations between biochemical changes and 
electrophysiology in 3xTg mice 
 
 
For some of the 3xTg mice the hippocampus was used for electrophysiological 
recordings while the cortex from the same animal was homogenised to generate 
protein lysates. In these samples, I tried to correlate levels of APP and tau to 
deficits in the maximum fEPSP amplitude and LTP values but the number of 
animals available was too small to reach solid conclusions. 
I could not demonstrate a direct linear association between the fEPSP amplitude 
(the strength of basal synaptic transmission) and the magnitude of LTP obtained 
suggesting that even in the mice with some neuronal dysfunction the ability of 
the neurons to undergo synaptic plasticity is not affected. However, it should be 
noted that due to the nature of the technique there is significant variation between 
individual slices even in the same mouse and that the values reported are an 
average of several results pooled together. It is interesting that the two 12 month 
old mice with the highest levels of tau had the smallest fEPSP, while the mouse 
with the lowest APP and tau expression had the highest fEPSP amplitude and 
magnitude of LTP. At 17 months, the mouse with the highest levels of APP and 
tau also had the lowest fEPSP amplitude and magnitude of LTP. This suggests 
that there is some link between the expression of the transgenic proteins and the 
electrophysiological changes. However, this clearly needs a more robust 
investigation with larger numbers of animals. Indeed ideally an inducible system, 
where the transgenes could be activated to specific levels, would be needed to 
truly show a cause and effect relationship between protein expression and 
electrophysiological deficit. Another group has reported that in double transgenic 
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APPSwe x PS1M146L mice there was no correlation between brain Aβ levels and 
basal synaptic transmission or LTP, although there was a weak correlation 
between LTP and cognitive deficits in a Morris water maze task (Trinchese et al., 
2004).  
The biochemical analysis was done in the cortex and the electrophysiology in the 
hippocampus, and although the levels of APP and tau are similar in both there 
may still be some variation between the brain regions. To improve this 
experiment, it would be necessary to carry out the Western blotting in the 
hippocampus; the cortex was generally used for experiments as a larger volume 
of tissue could be obtained. In our colony of 3xTg mice, no correlation was 
attempted between behavioural performance and electrophysiological or 
biochemical changes; Aβ load has been linked to cognitive deficits in a number 
of transgenic mouse models and has been suggested to correlate with synaptic 
loss (Gordon et al., 2001). 
 
4.3.5: Analysis of cortical expression of AD-related proteins in 
TASTPM mice 
 
 
I analysed the same set of proteins in the cortex of the TASTPM mouse to extend 
the search for abnormal expression or regulation of proteins that could be linked 
to the electrophysiological deficits in these models. I also wanted to compare the 
development of pathology between the double-transgenic TASTPM and the 
3xTg model. One consideration in interpreting this data is that the TASTPM 
mice are derived from a C57BL/6 background, while the control mice used are 
mixed C57BL/6 x 129/Sv, due to limitations in the animals available for these 
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experiments. Anatomical and metabolic differences have been observed in the 
brains of different inbred mouse strains (Penet et al., 2006), and so  it would be 
desirable to confirm the results obtained and compare any differences observed 
in the TASTPM mice with the pure C57BL/6 strain. 
 
4.3.5.1: APP expression in TASTPM mice 
 
 
I confirmed APPswe expression in the TASTPM mice, with none detectable in 
age-matched control mice. Amyloid deposition initiates at 3 months and shows 
an age-dependent progression in the cortex of this model (Howlett et al., 2004). 
Limited biochemical and immunohistochemical studies of Aβ pathology have 
previously been carried out in the TASTPM mouse. However, one study found 
both extensive APP and punctuate Aβ staining by the age of 6 months in the 
cortex and hippocampus (Maheswaran et al., 2009). The progression of plaque 
pathology has been better characterised in the TAS10 mouse from which the 
TASTPM mouse is derived. The TAS10 mouse shows significant age-dependent 
increases in Aβ in the hippocampus and cortex, with plaque deposition most 
marked in the cortex (Richardson et al., 2003). In theory  the development of 
pathology should occur more rapidly in the TASTPM mouse compared to the 
TAS10 line due to the presence of the PS1M146V transgene. 
 
 
4.3.5.2: Tau expression and phosphorylation in TASTPM mice 
 
 
I observed no difference in levels of total tau in TASTPM mice at either 2 and 6 
months, which is expected as these mice express only endogenous mouse tau 
protein.  I also checked whether the presence of the APPSwe and PS1M146V 
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transgenes are capable of causing biochemical alterations in tau. At 2 months of 
age tau phosphorylation is similar to control levels at the 396 and 404 epitopes, 
the only exception being a reduction in the phosphorylation of tau at the AT8 
epitope in the TASTPM which is not present at 6 months. Indeed at 6 months of 
age there are no significant differences in tau phosphorylation between TASTPM 
and controls. 
It has previously been reported that an increase in tau phosphorylation at the AT8 
epitope is associated with dystrophic neurites in the cortex of 8 month old 
TASTPM mice. These neurites are closely associated with amyloid plaque 
deposition (Howlett et al., 2008b). The location of the hyperphosphorylated tau 
suggests that it may be regulated by the functional alterations that occur in 
neuronal processes disrupted by amyloid deposition. This feature has also been 
reported in other mouse models. For example, a similar pattern of 
hyperphosphorylated tau has been observed adjacent to amyloid plaques in the 
APP23 model, which expresses the APPSwe mutation (Sturchler-Pierrat et al., 
1997). This implies that the presence of the APP mutation alone is sufficient to 
alter the pattern of phosphorylation at multiple tau residues and this may be 
associated with early tau pathology.  
However, the progression to neurofibrillary tangles has not been observed in 
mice in which a tau transgene is not present. This suggests that although there is 
an interaction between Aβ deposition and tau phosphorylation other mechanisms 
(or distinct phosphorylation sites) are involved in the initiation of tangle 
pathology.  
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4.3.5.3: CRMP2 phosphorylation in TASTPM mice 
 
 
I observed no difference in CRMP2 levels or phosphorylation at either the 
509/514 or 522 sites in 2 month old TASTPM mice compared with controls. 
However, by 6 months of age there is an increase in CRMP2 phosphorylation 
observed in the TASTPM mice at the 509/514 sites. Previous work in our lab on 
a different cohort described an increase in phosphorylation at these sites from 2 
months of age (Cole et al., 2007), again indicating some variability in the rate of 
progression of the disease between individual colonies. Cole et al. also showed 
that CRMP2 hyperphosphorylation is only observed in models which express a 
PS1 mutation which accelerates the deposition of Aβ and was not found in single 
transgenic mice such as the Tg2576 (APPSwe) model. This suggests that double or 
triple transgenic models such as the 3xTg or TASTPM may be better models of 
this aspect of human AD, with the more rapid development of this feature in the 
TASTPM mice making it a particularly useful model. Interestingly abnormally 
high CRMP2 phosphorylation appears very specific to AD, not being detectable 
in other forms of human dementia including tauopathy (Cole, AR, personal 
communication). Therefore the pathways responsible for the change in 
phosphorylation may represent AD specific cellular defects and CRMP2 
phosphorylation may provide an additional biochemical means to distinguish AD 
from non-AD dementia. 
 
4.3.5.4: p35/p25 in TASTPM mice 
 
 
In our colony of TASTPM mice there is no significant difference in p35 or p25 
levels compared to controls at 2 months or 6 months. This suggests that the 
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levels of this co-factor and subsequent alterations in Cdk5 activity do not make a 
major contribution to the biochemical changes observed in TASTPM mice. 
 
4.3.5.5: Synaptophysin in TASTPM mice 
 
 
In both 2 and 6 month TASTPM mice there is no difference in the levels of 
synaptophysin, which implies that there is no synaptic loss associated with the 
progression of Aβ deposition in TASTPM mice. This is in agreement with 
previously published work where no difference in synaptophysin levels was 
found in these mice (Hirata-Fukae et al., 2009), suggesting that the cognitive 
decline described in these mice is not associated with synaptic loss. This synaptic 
stability may explain reflect the lesser magnitude of cognitive changes in the 
TASTPM mice compared with the memory loss observed in AD (Howlett et al., 
2008b). It is not known whether synaptic loss would occur with further ageing of 
these mice, as the pathological features become more advanced and cognitive 
deficits become more severe. However, the lack of changes in synaptophysin at 6 
months suggest that, similar to the 3xTg mouse, the TASTPM mouse fails to 
model the synaptic loss observed in AD. As with the 3xTg mouse, it would be 
interesting to investigate more thoroughly if there were functional alterations 
occurring within the synapse, for example in the molecular composition or 
receptor numbers and distribution. This would be particularly relevant in the 
hippocampus where I observed that neuronal plasticity is impaired and this could 
potentially be linked to synaptic alterations. 
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4.3.5.6: Summary 
 
 
Although 2 month and 6 month old mice were not directly compared, the 
changes present in 6 month mice such as hyperphosphorylation of CRMP2 and 
suggest that there is an age-dependent increase in the severity of the biochemical 
phenotype observed. This correlates temporally with the reported cognitive 
deficits in these mice and the electrophysiological changes observed. However, 
one caveat is that the control mice were of a mixed background; to improve these 
experiments they would need to be repeated with pure C57BL/6 mice as a 
control and with a larger number of mice. However, the biochemical and 
electrophysiological differences in the TASTPM mice at 6 months show that the 
development of disease features occurs much earlier in this mouse model 
compared to the 3xTg mice. There are several possible reasons for this: 
differences in background strain, the method of transgene integration and 
generation of the model, and genetic drift in the 3xTg colony. Alternatively tau 
expression may have a protective effect when combined with APP and PS1 
mutations, although there is little other evidence for this. Therefore, the 
TASTPM mice appear a more practical model for the study of certain aspects of 
AD. However, they are not useful for the study of mechanisms related to tangle 
pathology. The TASTPM mouse does develop minor changes in the 
phosphorylation of tau, but it is not clear whether the pattern of phosphorylation 
is that similar to that observed in human AD. It is likely that there are multiple 
biochemical changes present in each transgenic model and further work is 
required to understand which of these is most important in the progression of AD. 
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4.3.6: AD related protein expression and phosphorylation in 
different brain regions of TASTPM mice 
 
 
Similar to the 3xTg mouse, the TASTPM mouse expresses the transgenes under 
the Thy-1 promoter, so as was expected the cerebellum expressed relatively low 
levels of APP even in 6 month old male mice. The expression pattern was similar 
to that observed in the 3xTg mice, with levels lowest in the cerebellum and 
highest in the cortex. In the TASTPM mouse, amyloid deposition initiates in the 
cortex (Howlett et al., 2004) so it is not surprising that this region shows the 
highest levels of APP. In contrast to 3xTg and control mice, there is a 
significantly elevated level of total tau in the cerebellum compared with the other 
brain regions; there is also a different pattern of phosphorylation in these mice, 
with the highest phosphorylation at the 396 epitope in the cortex and 
hippocampus, and the 404 epitope in the cortex. This shows that there is altered 
phosphorylation at these epitopes which may suggest that the levels of APP or 
APP processing is higher in these brain regions in the TASTPM compared to 
3xTg, but this was not assessed. Similarly, there is a higher level of 
phosphorylation of CRMP2 at the 509/514 and 522 sites in the hippocampus and 
cortex compared to cerebellum, despite higher total CRMP2 in the cerebellum. 
 
4.3.7: Effects of kynurenic acid 
 
 
In Chapter 3 I demonstrated that hippocampal slice viability was markedly 
improved by incubation with 1mM kynurenic acid, as observed by an increased 
probability of obtaining an fEPSP and an increase in the maximum fEPSP 
amplitude in both aged 3xTg and TASTPM mice. Identifying molecular 
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processes associated with the electrophysiogical deficits that are prevented by 
kynurenic acid would give clues to the underlying cause of the deficit. 
A number of signalling pathways have been implicated in glutamate-induced 
excitotoxicity, for example the mitogen-activated protein kinase cascade (MAPK 
cascade) which is one of the most important signalling pathways within the cell. 
In neurons, Ca2+ influx through the NMDA receptor or voltage-dependent Ca2+ 
channels leads to the sequential activation of the proteins Ras, Raf, MAPK/ERK 
kinase (MEK), and finally MAPK. This is followed by the activation of multiple 
cytoplasmic and nuclear targets including other kinases and transcription factors 
(Thomas and Huganir, 2004). Pharmacological inhibitor studies have shown that 
MAPK is involved in the induction of LTP in the hippocampus (English and 
Sweatt, 1997). In addition, there is a transient increase in the phosphorylation of 
MAPK at the activation sites (Thr 202/Tyr 204) in slices maintained in vitro in 
the first hour following slicing (Ho et al., 2004). However, no differences are 
observed in our colony of control or 3xTg mice in either total MAPK or Thr 202/ 
Tyr 204 phosphorylation between slices incubated in normal aCSF and 1mM 
kynurenic acid. 
The PI3K (phosphoinositide 3-kinase)/PKB (protein kinase B) cascade is also an 
important signalling pathway which regulates neuronal survival and aspects of 
cellular metabolism. The generation of phosphoinositides such as PIP3 by the 
enzyme PI3K results in the localisation of PKB to the membrane, where it is 
phosphorylated and activated by another kinase, PDK-1. This results in the 
activation of downstream signalling pathways, including the regulation of 
apoptotic proteins (Brunet et al., 2001). Although this pathway is usually 
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activated by trophic factors, stimulation of the NMDA receptor leads to a Ca2+ -
dependent phosphorylation and activation of PKB (Perkinton et al., 2002).  
However, there is no difference in either total levels of PKB or activated PKB 
(phosphorylated at the Ser 473 site) in slices treated with 1mM kynurenic acid. 
GSK3β is activated downstream of the PI3K/PKB pathway and has a number of 
diverse actions. It has been linked to neuronal survival following glutamate-
induced excitotoxicity, with activation resulting in neuronal death (Liang and 
Chuang, 2007). However, the expression of GSK3β and its phosphorylation at 
the activation site Ser 9 was not affected by kynurenic acid treatment of the slices, 
and not different between control and 3xTg tissue.  
As well as phosphorylation by GSK3, CRMP2 can be cleaved by neuronal 
calpains, and this modification is one of the main features observed in neurons 
surviving NMDA toxicity (Bretin et al., 2006). However, I found no differences 
in the phosphorylation or cleavage of CRMP2 following treatment with 
kynurenic acid in 3xTg mice or control. 
 
4.3.7.1: Technical aspects  
 
 
Although the data obtained in this study was negative there are a number of 
procedures that could be optimised or altered that may improve the chances of 
finding the molecules responsible for the electrophysiological deficits observed. 
Firstly there is a high degree of variation between individual slices when probing 
for expression and modification of these proteins (especially tau).  I would 
therefore recommend much larger sample sizes for each group when attempting 
this type of experiment. Unfortunately due to time and cohort numbers I was not 
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able to generate these sample sizes to give greater confidence in the data. In 
addition it should be noted that slices were incubated for one hour at room 
temperature before being snap frozen for analysis. Alterations in protein 
phosphorylation have been reported up to six hours after slicing (Taubenfeld et 
al., 2002) and so it may be worthwhile to obtain slices from several time points 
to investigate any delayed biochemical changes. However, my 
electrophysiological measurements were obtained in hippocampal slices 
maintained from one hour up to eight hours in vitro, therefore the changes 
responsible for the electrophysiological differences should be apparent in the 
timeframe studied. Thirdly, the slices which were used for biochemical analysis 
were maintained at room temperature while slices used for electrophysiological 
recordings were subsequently placed in a heated bath at approximately 32°C; 
previous work in our lab has shown that the phosphorylation of some proteins 
such as tau can be temperature-dependent (Ritchie Williamson, personal 
communication). Another limitation is that the recordings of neuronal function 
were made solely from the hippocampus while the whole slice was used for 
biochemical analysis, which included the full hippocampus and an area of cortex. 
This means that any region-specific differences might not be apparent in a whole 
slice lysate. The CA1 pyramidal neurons of the hippocampus are particularly 
susceptible to the effects of cellular stressors such as ischemia (Taubenfeld et al., 
2002) and so it is possible that a degree of neuronal dysfunction occurred in this 
population which was not observed in other cellular types. An alternative 
approach would be to employ microscopy to observe the morphology of the 
neurons within the hippocampus and assess single cell biochemical parameters 
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including neuronal death. However this also comes with limitations, in particular 
the semi quantitative nature and quality of antibodies. 
Finally, I have focused on specific candidate proteins based on current 
knowledge of signalling pathways and disease pathology. The key proteins in 
these neuronal changes in response to APP and tau overexpression may be 
unrelated to the biochemical pathways I studied. Other enzymes such as 
calmodulin-dependent kinase II (CaMKII) and Src family kinases, which can 
modulate NMDA receptor function, are transiently activated in hippocampal 
slices (Ho et al., 2004) along with the induction of multiple transcription factors 
which could mediate cellular survival (Taubenfeld et al., 2002). It would be 
interesting to know the levels of glutamate receptor subunits in case there are any 
alterations in receptor expression; this was attempted but was not successful due 
to the poor quality of Western blots with the specific antibodies available. 
Similarly, there might be alterations in other proteins associated with glutamate 
signalling such as amino-acid transporters. Therefore, further work is needed to 
elucidate the mechanisms by which kynurenic acid treatment protects neurons 
against the cellular stresses associated with the slicing process specifically in the  
AD model tissue. 
  
295 
 
 
 
Chapter 5 
 
Behaviour 
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5.1: Introduction 
 
 
3xTg mice show behavioural alterations such as alterations in circadian rhythm, 
locomotor activity and exploratory behaviour prior to 6 months of age, before the 
development of significant plaque pathology (see Chapter 1.4.5). In addition, 
cognitive deficits have been reported in the 3xTg mouse model from the age of 4 
months, when impairment is seen in long-term spatial learning in the MWM, and 
deficits in short-term memory are observed at 6 months (Billings et al., 2005). 
This chapter aims to characterise aspects of the behavioural and cognitive 
phenotype in 3xTg mice. These experiments used male mice only to avoid the 
complications of the oestrous cycle on mouse behaviour. Initially, 4 month old 
3xTg mice were placed in an activity box for 15 minutes on four consecutive 
days to observe locomotor and exploratory activity. When the mice reached 6 
months old, an age at which cognitive deficits are reported to be apparent, they 
were subsequently tested in a rewarded alternation T-maze task. This is a spatial 
learning task which measures aspects of hippocampal function and has not 
previously been reported in 3xTg mice. Initially, mice were tested without a 
delay between the phases of each trial, with a time delay added later to increase 
the difficulty of the task.  
In summary, the first section of this chapter describes the use of the activity box 
to characterise locomotor activity, while the second section reports the results of 
the rewarded alternation T-maze task used as a test of cognitive function in the 
3xTg mice.  
  
297 
5.2: Results 
 
 
5.2.1: Activity box in 4 month 3xTg males 
 
 
 
4 month 3xTg and control male mice were tested in an activity box, which 
consisted of a Perspex box attached to an activity monitor which used infrared 
beams to measure the movements of each mouse (see Chapter 2.2.3). Measures 
recorded were slow and fast mobile counts, which are a measure of horizontal 
exploratory activity, slow and fast rearing counts, which are a measure of vertical 
activity, and total mobile time. 
 
 
5.2.1.1: Mobile counts 
 
 
Mobile counts were recorded from the number of horizontal beam breaks and 
divided into fast mobile counts (Fig. 5.1A) and slow mobile counts (Fig. 5.1B). 
Main effects analysis of the slow mobile counts shows  a significant effect of 
strain (F(1,20) = 5.3,  p < 0.05, repeated measures ANOVA), day (F(3,60) = 3.2,  p < 
0.05, repeated measures ANOVA), and time (F(2,40) = 3.2,  p < 0.05, repeated 
measures ANOVA), with the interaction between these factors also significant 
(strain x day x subtrial F(6,120) = 3.8,  p < 0.05, repeated measures ANOVA). 
Main effects analysis of the fast mobile counts shows a significant effect of strain 
(F(1,20) = 7.8,  p < 0.05, repeated measures ANOVA), day (F(3,60) = 4.2,  p < 0.05, 
repeated measures ANOVA), and time (F(2,40) = 117.3,  p < 0.05, repeated 
measures ANOVA), with the interaction between these factors also significant 
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(strain x day x subtrial F(6,120) = 6.3,  p < 0.05, repeated measures ANOVA). This 
shows that there is a difference in activity between the control and 3xTg mice in 
this task. 
The significant effect of time suggests that habituation occurs to the novel 
environment in both strains of mice within each individual trial. However, 
control mice appear to show inter-trial habituation which is absent in the 3xTg 
mice; this is particularly noticeable in the first five minutes of each trial. This can 
be confirmed statistically, as for the slow mobile counts there is a significant 
interaction between the first time bin and the trial day in control mice (day x 
subtrial F(3,30) = 7.1,  p < 0.05, repeated measures ANOVA) while in the 3xTg 
mice there is no significant difference (day x subtrial F(3,30) = 8.5,  p > 0.05, 
repeated measures ANOVA). Similarly, in the fast mobile counts there is a 
significant interaction between the first time bin and the trial day in control mice 
(day x subtrial F(3,30) = 6.3,  p < 0.05, repeated measures ANOVA) while in the 
3xTg mice there is no significant difference (day x subtrial F(3,30) = 1.2,  p > 0.05, 
repeated measures ANOVA). 
 
 
5.2.1.2: Total mobile time 
 
 
When total mobile time is calculated (Fig. 5.2), main effects analysis of the slow 
mobile counts shows a significant effect of strain (F(1,20) = 6.3,  p < 0.05, repeated 
measures ANOVA), and time (F(2,40) = 124.2,  p < 0.05, repeated measures 
ANOVA), with the effects of day just failing to reach significance (F(3,60) = 2.7,  
p = 0.052, repeated measures ANOVA), The interaction between all three factors 
is significant (strain x day x subtrial F(6,120) = 4.1,  p < 0.05, repeated measures 
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ANOVA) showing that there is a difference between 3xTg and control, with 
3xTg mice less active overall in the activity box.  
As with the fast and slow mobile counts, the control mice appear to show inter-
trial habituation which is absent in the 3xTg mice. In control mice there is a 
significant interaction between the first time bin and the trial day (day x subtrial 
F(3,30) = 6.5,  p < 0.05, repeated measures ANOVA) while in the 3xTg mice there 
is no significant difference (day x subtrial F(3,30) = 0.5,  p > 0.05, repeated 
measures ANOVA). 
 
 
5.2.1.3: Other measures 
 
The slow and fast rearing counts were used as a measure of vertical exploratory 
behaviour, and there is no difference observed at any time point between 3xTg 
and control mice in this measure (p > 0.05, repeated measures ANOVA). 
 
 
5.2.1.4: Summary 
 
When performance of 4 month 3xTg male mice is measured in the activity box, 
the 3xTg mice show a decrease in the mobile counts and total mobile time 
calculated. This shows that there is a reduction in exploratory activity in 3xTg 
mice compared to control and this is particularly apparent during the first five 
minutes of each trial.  
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Figure 5.1: Fast and slow mobile counts measured in the activity box. Mean 
counts for each 5 minute time bin over four consecutive days are shown for fast 
mobile (A) and slow mobile (B) counts in 4 month 3xTg and control mice. 
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Figure 5.2: Total mobile counts measured in the activity box. Mean counts for 
each 5 minute time bin over four consecutive days are shown for the total mobile 
counts in 4 month 3xTg and control mice. 
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5.2.2: T-maze performance in 6 month 3xTg male mice 
 
 
6 month 3xTg and control mice were trained in a rewarded alternation T-maze 
task (see Chapter 2.2.3) and the mean percentage of correct entries was 
calculated for each group for each day of the trial. In 3xTg mice, the percentage 
of correct entries remains relatively stable over all days; this is similar to the 
control mice although the percentage correct in the control group is on average 
slightly higher (Fig. 5.3A). As there was no significant difference between the 
individual days (p > 0.05, repeated measures ANOVA), the data from all nine 
trials was pooled together. Overall, the mean percentage correct in the 3xTg mice 
is 74.2 ± 1.2% while in the control it is 80.6 ± 2.2% (Fig. 5.4) There is a small 
but statistically significant reduction in performance (p < 0.05, unpaired t-test) in 
the 3xTg mice compared with the control.  
 
5.2.2.1: T-maze results (delay) 
 
 
Following the initial experiments, further trials were carried out with a delay of 
either thirty or sixty seconds introduced between the forced stage and the choice 
stage. This makes the task more difficult and was intended to make any cognitive 
deficits in the 3xTg mice more apparent. A longer 120 second delay was also 
attempted, but the mice were unable to perform above chance levels on this task 
so further trials were not carried out with this time delay. Due to similar 
performance of the control and 3xTg mice on the delayed T-maze task only six 
trials were carried out. 
There is no difference between the performance of 3xTg and control at either 
delay time on any of the six trials (Fig. 5.3B). When the overall performance is 
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meaned, with a thirty second delay the percentage correct for 3xTg mice is 79.8 
± 4.2% while for the control mice it is 78.2 ± 3.3%. With a sixty second delay, 
the percentage correct for 3xTg mice is 75.5 ± 4.4% while for the control mice it 
is 67.8 ± 4.8% (Fig 5.4). The sixty second delay increases the difficulty of the 
task and the performance of the control mice is significantly lower (p < 0.05, 
paired t-test) while that of the 3xTg mice remains stable. There is however no 
difference in performance between the 3xTg and control mice at either a thirty or 
sixty second delay. 
 
5.2.2.2: Summary 
 
 
There is a minor reduction in performance in the no-delay T-maze task by the 
3xTg mice at 6 months but overall the marked cognitive deficits expected at this 
age are not observed. This is in agreement with the lack of electrophysiological 
and biochemical phenotype at this age. 
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Figure 5.3: Percentage of correct entries in 3xTg and control. The mean 
percentage correct for each group over nine consecutive days is shown in A. The 
mean percentage correct when a delay of thirty seconds or sixty seconds is added 
for six consecutive days is shown in B. 
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Figure 5.4: Mean percentage of correct entries for all trials. The graph 
shows the percentage correct when all the days of the trial are pooled together 
for 3xTg and control, with no delay, a thirty second delay or a sixty second 
delay. 
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5.3: Discussion 
 
 
In male 3xTg mice, the activity box was used to measure exploratory and 
locomotor activity, while the T-maze test was used to test cognitive function. 
Mice were tested in the activity box at 4 months and trained in the T-maze task at 
6 months, as this was an age when intraneuronal Aβ was expected to be present 
based on previous reports (Oddo et al., 2003). Previous studies have also shown 
an impairment in hippocampal-dependent cognitive performance from the age of 
4 months, which is though to be linked to Aβ accumulation (Billings et al., 2005). 
 
 
5.3.1: Activity box 
 
 
The activity box was used as a measure of spontaneous locomotor activity in 4 
month old 3xTg and control male mice. Mobile counts were used as a measure of 
horizontal exploratory activity and horizontal counts as a measure of vertical 
activity. It was found that the 3xTg mice were markedly less mobile in the initial 
five minutes after they are placed in the box, and this was most pronounced on 
the first of the four trials, showing that the 3xTg mice remain stationary for 
prolonged periods of time when first placed in the box. The 3xTg mice also show 
lower inter-trial habituation than the control mice, which showed a marked 
reduction in the number of mobile counts over the first three days. However, 
there was no difference in the number of rearing counts between the two groups, 
showing that vertical exploratory activity is similar. 
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Several other groups have carried out behavioural tests on the 3xTg mice at 
various ages using the activity box and larger open field, with similar findings. In 
young (2.5 month old) male 3xTg mice, there was no difference in activity in the 
two tests, showing that there are no locomotor changes present prior to the 
development of pathology. However, reduced activity was reported in 6 month 
male and 12 month female 3xTg mice, with the presence of ‘strong initial 
freezing behaviour’ in the open field test in the male mice (Gimenez-Llort et al., 
2007). Similarly, the behaviour of 8 month 3xTg mice in the open field was 
characterised by limited exploratory behaviour and freezing (Sterniczuk et al., 
2010a). Finally, in a ten minute activity box study, 3xTg mice showed both 
reduced horizontal and vertical activity with frequent short episodes of low 
activity lasting from 5-30 seconds (Arsenault et al., 2011). Importantly, these 
mice do not show any locomotor or co-ordination difficulties which could affect 
their behaviour (Sterniczuk et al., 2010a). This was also observed in our colony 
of 3xTg mice which could successfully complete a rotarod task (data not shown) 
and showed no noticeable differences in locomotion. These data are not included 
in the thesis as both groups of mice showed a high level of passive rotations 
(clinging onto and rotating with the rod) which prevented analysis of the results.  
It is clear that the phenotype of the 3xTg involves a reduction in exploratory 
behaviour and increased freezing which is linked to the development of 
pathological features in these mice. However, the motivating factor behind this 
behaviour is unclear. One study suggests it represents a higher level of anxiety 
and reduced fear threshold, another increased emotionality, and the other 
suggests the behaviour is ‘seizure-like’, although no evidence for the presence of 
seizures has been noted in the 3xTg mice (Gimenez-Llort et al., 2007, Sterniczuk 
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et al., 2010a, Arsenault et al., 2011).  It has been shown that freezing responses 
of 3xTg mice in a brightly lit chamber is significantly higher than control and can 
be reduced by the administration of the anxiolytic benzodiazepine diazepam 
(Espana et al., 2010).  This suggests that the freezing response may partially be 
an anxiety-linked behaviour. The presence of increased urination and defecation, 
an index of emotional behaviour, was also reported by Gimenez-Llort et al. in 
their study; this was also observed in our colony of 3xTg mice. However, in the 
elevated plus maze test, which is classically used as a measure of anxiety, no 
difference was observed between 3xTg and control by two separate groups 
(Gimenez-Llort et al., 2007, Sterniczuk et al., 2010a). In addition, it has been 
reported that there is no increase in plasma corticosterone levels, which can be 
used as a biochemical marker of the response to stressful tasks, in male 3xTg 
mice following testing in the MWM (Clinton et al., 2007). This suggests that the 
reduction in exploratory behaviour in the 3xTg mouse is a complex response to a 
novel environment which is not yet fully understood. In addition, a 
comprehensive study of both male and female mice at similar ages has not been 
carried out and would be required to fully characterise this type of behaviour. In 
our colony of 3xTg mice, only male mice were used and this was at 4 months of 
age, early in the time course of Aβ deposition. As the evidence suggests that the 
development of pathology is occurring more slowly in our colony of 3xTg mice, 
the behavioural changes are likely due to age-independent effects of transgene 
overexpression or very early biochemical alterations. Emotional behaviour in the 
3xTg mouse has been linked to the amygdala, where intraneuronal Aβ has been 
shown to accumulate at 6 months, earlier than in the cortex or the hippocampus 
(Espana et al., 2010). As biochemical changes in the amygdala were not studied 
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in our colony of 3xTg mice, the possibility of a link between Aβ accumulation in 
this region of the brain and the observed behaviour in the activity box cannot be 
ruled out. Further work would be required using a range of tests to examine 
emotional behaviour in 3xTg mice and how this may relate to behavioural 
disturbances which are observed in AD. 
 
5.3.2: T-maze performance 
 
 
At 6 months, both 3xTg and control mice were tested in a T-maze task to observe 
any hippocampal-dependent cognitive deficits that might be apparent at this age. 
Initially, mice were habituated to the apparatus by being placed inside with their 
littermates. It was observed at this stage and in the initial stages of testing that 
many of the 3xTg mice showed reduced activity and a reluctance to explore, 
which could be linked to the low levels of activity observed in the activity box. 
For this reason, food restriction was required to encourage the mice to carry out 
the task. Our colony of 3xTg mice showed a significantly higher body weight 
than control mice, which is thought to be due to increased appetite and food 
intake (Knight et al., 2010). In this respect, motivation to obtain a food reward 
might be different between the 3xTg mice and control. For this reason, food 
restriction was carried out proportionally to body weight to negate any 
differences in food-motivated behaviour. 
In the no-delay T-maze task, which was carried out for nine consecutive days, 
the mice show the ability to complete the task from the first trial, reaching rates 
of 70-80% correct choices. No improvement or decline was observed throughout 
subsequent trials. On nearly all days, there was a trend for the performance of the 
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3xTg mice being slightly lower than the control mice, suggesting that there may 
be a degree of cognitive decline in these mice. This results in a small but 
significant reduction of the percentage correct from 81% in the control mice to 
74% in the 3xTg mice. However, there was marked variation between individual 
mice in both the control and 3xTg groups, with some making consistently correct 
choices and others multiple errors. This shows the importance of using a large 
sample size of mice; an increased number of mice could not be used in this study 
due to the time constraints of the task, but would be a way to improve 
experiments by reducing the effects of individual variability. In addition, it 
would be interesting to measure biochemical changes in individual mice to see if 
there was any correlation between performance in the task and the levels of AD-
associated proteins. 
Following this task, a delay of 30 or 60 seconds was introduced in an attempt to 
make the trials more difficult, and this was carried out for six consecutive days. 
However, in this task there was no significant difference between the 
performance of control and 3xTg mice at either delay time on any of the trials. 
Overall, the percentage correct for the 30 second delay is slightly greater than the 
60 second delay, reflecting the additional difficulty produced by increasing the 
time between trials. Unfortunately, due to the way the study was carried out there 
is no coexisting data for these trials for responses without a delay. It would be 
interesting to observe if there was still a difference in this task between the two 
groups or if the 3xTg mice had shown an improvement. As the two sets of 
experiments were carried out back-to-back on the same cohort of mice, it is 
possible that the average performance of the 3xTg mice would have increased. 
Overall, the results on the harder 30 and 60 second delay trials show that the 
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3xTg mice are able to carry out this task without difficulty. This contrasts with 
previous work in which these mice show marked cognitive deficits at the same 
age (Billings et al., 2005). 
Surprisingly, relatively few cognitive tests have been carried out in 3xTg mice. 
Deficits have been observed in the MWM at 6 months (Billings et al., 2005) but 
enhanced performance in a contextual fear conditioning task, which depends 
upon both amygdala and hippocampus, is observed at the same age (Espana et al., 
2010).  One study using an object recognition task did not report deficits in 
performance in the 3xTg mice until the age of 9 months (Clinton et al., 2007); 
such a task requires hippocampal functioning but may also involve some cortical 
processing (Broadbent et al., 2004). It is therefore likely that the onset of 
cognitive deficits may vary depending on the specific task used.  
The rewarded alternation T-maze is also thought to be a task which is primarily 
hippocampal-dependent. Deficits in T-maze performance have previously been 
correlated to impairments in LTP in the CA1 and DG regions in APPSwe mice 
(Chapman et al., 1999b). However, at this age there are no electrophysiological 
changes apparent in our colony of 3xTg mice (see Chapter 3). The pathological 
features present in 3xTg mice have also been linked to the onset of behavioural 
deficits, with Aβ oligomers linked to cognitive performance in the Morris water 
maze (Billings et al., 2007) and intraneuronal Aβ accumulation in the amygdala 
thought to contribute to alterations in inhibitory avoidance learning (Espana et al., 
2010). A role has been suggested for both Aβ and tau, as reduction of the levels 
of both proteins is required to improve cognitive performance in aged 3xTg mice 
(Oddo et al., 2006b). In our colony of 3xTg mice, there is a lack of marked 
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biochemical changes in APP or tau at 6 months (see Chapter 4), suggesting that 
the pathological features are not yet well developed at this age. Overall, the lack 
of an electrophysiological or biochemical phenotype in these 3xTg mice at 6 
months therefore correlates with the behavioural findings which show that 
hippocampal functioning remains relatively unaffected at this age. 
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Chapter 6 
 
Conclusions and Perspectives 
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Table 6.1: Summary of main findings in 3xTg mice 
 
Electrophysiology 
 
Biochemistry Behaviour  
 
Age I/O  PPF Normalised 
LTP 
Non-norm. 
LTP 
Deficits  
prevented  
by KA 
APP Tau P-Tau 
AT8 
P-Tau 
396 
P-Tau 
404 
P-CRMP2  
 
 
2 months 
 
 
 
NC 
 
 
↓ 
 
 
NC 
 
 
↑ 
 
 
- 
 
 
↑ 
 
 
↑ 
 
 
NC 
 
 
NC 
 
 
NC 
 
 
NC 
 
 
6 months  
 
 
NC 
 
 
NC 
 
 
NC 
 
 
NC 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
↓ locomotor 
activity (4 
months) 
 
NC in T-maze 
alternation task 
(6 months) 
 
 
 
12 months 
 
 
 
↓ 
 
 
NC 
 
 
↑
 
initial
 
 
 
↓
 
 
 
YES 
 
 
↑ 
 
 
↑ 
 
 
NC 
 
 
NC 
 
 
NC 
 
 
NC 
 
 
- 
 
 
17 months  
 
 
 
↓ 
 
 
NC 
 
 
↑
 
plateau
 
 
 
↓ 
 
 
- 
 
 
↑ 
 
 
↑ 
 
 
NC 
 
 
NC 
 
 
NC 
 
↑ 
509/514 
 
 
- 
 
All data are in comparison with control mice. NC = no change, ↑ = increase, ↓ = decrease, - = not measured. 
I/O = input-output, PPF = paired-pulse facilitation, LTP = long-term potentiation, KA = kynurenic acid, P-tau = phosphorylated tau, P-CRMP2 = 
phosphorylated CRMP2. 
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Table 6.2: Summary of main findings in TASTPM mice 
 
Electrophysiology 
 
Biochemistry  
 
Age I/O  PPF Normalised 
LTP 
Non-norm. 
LTP 
Deficits  
prevented  
by KA 
APP Tau P-Tau 
AT8 
P-Tau 
396 
P-Tau 
404 
P-CRMP2 
 
 
2 months 
 
 
 
NC 
 
 
↓ 
50ms only 
 
 
NC 
 
 
NC 
 
 
- 
 
 
↑ 
 
 
↑ 
 
 
↓ 
 
 
NC 
 
 
NC 
 
 
NC 
 
 
6 months  
 
 
 
 
Not measured due to marked reduction in 
fEPSP amplitude 
 
 
YES 
 
 
↑ 
 
 
↑ 
 
 
NC 
 
 
NC 
 
 
NC 
 
 
↑ 
 
All data are in comparison with control mice. NC = no change, ↑ = increase, ↓ = decrease, - = not measured. 
I/O = input-output, PPF = paired-pulse facilitation, LTP = long-term potentiation, KA = kynurenic acid, P-tau = phosphorylated tau, P-CRMP2 = 
phosphorylated CRMP2. 
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Conclusions and perspectives 
 
 
The work presented here has further characterised the phenotype of the 3xTg and 
TASTPM mouse models of AD through biochemical, behavioural and 
electrophysiological studies. This section summarises the key findings of this 
thesis and the contribution of these to AD research, limitations of these studies 
and suggestions for alternative approaches or further work. 
 
The major biochemical, behavioural and electrophysiological findings reported 
for 3xTg mice are summarised in Table 6.1, and for TASTPM mice in Table 6.2. 
 
6.1: Electrophysiology 
 
 
I have carried out experiments to study synaptic function, including basal 
synaptic transmission and LTP, in the 3xTg and TASTPM models. Previous 
work has shown that the 3xTg mice show an age-dependent reduction in the 
magnitude of LTP from the age of 6 months (Oddo et al., 2003) while no 
previous electrophysiological studies of the TASTPM mouse have been 
published.  
In this thesis, I have shown that in our colony of 3xTg mice early alterations in 
synaptic function occur at the age of 2 months and manifest as an increase in 
basal synaptic transmission with no change in the magnitude of LTP. The 
mechanisms underlying this are not known and would require further, more 
detailed studies, for example the use of voltage clamp techniques to measure the 
properties of individual neurons. It is possible that the elevation in basal 
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transmission may represent an increase in the intrinsic excitability of 
glutamatergic neurons which has previously been reported in this model 
(Arsenault et al., 2011) or alterations in postsynaptic Ca2+ regulation associated 
with the presence of the transgenes (Chakroborty et al., 2009).  
I have also shown that, in contrast to the colony of 3xTg mice studied by Oddo et 
al., alterations in synaptic function are not present in our colony of 3xTg mice 
until the age of 12 months.  This is observed as a marked reduction in the 
amplitude of the fEPSP suggesting a deficit in basal synaptic transmission. 
Despite this, LTP can be induced normally up to the age of 17 months although 
the absolute magnitude of potentiation is reduced due to the smaller fEPSP 
amplitude. This shows that there are major differences in the phenotype of our 
colony of 3xTg mice compared with that originally characterised. 
Previous studies in APP transgenic mice have shown a similar reduction in the 
fEPSP amplitude, but this could be reversed by the presence of the glutamate 
receptor antagonist kynurenic acid within the solution during hippocampal slice 
preparation (Fitzjohn et al., 2001). I replicated this in 3xTg mice and have shown 
that treatment with 1mM kynurenic acid during slicing restores fEPSP amplitude 
to the levels observed in control mice. Importantly, this shows that glutamate-
induced excitotoxicity is a major factor influencing slice viability and may have 
an effect on the results obtained using the hippocampal slice preparation. This 
has relevance for the wider study of synaptic plasticity in transgenic mouse 
models, as it highlights the importance of standardising extracellular recording 
protocols and taking measures to improve neuronal viability within the 
hippocampal slice.   
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I have shown that in the TASTPM mouse model, there are no alterations in basal 
synaptic transmission or LTP at the age of 2 months showing that synaptic 
function at this age remains normal.  However, at 6 months, there is a marked 
reduction in the amplitude of the fEPSP and the percentage of successful fEPSPs 
obtained. Similar to the 3xTg mice, this can be completely prevented by 
incubation with 1mM kynurenic acid during slicing.  
These findings suggest that a common feature of mouse models of AD 
possessing the APP and PS1 transgenes may be an enhanced vulnerability to the 
high levels of glutamate release associated with the slice preparation process. 
This increased susceptibility to excitotoxicity may represent the presence of 
neurons within the hippocampus which are ‘primed’ to undergo dysfunction 
under conditions of enhanced cellular stress. The molecular mechanisms 
underlying this process are not known, but are likely to involve dysfunction of 
components of the glutamatergic neurotransmitter pathway, for example 
alterations in glutamate release or uptake by astrocytes, the influence of  Aβ 
oligomers on NMDA receptor function, or the alterations in intracellular Ca2+ 
regulation which can occur with the PS1 mutation. Further study of these 
mechanisms would require the combined use of several different techniques, for 
example the use of immunofluorescence to observe NMDA receptor numbers 
and localisation combined with electrophysiological techniques to measure 
glutamate uptake and release within the synapse or with neuronal Ca2+ imaging 
to measure intracellular Ca2+ transients. 
It is not known if the increased susceptibility to excitotoxicity occurs in 
hippocampal neurons in vivo in the 3xTg or TASTPM mice, and this would 
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require further studies in the intact animal. It would be interesting to observe if 
the hippocampal neurons of these mice are more susceptible to a variety of other 
cellular stressors, for example conditions of metabolic or oxidative stress, and if 
this is a contributory mechanism to neuronal dysfunction in AD. 
 
6.2: Biochemistry 
 
 
In this thesis I have quantified the expression of several AD-associated proteins 
associated with the pathological features of AD in order to observe the presence 
of any biochemical changes which might be associated with my 
electrophysiological findings in the 3xTg and TASTPM mice. 
I have found that in 3xTg mice, although the presence of elevated levels of APP 
and tau confirmed the presence of the transgenes, there was little age-dependent 
increase in the levels of these proteins. I did not observe hyperphosphorylation of 
tau at the AT8, 396 or 404 epitopes which has been reported to occur from the 
age of 12 months (Oddo et al., 2007) although there was a trend for increased 
phosphorylation at the age of 17 months. The lack of biochemical changes in our 
colony of 3xTg mice suggest that there may be a delayed onset of the 
pathological features associated with the phenotype, although this would require 
further imaging or immunohistochemical studies to observe plaque and tangle 
deposition. 
I have also studied other cellular proteins such as CRMP2, which may be 
phosphorylated in the early stages of AD progression and seems to be a feature 
relatively specific to AD (Williamson et al 2011, in press). At 17 months, 
enhanced phosphorylation of the 509/514 residues (GSK3 sites) was observed. 
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Although this is later than previously observed in our lab, it did occur prior to 
other biochemical changes in the 3xTg mice studied and thus may be an early 
feature of disease progression. Other proteins such as synaptophysin were not 
altered in this model, suggesting that synaptic loss does not occur; to provide a 
more sensitive measure of synaptic number this could be confirmed by imaging 
in these mice to observe the density of dendritic spines.  
The relatively minor biochemical changes in our colony of 3xTg mice supports 
the conclusion of my electrophysiological studies, which suggest the delayed 
onset of disease-related deficits in our colony (observed as a normal magnitude 
of LTP at 17 months). Unfortunately, I was unable to observe any molecular 
changes which might be associated with the enhanced susceptibility to 
excitotoxicity observed in these mice. Further work would be required to 
elucidate the biochemical pathways associated with this feature; candidates for 
further Western blotting or immunohistochemistry experiments include NMDA 
receptor subunits, α and β-secretase enzymes, and the excitatory amino acid 
transporters. 
I also carried out similar biochemical studies in the TASTPM mice. In these mice, 
I found no major alterations in protein levels at 2 months, supporting the finding 
that synaptic function is normal in these mice at this age. At 6 months, I observed 
increased phosphorylation at the CRMP2 509/514 residue, which suggests that 
the early development of biochemical changes occurs more rapidly in this model 
than in our 3xTg colony. This may explain the earlier onset of the reduction of 
fEPSP amplitude observed in slices prepared under normal conditions (6 months 
in TASTPM mice vs. 12 months in 3xTg mice). Unfortunately, I was unable to 
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characterise the progression of biochemical changes at older ages in these mice 
due to breeding difficulties and premature mortality; it would be interesting to 
follow the progression of pathology in these mice as they age and whether this is 
linked to the development of alterations in basal synaptic transmission or LTP.  
 
6.3: Behaviour 
 
 
In this thesis I also carried out behavioural experiments on the 3xTg mice, 
comprising an activity box study and cognitive testing in the rewarded 
alternation T-maze task. Performance in the T-maze has not previously been 
reported in these mice but is thought to be hippocampal-dependent, similar to the 
MWM. I found that in the activity box the 3xTg mice showed a reduced level of 
activity when compared to control mice, and this is in support of previously 
reported findings which have shown increased freezing and anxiety-like 
behaviour in this model. This is independent of the development of pathological 
features as it was observed at 4 months and shows that these mice have an early 
behavioural phenotype due to the presence of the transgenes. In cognitive studies 
of 6 month 3xTg mice, I did not observe any deficits in performance in the T-
maze alternation task. This is in agreement with the lack of biochemical changes 
present in these mice at this age. Based on this knowledge, it would be 
interesting to carry out cognitive testing in older 3xTg mice, for example at 12 or 
17 months, although it would be necessary to use a more complex task capable of 
detecting early, more subtle cognitive deficits.  
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6.4: Final conclusions  
 
The main aims of this thesis were to observe the progression of synaptic, 
biochemical and behavioural alterations in the 3xTg and TASTPM models of AD. 
Unfortunately, I did not observe the electrophysiological and cognitive deficits 
originally reported with the generation of the 3xTg model, and this is  supported 
by the lack of biochemical changes I observed using Western blotting. This 
suggests that the development of the pathological features is delayed in our 
colony of 3xTg mice. The most likely reason for the delay is a degree of genetic 
drift which has occurred in this model over multiple generations when housed in 
separate locations.  To resolve this, the only solution would be to re-derive the 
mice from the original colony. These findings show the importance of careful 
characterisation of the development of pathological features in individual 
colonies of transgenic mice in order to link this with other experimental findings 
such as electrophysiology studies. 
The delayed onset of the phenotype in the 3xTg mice has made it difficult to 
carry out one of the initial aims of my thesis, which was to observe any early 
biochemical alterations associated with disease progression. However, in the 
TASTPM mice the development of a biochemical phenotype occurred more 
rapidly and one of the early changes observed was the hyperphosphorylation of 
CRMP2 (also observed in the 3xTg mice at 17 months). This suggests that this 
feature is an early molecular change associated with APP transgene expression. 
As it has been suggested that hyperphosphorylation of CRMP2 is an event 
specific to AD, this could be an important marker of disease progression and 
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suggests that the activation of protein kinases such as GSK3 is an important early 
feature of AD development. 
Another initial aim of my thesis was to directly compare electrophysiological and 
biochemical decline in the 3xTg and TASTPM models in order to gain insight 
into the role of tau in AD pathology, but the dramatic differences observed 
between different cohorts of 3xTg mice makes this difficult. However, the 
presence of an enhanced susceptibility to excitotoxicity in both the 3xTg and 
TASTPM mice does suggest that this feature is independent of the expression of 
the tau transgene.  As the TASTPM mouse develops both electrophysiological 
and biochemical changes at a relatively early age, it may be a useful model for 
studying aspects of AD associated with Aβ pathology. It would be interesting to 
add a mutant tau transgene into this model to establish whether tau mutation has 
any effect on these features.  
One of the major findings of my thesis is the enhanced susceptibility of 
hippocampal neurons to excitotoxicity which occurs in both the 3xTg and 
TASTPM mouse models and so may represent a common feature of transgenic 
mouse models of AD possessing the APP transgene. The molecular mechanisms 
which underlie this process require further study, but could result in a degree of 
neuronal dysfunction which, if present in the intact animal, could render 
hippocampal neurons more susceptible to the effects of cellular stressors and 
accelerate the progression of AD pathology.  
Although transgenic mice such as the 3xTg or TASTPM mice have their 
limitations and cannot model all aspects of AD they have been critical in 
increasing our understanding of the disease. I hope that the work presented in this 
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thesis and the characterisation of the phenotype of these mice can contribute to 
our knowledge of the molecular mechanisms underlying human AD and 
subsequently provide a means to confirm whether potential interventions have 
physiological or behavioural outcomes prior to human studies. 
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